
<html lang="en"     class="pb-page"  data-request-id="0b8cfa85-2bc0-4f76-ac40-4800cbab5793"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-2;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01372;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder" /></meta><meta name="dc.Creator" content="Scott D.  Edmondson" /></meta><meta name="dc.Creator" content="Cheng  Zhu" /></meta><meta name="dc.Creator" content="Nam Fung  Kar" /></meta><meta name="dc.Creator" content="Jerry  Di Salvo" /></meta><meta name="dc.Creator" content="Hiroshi  Nagabukuro" /></meta><meta name="dc.Creator" content="Beatrice  Sacre-Salem" /></meta><meta name="dc.Creator" content="Karen  Dingley" /></meta><meta name="dc.Creator" content="Richard  Berger" /></meta><meta name="dc.Creator" content="Stephen D.  Goble" /></meta><meta name="dc.Creator" content="Gregori  Morriello" /></meta><meta name="dc.Creator" content="Bart  Harper" /></meta><meta name="dc.Creator" content="Christopher R.  Moyes" /></meta><meta name="dc.Creator" content="Dong-Ming  Shen" /></meta><meta name="dc.Creator" content="Liping  Wang" /></meta><meta name="dc.Creator" content="Richard  Ball" /></meta><meta name="dc.Creator" content="Aileen  Fitzmaurice" /></meta><meta name="dc.Creator" content="Tara  Frenkl" /></meta><meta name="dc.Creator" content="Loise N.  Gichuru" /></meta><meta name="dc.Creator" content="Sookhee  Ha" /></meta><meta name="dc.Creator" content="Amanda L.  Hurley" /></meta><meta name="dc.Creator" content="Nina  Jochnowitz" /></meta><meta name="dc.Creator" content="Dorothy  Levorse" /></meta><meta name="dc.Creator" content="Shruty  Mistry" /></meta><meta name="dc.Creator" content="Randy R.  Miller" /></meta><meta name="dc.Creator" content="James  Ormes" /></meta><meta name="dc.Creator" content="Gino M.  Salituro" /></meta><meta name="dc.Creator" content="Anthony  Sanfiz" /></meta><meta name="dc.Creator" content="Andra S.  Stevenson" /></meta><meta name="dc.Creator" content="Katherine  Villa" /></meta><meta name="dc.Creator" content="Beata  Zamlynny" /></meta><meta name="dc.Creator" content="Stuart  Green" /></meta><meta name="dc.Creator" content="Mary  Struthers" /></meta><meta name="dc.Creator" content="Ann E.  Weber" /></meta><meta name="dc.Description" content="The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical β3-AR agonist MK-0634 (3) exhibited e..." /></meta><meta name="Description" content="The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical β3-AR agonist MK-0634 (3) exhibited e..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 8, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01372" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01372" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01372" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01372" /></link>
        
    
    

<title>Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01372" /></meta><meta property="og:title" content="Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0015.jpeg" /></meta><meta property="og:description" content="The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical β3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclinical species. Optimization of a series of second-generation pyrrolidine-derived β3-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclinical species. These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclinical profile compared to MK-0634. Structure–activity relationships leading to the discovery of vibegron and a summary of its preclinical profile are described." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01372"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01372">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01372&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01372&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01372&amp;href=/doi/10.1021/acs.jmedchem.5b01372" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 609-623</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01369" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01451" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Vibegron: A Potent and Selective β<sub>3</sub> Adrenergic Receptor Agonist for the Treatment of Overactive Bladder</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+D.++Edmondson">Scott D. Edmondson</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Zhu">Cheng Zhu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nam+Fung++Kar">Nam Fung Kar</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jerry++Di+Salvo">Jerry Di Salvo</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hiroshi++Nagabukuro">Hiroshi Nagabukuro</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beatrice++Sacre-Salem">Beatrice Sacre-Salem</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Dingley">Karen Dingley</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Berger">Richard Berger</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+D.++Goble">Stephen D. Goble</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregori++Morriello">Gregori Morriello</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bart++Harper">Bart Harper</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+R.++Moyes">Christopher R. Moyes</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dong-Ming++Shen">Dong-Ming Shen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liping++Wang">Liping Wang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Ball">Richard Ball</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aileen++Fitzmaurice">Aileen Fitzmaurice</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tara++Frenkl">Tara Frenkl</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Loise+N.++Gichuru">Loise N. Gichuru</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sookhee++Ha">Sookhee Ha</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amanda+L.++Hurley">Amanda L. Hurley</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nina++Jochnowitz">Nina Jochnowitz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dorothy++Levorse">Dorothy Levorse</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shruty++Mistry">Shruty Mistry</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Randy+R.++Miller">Randy R. Miller</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James++Ormes">James Ormes</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gino+M.++Salituro">Gino M. Salituro</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony++Sanfiz">Anthony Sanfiz</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andra+S.++Stevenson">Andra S. Stevenson</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine++Villa">Katherine Villa</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beata++Zamlynny">Beata Zamlynny</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stuart++Green">Stuart Green</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary++Struthers">Mary Struthers</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ann+E.++Weber">Ann E. Weber</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box 539, Kenilworth, New Jersey 07033, United States</span></div><div class="corresp-info"><strong>*</strong>Telephone: (908) 740-0287. E-mail <a href="/cdn-cgi/l/email-protection#9eedfdf1eaeab0fbfaf3f1f0faedf1f0def3fbecfdf5b0fdf1f3"><span class="__cf_email__" data-cfemail="5526363a21217b3031383a3b31263a3b15383027363e7b363a38">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01372&amp;href=/doi/10.1021%2Facs.jmedchem.5b01372" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 609–623</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 27, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 September 2015</li><li><span class="item_label"><b>Published</b> online</span>8 January 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01372" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01372</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D609%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DScott%2BD.%2BEdmondson%252C%2BCheng%2BZhu%252C%2BNam%2BFung%2BKar%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D2%26contentID%3Dacs.jmedchem.5b01372%26title%3DDiscovery%2Bof%2BVibegron%253A%2BA%2BPotent%2Band%2BSelective%2B%25CE%25B23%2BAdrenergic%2BReceptor%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BOveractive%2BBladder%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D623%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01372"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4845</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">41</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01372" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;D. Edmondson&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Nam&quot;,&quot;last_name&quot;:&quot;Fung Kar&quot;},{&quot;first_name&quot;:&quot;Jerry&quot;,&quot;last_name&quot;:&quot;Di Salvo&quot;},{&quot;first_name&quot;:&quot;Hiroshi&quot;,&quot;last_name&quot;:&quot;Nagabukuro&quot;},{&quot;first_name&quot;:&quot;Beatrice&quot;,&quot;last_name&quot;:&quot;Sacre-Salem&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Dingley&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Berger&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;D. Goble&quot;},{&quot;first_name&quot;:&quot;Gregori&quot;,&quot;last_name&quot;:&quot;Morriello&quot;},{&quot;first_name&quot;:&quot;Bart&quot;,&quot;last_name&quot;:&quot;Harper&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;R. Moyes&quot;},{&quot;first_name&quot;:&quot;Dong-Ming&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Liping&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Ball&quot;},{&quot;first_name&quot;:&quot;Aileen&quot;,&quot;last_name&quot;:&quot;Fitzmaurice&quot;},{&quot;first_name&quot;:&quot;Tara&quot;,&quot;last_name&quot;:&quot;Frenkl&quot;},{&quot;first_name&quot;:&quot;Loise&quot;,&quot;last_name&quot;:&quot;N. Gichuru&quot;},{&quot;first_name&quot;:&quot;Sookhee&quot;,&quot;last_name&quot;:&quot;Ha&quot;},{&quot;first_name&quot;:&quot;Amanda&quot;,&quot;last_name&quot;:&quot;L. Hurley&quot;},{&quot;first_name&quot;:&quot;Nina&quot;,&quot;last_name&quot;:&quot;Jochnowitz&quot;},{&quot;first_name&quot;:&quot;Dorothy&quot;,&quot;last_name&quot;:&quot;Levorse&quot;},{&quot;first_name&quot;:&quot;Shruty&quot;,&quot;last_name&quot;:&quot;Mistry&quot;},{&quot;first_name&quot;:&quot;Randy&quot;,&quot;last_name&quot;:&quot;R. Miller&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;Ormes&quot;},{&quot;first_name&quot;:&quot;Gino&quot;,&quot;last_name&quot;:&quot;M. Salituro&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;Sanfiz&quot;},{&quot;first_name&quot;:&quot;Andra&quot;,&quot;last_name&quot;:&quot;S. Stevenson&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;Villa&quot;},{&quot;first_name&quot;:&quot;Beata&quot;,&quot;last_name&quot;:&quot;Zamlynny&quot;},{&quot;first_name&quot;:&quot;Stuart&quot;,&quot;last_name&quot;:&quot;Green&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Struthers&quot;},{&quot;first_name&quot;:&quot;Ann&quot;,&quot;last_name&quot;:&quot;E. Weber&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;609-623&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01372&quot;},&quot;abstract&quot;:&quot;The discovery of vibegron, a potent and selective human β3-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical β3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclinical species. Optimization of a series of second-generation pyrrolidine-derived β3-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclinical species. These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclinical profile compared to MK-0634. Structure–activity relationships leading to the discovery of vibegron and a summary of its preclinical profile are described.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01372&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01372" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01372&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01372" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01372&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01372" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01372&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01372&amp;href=/doi/10.1021/acs.jmedchem.5b01372" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01372" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01372" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01372%26sid%3Dliteratum%253Aachs%26pmid%3D26709102%26genre%3Darticle%26aulast%3DEdmondson%26date%3D2016%26atitle%3DDiscovery%2Bof%2BVibegron%253A%2BA%2BPotent%2Band%2BSelective%2B%25CE%25B23%2BAdrenergic%2BReceptor%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BOveractive%2BBladder%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D2%26spage%3D609%26epage%3D623%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/jmcmar.2016.59.issue-2/20160128/jmcmar.2016.59.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery of vibegron, a potent and selective human β<sub>3</sub>-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical β<sub>3</sub>-AR agonist MK-0634 (<b>3</b>) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclinical species. Optimization of a series of second-generation pyrrolidine-derived β<sub>3</sub>-AR agonists included reducing the risk for phospholipidosis, the risk of formation of disproportionate human metabolites, and the risk of formation of high levels of circulating metabolites in preclinical species. These efforts resulted in the discovery of vibegron, which possesses improved druglike properties and an overall superior preclinical profile compared to MK-0634. Structure–activity relationships leading to the discovery of vibegron and a summary of its preclinical profile are described.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06150" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06150" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the 1990s, β<sub>3</sub>-adrenergic receptor (β<sub>3</sub>-AR) agonists were investigated as potential treatments for obesity and/or diabetes owing to their ability to induce lipolysis, thermogenesis, and antihyperglycemic activity in preclinical species.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Although a number of compounds entered clinical studies, none demonstrated sustained efficacy in these therapeutic areas.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Moreover, many compounds also exhibited either suboptimal pharmacokinetic profiles and/or cardiovascular adverse effects that led to their discontinuation. Consequently, interest in β<sub>3</sub>-AR agonists for the treatment of obesity and/or diabetes waned. Within the last 15 years, however, evidence for the presence of the β<sub>3</sub>-AR on human and rat detrusor muscles has emerged,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and in vitro studies demonstrated that selective β<sub>3</sub>-AR agonists cause relaxation of isolated rat and human detrusor muscle strips.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> Moreover, compelling in vivo evidence also supports a role for β<sub>3</sub>-AR agonists to increase bladder capacity in anesthetized rats and dogs.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a></div><div class="NLM_p">Overactive bladder (OAB) is a chronic and sometimes debilitating condition of the lower urinary tract that negatively impacts the quality of life of millions of people worldwide.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> A large international survey published in 2006 estimated the prevalence of OAB to be ∼12%.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> As OAB prevalence increases with age, it is likely that the prevalence of OAB will continue to increase in the future due to an aging population. Muscarinic antagonists (anticholinergics) were the standard-of-care pharmacotherapy of OAB for decades, and these drugs have demonstrated improvements in urgency, frequency of micturition, and urge incontinence, all of which are primary symptoms of OAB. Unfortunately, blockade of the M3 muscarinic receptor can lead to adverse effects such as dry mouth and constipation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These adverse effects can be mitigated somewhat by reducing <i>C</i><sub>max</sub> with the use of extended release formulations and by improving the muscarinic receptor selectivities.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Nevertheless, there is still a high discontinuation rate for the use of antimuscarinic agents and, therefore, an unmet medical need for a pharmacological agent that can treat the symptoms of OAB with an improved overall side-effect profile.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Consequently, efforts to discover potent and selective β<sub>3</sub>-AR agonists as potential new treatments for OAB have been reinvigorated in recent years.<a onclick="showRef(event, 'ref5 ref15'); return false;" href="javascript:void(0);" class="ref ref5 ref15">(5, 15)</a> Mirabegron (<b>1</b>) and solabegron (<b>2</b>) entered clinical trials, and <b>1</b> was approved in 2012 for the treatment of OAB at a dose of 25 mg once-daily (QD) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Patients may be titrated up to a dose of 50 mg QD as needed, but the dose escalation is not recommended for patients with renal or hepatic impairment.<a onclick="showRef(event, 'cit16b'); return false;" href="javascript:void(0);" class="ref cit16b">(16b)</a> Furthermore, compound <b>1</b> inhibits CYP2D6 and therefore codosing with substrates of CYP2D6 is cautioned. Meanwhile, compound <b>2</b> was safe, well-tolerated, and effective in the treatment of women with OAB in a Phase 2 study at doses of 125 and 50 mg dosed twice-daily (BID).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of β<sub>3</sub>-AR agonists that entered clinical trials for OAB.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">MK-0634 (<b>3</b>) is a potent and selective β<sub>3</sub>-AR agonist that progressed into clinical studies for the treatment of obesity in the early 2000s.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a> Efficacy for treatment of obesity was not achieved, however, and the compound was instead pursued for the treatment of OAB, where it demonstrated proof-of-concept in humans. Reduction in the number of daily micturitions after 8 weeks of once-daily dosing in patients with symptoms of OAB was the primary endpoint of the Phase 2 study, and dose-dependent reductions compared to placebo of 0.85, 1.14, and 1.20 were observed at doses of 50, 125, and 375 mg, respectively. Reductions in secondary endpoints such as episodes of strong urge, urge incontinence, and total incontinence per day were also observed. In a cross-study comparison, the efficacy of <b>3</b> appeared similar or superior to that of the antimuscarinic agent Detrol-LA after 12 weeks of treatment (reduction of micturitions per day is reported as 0.6 for Detrol-LA).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Importantly, there was also a low rate of prevalence of dry mouth for <b>3</b> in these studies, in contrast to Detrol-LA in trials of similar duration.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The overall profile of <b>3</b> was promising, and the team therefore began preparations for continued clinical development.</div><div class="NLM_p">Compound <b>3</b> was initially identified as a development candidate in the late 1990s when it differentiated itself from previously reported β<sub>3</sub>-AR agonists by exhibiting (a) potent agonism at the human β<sub>3</sub>-AR, thus overcoming the rodent selectivity of previous β3-AR agonists, and (b) improved oral bioavailability across species in comparison to many of the previously reported β<sub>3</sub>-AR agonists.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This compound also possesses many physicochemical properties that have been linked to clinical attrition including high molecular weight, high lipophilicity, more than three aromatic rings, and poor solubility.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Compound <b>3</b> was metabolized in humans primarily by oxidative metabolism and possessed high unbound clearance. Metabolism was primarily CYP3A4-mediated, and consequently <b>3</b> suffered from a drug–drug interaction when codosed with ketoconazole in which the exposure of <b>3</b> was increased by approximately sixfold. Continued development of <b>3</b> was potentially delayed, however, because of the need to perform bridging safety studies in preclinical species to achieve sufficient exposure coverage of a human-specific metabolite that accumulated after multiple days of dosing in humans. Ultimately, the development of <b>3</b> was discontinued due to structure-based toxicities in preclinical species. In addition to these toxicity findings, treatment of <b>3</b> to rats, dogs, and monkeys resulted in drug-induced phospholipidosis in multiple-dose toxicology studies. Finally, several metabolites arising from oxidative cleavage of the C–N bonds at either side of the secondary amine were found to be circulating at high levels in preclinical safety studies.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Many of the liabilities associated with <b>3</b> are likely linked to its poor physicochemical properties, including long-lived metabolites derived from the lipophilic polyaromatic right-hand side of the molecule. However, the relationship between the toxicities observed in preclinical species and the high levels of circulating metabolites or phospholipidosis is unclear. Nevertheless, to address the liabilities associated with <b>3</b>, a back-up β<sub>3</sub>-AR agonist program was initiated to discover a compound with improved physicochemical properties with the potential to be a best-in-class β<sub>3</sub>-AR agonist.</div><div class="NLM_p">A key discovery for the back-up program was a novel pyrrolidine scaffold (<b>4</b>) that blocked the major site of metabolism of <b>3</b> and eliminated metabolites associated with oxidative cleavage of the secondary C–N amine linkage (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Data indicating a genotoxicity risk associated with the aminothiazole moiety of <b>4</b> prompted a search for a suitable replacement of the aminothiazole group, and thiazole <b>5</b> and pyrazole <b>6</b> were identified as potent β<sub>3</sub>-AR agonists with excellent preclinical ADME (absorption, distribution, metabolism, and excretion) profiles.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Extensive evaluation of off-target selectivities of <b>5</b> and <b>6</b> revealed moderate selectivity over the serotonin transporter (SERT, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), and further optimization was necessary to identify a suitable clinical candidate. This manuscript will describe structure–activity relationships (SARs) in a series of 6-membered ring heteroaryl N-linked acetamides that address the liabilities associated with <b>5</b> and <b>6</b> to ultimately afford vibegron (<b>7</b>, MK-4618), which successfully progressed through preclinical toxicity studies and into Phase 3 clinical trials. A comparison of the overall properties of compounds <b>3</b> and <b>7</b> are also presented in this manuscript.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of second-generation pyrrolidine-based β<sub>3</sub>-AR agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60248" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60248" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Final compounds were prepared by simple amide bond coupling reactions between anilines <b>8a/b</b><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and a series of heteroaryl-substituted acetic acid derivatives such as commercially available 4-oxo-3(4<i>H</i>)-quinazolineacetic acid (<b>9</b>, W and X = fused phenyl; Y and Z = H), 2-(2-oxopyridin-1(2<i>H</i>)-yl)acetic acid (<b>10</b>, W, X, Y, and Z = H), or the novel acetic acid derivatives <b>11</b>–<b>16</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). In cases where a chiral center was adjacent to the carbonyl group, chiral chromatography was used to isolate the desired <i>S</i> stereoisomers. The resulting optically pure amides were then deprotected under acidic conditions to afford <b>17</b>–<b>24</b> and <b>7</b>. Verification of the stereochemical configuration of <b>7</b> was obtained through small-molecule X-ray crystallography (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis Route to Six-Membered Ring Targets<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) EDC, HOAt, Hünig’s Base, dimethylformamide (DMF); (b) chiral HPLC separation; (c) trifluoroacetic acid (TFA), dichloromethane (DCM).</p></p></figure><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ORTEP diagram of compound <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Novel substituted acetic acid coupling partners were synthesized by a variety of methods described in <a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a>–<a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Commercially available chloropyridazine acetic acid <b>25</b> underwent hydrogenolysis to remove the chlorine to afford <b>11</b>. A series of 2-oxopyridine-based heterocycles <b>28</b> underwent smooth S<sub>N</sub>2 reactions with either chloroacetic acid (<b>26</b>) or α-bromopropanoic acid (<b>27</b>) to afford substituted acetic acids <b>12</b>–<b>14</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The fused pyridone acid intermediate <b>15</b> was generated from the known piperidone <b>29</b><a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> by oxidation to form the pyridone ring followed by ester hydrolysis to give the carboxylic acid product (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The synthesis of pyrimidone <b>16</b> began by formation of the methyl imidate <b>31</b> from the reaction of dimethylsulfate with lactam <b>30</b>. Meanwhile, [2 + 2] cycloaddition between norbornadiene (<b>32</b>) and chlorosulfonylisocyanate followed by hydrolysis of the chlorosulfonyl group affords β-lactam <b>33</b>, which underwent condensation with <b>31</b> to afford <b>34</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). When heated to 150 °C, compound <b>34</b> underwent a retro-Diels–Alder reaction, and after hydrolysis of the methyl ester, the enantiomerically enriched pyrimidone acid <b>16</b> was obtained.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of RHS Carboxylic Acid Intermediates <b>10–14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) H<sub>2</sub>, 10% Pd/C, MeOH; (b) 5N NaOH, Δ.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Fused Pyridone <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, Δ; (b) LiOH<sub>aq</sub>, tetrahydrofuran (THF).</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Fused Pyrimidinone <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) (MeO)<sub>2</sub>SO<sub>2</sub>; (b) (OCN)SO<sub>2</sub>Cl; (c) Na<sub>2</sub>SO<sub>3</sub>; (d) 110 °C; (e) 150 °C; (f) LiOH, H<sub>2</sub>O, MeOH.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Final compounds were evaluated for β<sub>3</sub>-AR agonism by measuring their ability to stimulate increases in intracellular cyclic adenosine monophosphate (cAMP) in Chinese hamster ovary (CHO) cell lines stably expressing the human (or other species) β<sub>3</sub>-AR (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Selectivity over β<sub>1</sub>- and β<sub>2</sub>-ARs was assessed by measuring the binding affinity of compounds for these receptors using membranes prepared from recombinant cells expressing either β<sub>1</sub>- or β<sub>2</sub>-AR.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Selectivities for promising compounds were also routinely assessed over a panel of cardiac ion channels<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> including hERG, hCa<sub>v</sub>1.2, and hNa<sub>v</sub>1.5 as well as CYP3A4, CYP2D6, CYP2C9, and the human SERT.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To address the risk for phospholipidosis, an in vitro phospholipidosis assay was incorporated into the compound triage strategy to support compound progression. Compounds were assessed for their propensity to induce the uptake of a fluorescently labeled probe compound, and their potencies were compared to that of the known phospholipidogenic compound amiodarone.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The relative potencies of compounds to induce phospholipidosis (PLDS) were calculated by determining the concentration of test compounds that produce the same normalized fluorescence response as half the response of amiodarone at 10 μM (<i>A</i><sub>50</sub>). To identify improved compounds compared to <b>3</b> (<i>A</i><sub>50</sub> = 560 nM), the team sought to identify compounds with <i>A</i><sub>50</sub>’s > 20 000 nM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Results for Six-Membered Ring RHS Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center" char="±">hEC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> (% Act)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">hIC<sub>50</sub>’s<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> (μM)</th><th class="rowsep1 colsep0" colspan="2" align="center">physical properties</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">W</th><th class="colsep0 rowsep0" align="center">V</th><th class="colsep0 rowsep0" align="center" char="±">β<sub>3</sub></th><th class="colsep0 rowsep0" align="center">β<sub>1</sub></th><th class="colsep0 rowsep0" align="center">β<sub>2</sub></th><th class="colsep0 rowsep0" align="center">cLogD<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">Log <i>D</i><a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.5 (93)</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">0.67</td><td class="colsep0 rowsep0" align="center">4.6</td><td class="colsep0 rowsep0" align="center">4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.6 (92)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.0</td><td class="colsep0 rowsep0" align="center">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.7 (82)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.6</td><td class="colsep0 rowsep0" align="center">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 2.9 (84)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–2.0</td><td class="colsep0 rowsep0" align="center">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">C(CH)<sub>4</sub>C</td><td class="colsep0 rowsep0" align="center">C(CH)<sub>4</sub>C</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 1.4 (108)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">2.2</td><td class="colsep0 rowsep0" align="center">–0.1</td><td class="colsep0 rowsep0" align="center">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 1.3 (105)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.7</td><td class="colsep0 rowsep0" align="center">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">3.9 ± 1.8 (91)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.7</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.7 (113)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.5</td><td class="colsep0 rowsep0" align="center">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 2.3 (97)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.0</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.1 (92)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.3</td><td class="colsep0 rowsep0" align="center">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center">Me</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.5 (87)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–2.0</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CH<sub>2</sub>C</td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CH<sub>2</sub>C</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.12 (94)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–1.2</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CH<sub>2</sub>C</td><td class="colsep0 rowsep0" align="center">CH<sub>2</sub>CH<sub>2</sub>C</td><td class="colsep0 rowsep0" align="center">N</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="center">CH</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.5 (84)</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center"> >20</td><td class="colsep0 rowsep0" align="center">–2.0</td><td class="colsep0 rowsep0" align="center">0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Unless otherwise noted, β<sub>3</sub> values reported in thi table are the mean from a minimum of three experiments.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Percent activation defined as the fitted maximal value of the test compound concentration response expressed as a percent of the maximal response to <i>R</i>-(−)-isoproterenol.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Single diastereoisomer with only more potent isomer indicated.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">The algorithm used to calculate cLogD is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01372/suppl_file/jm5b01372_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Log <i>D</i> measurements were performed at pH = 7.4.</p></div></div></div><div class="NLM_p">An early disclosure from our laboratories described SAR around a series of acetanilides in a linear (nonpyrrolidine) series including a group of N-linked quinolone/isoquinolone acetamides.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Introduction of an N-linked isoquinolone acetamide onto the pyrrolidine scaffold afforded <b>17</b>, which exhibited excellent potency at human β<sub>3</sub>-AR (EC<sub>50</sub> = 1.7 nM) and >1000-fold selectivity over human β<sub>1</sub> and β<sub>2</sub>-ARs (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). This compound also possessed a risk for phospholipidosis (<i>A</i><sub>50</sub> = 8 600 nM) and insufficient selectivities over hERG (IC<sub>50</sub> = 2 000 nM) and SERT (IC<sub>50</sub> = 200 nM, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). To improve selectivity and reduce the risk for phospholipidosis, the team pursued a design strategy to increase polarity by removing the fused phenyl group to afford pyridazinone <b>18</b>, pyrimidones <b>19</b> and <b>20</b>, and pyridone <b>21</b>. These compounds possessed lower cLogD and lower measured Log <i>D</i> values, which was expected to reduce the risk of phospholipidosis and off-target activities. All of these compounds possessed excellent β<sub>3</sub>-AR agonist potencies with EC<sub>50</sub>s between 1 and 5 nM. Selectivities over β<sub>1/2</sub>-ARs and the cardiac ion channel panel were also uniformly excellent (>1000-fold) as were their phospholipidosis <i>A</i><sub>50</sub>’s. With respect to SERT, however, only pyrimidone <b>20</b> exhibited >1000-fold selectivity, and most analogues exhibited SERT IC<sub>50</sub>’s in the low micromolar range. Nevertheless, the reduced lipophilicity of compounds <b>18</b>–<b>21</b> compared to <b>17</b> translated to improved selectivities over hERG and SERT and a reduced risk for phospholipidosis. To further improve selectivity over SERT, the team focused on improving potency at β<sub>3</sub>-AR.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selectivities of Selected Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0014.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">P450 inhibition IC<sub>50</sub>’s<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (μM)</th><th class="rowsep1 colsep0" colspan="3" align="center">ion channel IC<sub>50</sub>’s (μM)</th><th class="rowsep1 colsep0" align="center">SERT</th><th class="rowsep1 colsep0" align="center">PLDS</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">2C9</th><th class="colsep0 rowsep0" align="center">2D6</th><th class="colsep0 rowsep0" align="center">3A4</th><th class="colsep0 rowsep0" align="center">hERG<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">hCa<sub>v</sub>1.2<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">hNa<sub>v</sub>1.5<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>A</i><sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">24</td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">9.3</td><td class="colsep0 rowsep0" align="center">0.22</td><td class="colsep0 rowsep0" align="center">1.7</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">5.0</td><td class="colsep0 rowsep0" align="center">0.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center">2.2</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center">19</td><td class="colsep0 rowsep0" align="center">8.2</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center">79</td><td class="colsep0 rowsep0" align="center">  >100</td><td class="colsep0 rowsep0" align="center">6.1</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">0.42</td><td class="colsep0 rowsep0" align="center">79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">0.90</td><td class="colsep0 rowsep0" align="center">94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center">31</td><td class="colsep0 rowsep0" align="center">96</td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">0.20</td><td class="colsep0 rowsep0" align="center">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">4.4</td><td class="colsep0 rowsep0" align="center">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">0.70</td><td class="colsep0 rowsep0" align="center"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center">39</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">0.80</td><td class="colsep0 rowsep0" align="center"> >100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center">7.1</td><td class="colsep0 rowsep0" align="center">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >100</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >30</td><td class="colsep0 rowsep0" align="center"> >10</td><td class="colsep0 rowsep0" align="center"> >70</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Human liver microsome P450 marker enzyme activities with diclofenac α′-hydroxylation for 2C9, dextromethorphan <i>O</i>-demethylation for 2D6, and testosterone 6β-hydroxylation for 3A4.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">IKr binding assay, ref <a onclick="showRef(event, 'cit30a'); return false;" href="javascript:void(0);" class="ref cit30a">30a</a>.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Binding assay with [<sup>3</sup>H]-diltiazem, ref <a onclick="showRef(event, 'cit30b'); return false;" href="javascript:void(0);" class="ref cit30b">30b</a>.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Reference <a onclick="showRef(event, 'cit30c'); return false;" href="javascript:void(0);" class="ref cit30c">30c</a>.</p></div></div></div><div class="NLM_p">A previous study on conformationally restricted acetanilides revealed that α-substitution improved β<sub>3</sub>-AR potency, especially α-methyl groups and fused 5-membered rings.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Incorporation of conformationally restricted methyl acetanilides <b>22</b> and <b>23</b> and conformationally locked 5-membered ring acetanilides <b>24</b> and <b>7</b> resulted in modest improvements on β<sub>3</sub>-AR potency while maintaining excellent selectivity over β<sub>1/2</sub>-ARs, cardiac ion channels, and phospholipidosis <i>A</i><sub>50</sub>’s. A matched-pair comparison of the left-hand side (LHS) phenyl derivative <b>22</b> with a LHS pyridine derivative <b>23</b> showed that <b>22</b> possesses superior selectivity over SERT compared to <b>23</b>. Both of the phenyl-bearing conformationally locked 5-membered ring derivatives <b>24</b> and <b>7</b> exhibited excellent selectivity over SERT.</div><div class="NLM_p">Representative compounds were evaluated in preclinical pharmacokinetics studies (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). The 2-pyrimidone derivative <b>20</b> and the LHS pyridine derivative <b>23</b> both exhibited low oral bioavailabilities in rats (<i>F</i> ≤ 1%) while the LHS phenyl derivatives <b>18</b>, <b>22</b>, <b>24</b>, and <b>7</b> all exhibited modest oral bioavailabilities in rats (rat <i>F</i> = 10–21%). Bioavailabilities of these compounds were higher in dogs and monkeys. Half-lives in preclinical species for <b>18</b>, <b>22</b>, <b>24</b>, and <b>7</b> were all in acceptable ranges, and the unbound clearances were generally low. The overall selectivity and preclinical pharmacokinetic (PK) profiles of these four compounds were superior to other compounds in the series, and consequently they were selected for more extensive ADME characterization.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Mean Pharmacokinetic Parameters of Selected β<sub>3</sub> Adrenergic Agonists in Non-Clinical Species<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">Cl<sub>p</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center">Cl<sub>u</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">PO AUC<sub>N,total</sub> (nM·h/mpk)</th><th class="colsep0 rowsep0" align="center">PO AUC<sub>N</sub>,<sub>u</sub> (nM·h/mpk)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center">% unbound</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="center"> >3100</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="center">70</td><td class="colsep0 rowsep0" align="center"> ≤1</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center"> ≤2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="center"> >1000</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="center">290</td><td class="colsep0 rowsep0" align="center"> ≤6</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center"> ≤2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rhesus</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="center"> >950</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center"> ≤1</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center"> ≤2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="center">67</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="center">590</td><td class="colsep0 rowsep0" align="center">212</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="center">49</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="center">1680</td><td class="colsep0 rowsep0" align="center">1176</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rhesus</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="center">36</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="center">148</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="center">66</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="center">1200</td><td class="colsep0 rowsep0" align="center">612</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rhesus</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="center">820</td><td class="colsep0 rowsep0" align="center">517</td><td class="colsep0 rowsep0" align="center">46</td><td class="colsep0 rowsep0" align="center">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="center">24</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="center">180</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="center">59</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="center">290</td><td class="colsep0 rowsep0" align="center">113</td><td class="colsep0 rowsep0" align="center">91</td><td class="colsep0 rowsep0" align="center">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rhesus</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="center">46</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="center">300</td><td class="colsep0 rowsep0" align="center">213</td><td class="colsep0 rowsep0" align="center">29</td><td class="colsep0 rowsep0" align="center">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="center"> <LOQ</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> <1</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="center">110</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="center">67</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="center">540</td><td class="colsep0 rowsep0" align="center">113</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="center">37</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="center">1200</td><td class="colsep0 rowsep0" align="center">490</td><td class="colsep0 rowsep0" align="center">44</td><td class="colsep0 rowsep0" align="center">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rhesus</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="center">540</td><td class="colsep0 rowsep0" align="center">260</td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">cyno</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="center">870</td><td class="colsep0 rowsep0" align="center">500</td><td class="colsep0 rowsep0" align="center">46</td><td class="colsep0 rowsep0" align="center">58</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Dose; rat iv: 1 mpk (milligrans per kilogram), po: 2 mpk; dog/monkey iv: 0.5 mpk, po: 2 mpk.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Data taken from ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">26</a>.</p></div></div></div><div class="NLM_p">Evaluation of <b>18</b>, <b>22</b>, <b>24</b>, and <b>7</b> in cross-species liver microsome intrinsic clearance and plasma stability studies revealed low recovery of parent for <b>18</b> in human plasma but not in rat, dog, or rhesus plasma (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Acetamides <b>5</b> and <b>6</b> also exhibited poor stability in human plasma, and LC-MS analysis of compound <b>18</b> incubated with plasma over 24 h revealed that the central amide bond was undergoing hydrolytic cleavage, presumably due to hydrolase enzymes present in human plasma but not in plasma from preclinical species. All compounds demonstrated low intrinsic clearance in human liver microsome incubations, although <b>5</b>, <b>6</b>, and <b>22</b> exhibited moderate intrinsic clearance in rhesus microsomes. The instability in human plasma revealed a risk for formation of disproportionate human metabolites for compounds <b>5</b>, <b>6</b>, and <b>18</b> and, thus, a potential lack of sufficient coverage of these metabolites in preclinical toxicity studies. Additionally, the poor stability in human plasma also contributed to additional uncertainty in human PK predictions. On the other hand, compounds <b>22</b>, <b>24</b>, and <b>7</b> exhibited low intrinsic clearance in human microsomes and good stability in human plasma and, thus, were viewed as lower risk for further development compared to <b>18.</b></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Intrinsic Clearance of Compounds in Liver Microsomes and Plasma Stability</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">intrinsic clearance (mL/min/kg body weight)</th><th class="rowsep1 colsep0" colspan="4" align="center">plasma stability (% parent at 24 h)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">rhesus</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">rhesus</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="center"> <10</td><td class="colsep0 rowsep0" align="center"> <15</td><td class="colsep0 rowsep0" align="center"> <10</td><td class="colsep0 rowsep0" align="center">205</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">79</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center">19</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="center">31</td><td class="colsep0 rowsep0" align="center">261</td><td class="colsep0 rowsep0" align="center">0</td><td class="colsep0 rowsep0" align="center">97</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center"> <10</td><td class="colsep0 rowsep0" align="center"> <15</td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center"> <10</td><td class="colsep0 rowsep0" align="center">26</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">31</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">77</td><td class="colsep0 rowsep0" align="center">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="center">19</td><td class="colsep0 rowsep0" align="center">29</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">137</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">92</td><td class="colsep0 rowsep0" align="center">92</td><td class="colsep0 rowsep0" align="center">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center"> <10</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">93</td></tr></tbody></table></div></div><div class="NLM_p">In a large panel of >100 off-target binding assays, compounds <b>18</b>, <b>22</b>, <b>24</b>, and <b>7</b> all exhibited binding to the serotonin transporter (SERT); however, follow-up in the SERT functional assay (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) demonstrated >800-fold selectivities. Compounds <b>18</b> and <b>7</b> possessed no additional off-target activities, and additional off-target activities were generally weak for <b>22</b> (rat choline transporter IC<sub>50</sub> = 2.3 μM) and <b>24</b> (human dopamine transporter IC<sub>50</sub> = 4.8 μM). Although compounds <b>24</b> and <b>7</b> were similar in potency at human β<sub>3</sub>-AR and overall ADME properties, compound <b>7</b> was less lipophilic than <b>24</b>, possessed a reduced risk for phospholipidosis, and possessed fewer off-target liabilities. Consequently, compound <b>7</b> was selected for further characterization.</div><div class="NLM_p">Compounds <b>3</b>, <b>18</b>, <b>22</b>, and <b>7</b> were evaluated in cross-species β<sub>3</sub>-AR agonism assays in buffer and in the presence of 40% serum in comparison to <b>3</b> (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Large species disconnects for potent β<sub>3</sub>-AR agonists have been reported previously, and these compounds all demonstrated divergent potencies between human and rat β<sub>3</sub>-ARs but similar potencies between human and nonhuman primate β<sub>3</sub>-ARs.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref33'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref33">(1-4, 33)</a> Compound <b>3</b> lacked sufficient potency at the rat β<sub>3</sub>-AR for in vivo assessment in this species, although this compound was potent at the rhesus β<sub>3</sub>-AR. The rat β<sub>3</sub>-AR EC<sub>50</sub>’s for <b>18</b>, <b>22</b>, and <b>7</b> were sufficiently potent to assess them in a rat acetic-acid-induced bladder hyperactivity model.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> In this rat model, each of these compounds exhibited dose-dependent decreases in micturition pressure and increases in functional bladder capacity, which are indirect measures of detrusor muscle relaxation (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Each compound demonstrated bladder effects with a similar magnitude and at similar unbound plasma levels relative to potency.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. β<sub>3</sub>-AR Activity of Selected Compounds in Different Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">EC<sub>50</sub><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> (nM) (%Act)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="3" align="center">EC<sub>50</sub> (nM) + 40% serum<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (%Act)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">rhesus</th><th class="colsep0 rowsep0" align="center">human</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">rhesus</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">2.0 (93)</td><td class="colsep0 rowsep0" align="center">3400 (17)</td><td class="colsep0 rowsep0" align="center">25 (80)</td><td class="colsep0 rowsep0" align="center">0.43 (81)</td><td class="colsep0 rowsep0" align="center">7.9 (106)</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">17 (102)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">4.8 (105)</td><td class="colsep0 rowsep0" align="center">615 (79)</td><td class="colsep0 rowsep0" align="center">47 (87)</td><td class="colsep0 rowsep0" align="center">3.5 (91)</td><td class="colsep0 rowsep0" align="center">5.9 (96)</td><td class="colsep0 rowsep0" align="center">1064 (99)</td><td class="colsep0 rowsep0" align="center">NT<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="center">2.7 (92)</td><td class="colsep0 rowsep0" align="center">531 (85)</td><td class="colsep0 rowsep0" align="center">39 (86)</td><td class="colsep0 rowsep0" align="center">2.5 (91)</td><td class="colsep0 rowsep0" align="center">2.1 (98)</td><td class="colsep0 rowsep0" align="center">245 (83)</td><td class="colsep0 rowsep0" align="center">12 (91)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center">1.1 (84)</td><td class="colsep0 rowsep0" align="center">86 (83)</td><td class="colsep0 rowsep0" align="center">11 (82)</td><td class="colsep0 rowsep0" align="center">0.57 (87)</td><td class="colsep0 rowsep0" align="center">1.6 (101)</td><td class="colsep0 rowsep0" align="center">122 (89)</td><td class="colsep0 rowsep0" align="center">7.1 (103)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Unless otherwise noted, values reported are the minimum of six experiments with a standard deviation <25% of the mean.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">% Activation defined as the fitted maximal value of the test compound concentration response expressed as a percent of the maximal response to <i>R</i>-(−)-isoproterenol.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Serum from the species tested was used for these measurements.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">NT = not tested.</p></div></div></div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of intravenous (iv) dosed compounds <b>18</b>, <b>22</b>, and <b>7</b> on (A) functional bladder capacity and (B) micturition pressure in the acetic-acid-induced bladder hyperreflexia model. Percent of baseline was calculated as ratio of predose values. Mean + SEM <i>N</i> = 5–7 per group. *<i>P</i> < 0.05, **<i>P</i> < 0.01, Dunnett’s multiple comparison test. Unbound drug concentrations at the doses tested are noted in the bars in panel A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, both <b>1</b> and <b>7</b> were further evaluated for their ability to activate β<sub>3</sub>-ARs on adipocytes through monitoring lipolysis in rats as measured by increases in circulating glycerol and free fatty acid levels after oral administration (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(36)</a> A dose-dependent increase in glycerol and free fatty acids (FFAs) was observed with a minimum effective dose of 0.3 mg/kg. Doses of <b>7</b> that decreased micturition pressure and/or increased bladder capacity in rats also induced increases in circulating glycerol and free fatty acids in rats. The minimum effective dose (MED) for increases in glycerol and FFAs in rats was 0.3–1 mg/kg for compound <b>7</b>, which is lower than the MEDs for bladder relaxation in this species. Compound <b>1</b>, which exhibits in vivo effects on the rat bladder consistent with <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>,<a onclick="showRef(event, 'cit8b'); return false;" href="javascript:void(0);" class="ref cit8b">(8b)</a> also induced dose-dependent increases in plasma glycerol and FFAs in rats with a maximal effect similar to compound <b>7</b>.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>1</b> and <b>7</b> on plasma glycerol (A) and FFA (B) levels in anesthetized rats. Each plot represents mean ± SEM <i>N</i> = 4–5 per group. *<i>P</i> < 0.05, **<i>P</i> < 0.01, Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The overall potency, selectivity, in vivo efficacy, and ADME profile of <b>7</b> supported progression of this compound into a more advanced series of ADME studies. After P.O. dosing of [<sup>3</sup>H]-<b>7</b> to bile duct cannulated (BDC) rats, approximately 32 and 36% of radioactivity was recovered in urine and bile, respectively (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). After intravenous (iv) dosing to BDC rats, an average of 13% of the dose was recovered in feces. The metabolite profiles after oral and iv administration were similar, and the parent compound accounted for 87, 56, and 96% of the radioactivity recovered in urine, bile, and feces following iv dosing, respectively. These data indicate that renal, biliary, and intestinal excretion of unchanged <b>7</b> were the major routes of elimination in rats, while metabolism accounted for ∼24% after an iv dose. The major biotransformation pathways for [<sup>3</sup>H]-<b>7</b> based on metabolite profiles in vitro (liver microsomes and hepatocytes) and in vivo (rat plasma, bile, and urine) were evaluated on the basis of LC/MS/MS fragmentation patterns. There were no human-specific metabolites when compared to the nonclinical safety species. The major metabolite was a hydroxylated metabolite, which contributed 15% of the radioactivity in urine and up to 20% of the radioactivity in bile following oral dosing. The presence of multiple elimination pathways for <b>7</b> (metabolism, renal, biliary, and intestinal excretion) suggests that this compound may have a low risk to be a victim of a significant drug–drug interaction.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(37)</a></div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of compounds <b>3</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Total Recovery of Radioactivity after P.O. and iv Administration of [<sup>3</sup>H]-<b>7</b> to BDC Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">% radioactive dose recovered (0–48 h)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">route<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> and dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">urine</th><th class="colsep0 rowsep0" align="center">bile</th><th class="colsep0 rowsep0" align="center">feces</th><th class="colsep0 rowsep0" align="center">total</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P.O. 10<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">32 ± 5</td><td class="colsep0 rowsep0" align="center">36 ± 5</td><td class="colsep0 rowsep0" align="center">19 ± 2</td><td class="colsep0 rowsep0" align="center">87 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv 5<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">37</td><td class="colsep0 rowsep0" align="center">33</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">83</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Compound <b>7</b> was administered P.O. in 0.5% methylcellulose or by iv in ethanol/PEG400/acetate buffer (2:5:3).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Data expressed as the mean ± SD (<i>n</i> = 3 subjects) or average (<i>n</i> = 2).</p></div></div></div><div class="NLM_p">Compound <b>7</b> was also evaluated for its ability to inhibit a larger panel of cytochrome P450s, and the compound showed IC<sub>50</sub>’s > 100 μM against CYPs 1A2, 2B6, 2C8, and 2C19 in addition to the CYPs 3A4, 2D6, and 2C9 (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Additionally, <b>7</b> did not exhibit time-dependent inhibition of CYP3A4 up to 50 μM concentrations. Finally, compound <b>7</b> was assessed for its ability to cause CYP3A4 induction in human hepatocytes and did not cause an increase in mRNA or CYP3A4 activity at concentrations up to 10 μM. Moreover, <b>7</b> did not activate the PX receptor in vitro (EC<sub>50</sub> > 30 μM). The excellent selectivity over inhibition and induction of the CYPs tested suggests that compound <b>7</b> has a low risk to be a perpetrator of drug–drug interactions when coadministered with drugs metabolized by these enzymes.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(38)</a></div><div class="NLM_p">The free base of compound <b>7</b> forms a highly crystalline powder that possesses good solubility (>4 mg/mL in simulated gastric fluid, fed-simulated intestinal fluid, and fasted-simulated intestinal fluid, and buffers with various physiologically relevant pHs) as well as good physical and chemical stability under a variety of forced degradation conditions. Compound <b>7</b> possesses high solubility and low permeability based on LLC-PK1 cell monolayer data (<i>P</i><sub>app</sub> = 2.4 × 10<sup>–6</sup> cm/s compared to the highly permeable positive control verapamil with <i>P</i><sub>app</sub> = 39 × 10<sup>–6</sup> cm/s) and is therefore classified as a Biopharmaceutics Classification System (BCS) class III compound.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(39)</a></div><div class="NLM_p last">In extensive preclinical safety studies, data from the evaluation of compound <b>7</b> supported advancement into human clinical trials, including longer-duration Phase 3 clinical trials. The toxicity profile of this compound was well-characterized in a battery of in vitro and in vivo genetic toxicity studies; safety and ancillary studies; repeat-dose oral toxicity in mice, rats, and cynomolgus monkeys up to 3, 6, and 9 months, respectively; and reproductive and embryo-fetal developmental toxicity studies in rats and rabbits. Improvement in metabolite liabilities was achieved for compound <b>7</b> when compared to compound <b>3</b> based on appropriate metabolite coverage of human metabolites in preclinical species exposed to compound <b>7</b>. At adequate margins to support continued development, no unacceptable toxicity in preclinical species occurred, and no histomorphologic changes morphologically consistent with phospholipidosis were observed at any dose in any tissue over the preclinical development program up to 6-month (rat) and 9-month (monkey) oral toxicity studies. Data from these toxicity studies supported advancement of compound <b>7</b> into human clinical trials. Compound <b>7</b> is currently in Phase 3 human clinical trials for the treatment of OAB.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, we described the optimization of a pyrrolidine-derived amide series of β<sub>3</sub>-AR agonists to afford <b>7</b>, currently under development in human clinical trials for the treatment of OAB. Liabilities associated with our first-generation clinical β<sub>3</sub>-AR agonist <b>3</b> include the disproportionate formation of human metabolites, high levels of circulating metabolites in preclinical species, a drug–drug interaction (DDI) with ketoconazole, and structure-based toxicity in preclinical species. A medicinal chemistry design strategy that focused on improving physicochemical properties within the pyrrolidine amide lead class helped guide the medicinal chemistry team to optimize this second generation of β<sub>3</sub>-AR agonists toward less lipophilic, lower molecular weight (MW) compounds with greater solubility and reduced unbound clearance. Additionally, the series was more selective and exhibited a reduced risk for phospholipidosis in preclinical species compared to <b>3</b>. Furthermore, a careful evaluation of cross-species in vitro metabolite formation in microsomes as well as plasma helped reduce the risk for formation of disproportionate human metabolites with <b>7</b>. Moreover, a detailed ADME analysis of <b>7</b> in rats suggests that this compound will have a low overall risk of being a perpetator or a victim of drug–drug interactions, thus supporting the development of this compound in patient populations already taking other medications. The overall preclinical toxicity and ADME profile for <b>7</b> compared to <b>3</b> underscores advances made in drug discovery over the past decade to improve developability by focusing on improving physicochemical properties of molecules. Compared to <b>3</b>, <b>7</b> is lower molecular weight, more hydrophilic (lower cLogD and Log <i>D</i>), possesses fewer aromatic rings, and exhibits increased solubility (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Consequently, <b>7</b> is more selective than <b>3</b> over counterscreens, possesses reduced unbound clearance in preclinical species, does not induce phospholipidosis, and exhibited an overall improved preclinical toxicity profile. These improvements in physicochemical properties are consistent, therefore, with changes that translated into improved developability of <b>7</b> compared to <b>3</b>.<a onclick="showRef(event, 'ref22 ref23 ref40'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref40">(22, 23, 40)</a></div><div class="NLM_p">The ability to maintain excellent selectivity for activation of β<sub>3</sub>-AR over binding to β<sub>1</sub>- and β<sub>2</sub>-ARs with <b>7</b> is noteworthy. Although X-ray crystal structures of β<sub>1</sub>-AR and/or β<sub>2</sub>-AR were not used to optimize selectivity over these antitargets,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> a preliminary model of a potential binding mode of <b>7</b> with the human β<sub>3</sub>-AR (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) based on homology modeling with a β<sub>2</sub>-AR X-ray structure suggests that the pyrrolidine ring nitrogen of <b>7</b> may interact with Asp117, similar to ethanolamine ligands that bind to β<sub>1</sub>- and β<sub>2</sub>-ARs. The excellent selectivity of <b>7</b> over these antitargets may arise from differences in the orientation of the upper transmembrane helices (TMs) and extracellular loop 3 (EC3). In particular, Valine 205 of β<sub>3</sub>-AR replaces an alanine residue in β<sub>1</sub>- and β<sub>2</sub>-ARs. Although Val205 in β<sub>3</sub>-AR makes a hydrophobic contact with the ring, this hydrophobic interaction decreases in β<sub>1</sub>- and β<sub>2</sub>-ARs with Ala. Additionally, in the β<sub>3</sub>-AR Ala197 is located proximal to the carbonyl group of the aniline amide of <b>7</b>, but in β<sub>1</sub>- and β<sub>2</sub>-ARs a corresponding Asp makes unfavorable interactions with this carbonyl group with respect to both electrostatic interactions and size. The excellent potency exhibited by compounds in the pyrrolidine series may arise in part from a reduction of the rotational degrees of freedom imparted by the pyrrolidine ring to fix the orientation of the two substituent “arms” into the appropriate binding/activation conformation of hβ<sub>3</sub>-AR. The larger hydrophobic agonist <b>3</b> also shows excellent intrinsic potency at hβ<sub>3</sub>-AR, and we speculate that the excellent potency may arise from the reduction in entropy due to displacement of unordered water molecules from the binding site by the large hydrophobic triaryl moiety of this compound.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Preliminary docking of compound <b>7</b> with the human β<sub>3</sub>-AR based on the β<sub>2</sub>-AR crystal structure (EC = extracellular loop, TM = transmembrane helices).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>7</b> also possesses potential advantages over compounds <b>1</b> and <b>2</b>, which have been studied in humans for the treatment of OAB. Due to its excellent selectivity profile over CYP inhibition/induction, compound <b>7</b> is not likely to be a perpetrator of DDIs in humans, which would positively differentiate <b>7</b> from compound <b>1</b>, which is reported to be a moderate CYP2D6 inhibitor.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Additionally, compound <b>7</b> exhibits an overall drug metabolism and pharmacokinetic (DMPK) profile that supports QD dosing in humans, thus offering a potential advantage over compound <b>2</b>, which was reported to afford efficacy in OAB patients with BID dosing in a Phase 2 study.</div><div class="NLM_p last">In rats, <b>7</b> increases bladder capacity and decreases micturition pressure, both indicators of increased relaxation of the rat detrusor muscle. Compound <b>7</b> also induced lipolysis in rats at doses that induce bladder pharmacodynamics effects, suggesting that lipolytic readouts may serve as a surrogate target engagement readout for β<sub>3</sub>-AR engagement in the bladder. Caution must be exercised, however, when comparing the effects of compounds in distinct tissue beds, especially after only a single dose.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> In summary, this manuscript describes the discovery of <b>7</b>—a potential best-in-class β<sub>3</sub>-AR agonist for the treatment of OAB. Further studies on the preclinical and clinical pharmacology of <b>7</b> will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General</h3><div class="NLM_p">Unless otherwise stated, all reactions were carried out under an atmosphere of dry argon or nitrogen in dried glassware. Indicated reaction temperatures refer to those of the reaction bath, while room temperature (rt) is noted as 25 °C. All solvents and reagents were obtained from commercial sources and were used as received. Analytical thin layer chromatography (TLC) was performed with Whatman TLC plates (Partisil K6F, 60 Å, 250 μm). Visualization was accomplished by irradiation under a 254 nm UV lamp. Chromatography on silica gel was performed using forced flow (liquid) of the indicated solvent system on either a Biotage Horizon flash chromatography system or a Teledyne ISCO Combiflash Companion flash chromatography system. If needed, products were purified by reverse-phase chromatography, which was performed using a Gilson purification system employing a YMC Pro-Pac C18 column (5 μm, 20 × 100 mm). The mobile phase was a mixture of acetonitrile and H<sub>2</sub>O, each containing 0.1% trifluoroacetic acid. If needed, products were purified by preparative TLC on silica gel precoated 20 × 20 cm 1000 μm from Analtech. <sup>1</sup>H NMR spectra were recorded on a Varian Unity Inova AS500 500 MHz spectrometer. Chemical shifts are reported in ppm with the solvent resonance as the internal standard (CDCl<sub>3</sub> 7.26 ppm, dimethyl sulfoxide (DMSO-<i>d</i><sub>6</sub>) 2.49 ppm, CD<sub>3</sub>OD 3.34 ppm, respectively). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, br = broad, m = multiplet), coupling constants, and number of protons. Low-resolution mass spectra (electrospray ionization) were acquired on a Waters Micromass ZQ2000 quadrupole spectrometer coupled to a high-performance liquid chromatography (HPLC) system. High-resolving power accurate mass measurements were acquired by use of a Bruker Daltonics 7T Fourier transform ion cyclotron resonance (FTICR) mass spectrometer. Samples were dissolved in acetonitrile/water (50:50)/0.1% acetic acid (v/v) and ionized by use of electrospray ionization (ESI). External calibration was accomplished with oligomers of polypropylene glycol (PPG, average molecular weight 1000 Da). All final samples with <sup>1</sup>H NMR data and LC-MS data are >95% pure as assessed by these analytical methods.</div><div class="NLM_p">All animal studies including the study design and animal procedures were reviewed and approved by the Merck Institutional Animal Care and Use Committee (IACUC). The Guide for the Care and Use of Laboratory Animals and Animal Welfare regulations were followed in the conduct of the animal studies. Veterinary care was given to any animals requiring medical attention.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 2-[6-Oxopyridazin-1(6<i>H</i>)-yl]acetic Acid (<b>11</b>)</h4><div class="NLM_p last">To 2-[3-chloro-6-oxopyridazin-1(6<i>H</i>)-yl]acetic acid (1.00 g, 5.30 mmol) in methanol (40 mL) was added 100 mg of 10% Pd/C. After the reaction mixture was stirred at ambient temperature under a H<sub>2</sub> balloon for 1 h, the Pd was filtered off through Celite. The filtrate was concentrated in vacuo and purified by reverse-phase HPLC (TMC Pro-Pac C18; 0–40% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). Removal of the volatiles in vacuo afforded <b>11</b> as a white crystalline solid (520 mg, 64% yield). LC/MS <i>m</i>/<i>e</i> 155.2 (M+1)<sup>+</sup>. <sup>1</sup>H NMR (D<sub>2</sub>O): δ 8.06 (dd, <i>J</i> = 3.9, 1.4 Hz, 1H), 7.56 (dd, <i>J</i> = 9.4, 3.9 Hz, 1H), 7.12 (dd, <i>J</i> = 9.4, 1.5 Hz, 1H), 4.95 (s, 2H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 2-[6-Oxopyrimidin-1(6<i>H</i>)-yl]acetic Acid (<b>12</b>)</h4><div class="NLM_p last">To pyrimidin-4(3<i>H</i>)-one (0.304 g, 3.16 mmol) was added 5 N sodium hydroxide solution (1.27 mL) followed by chloroacetic acid (0.299 g, 3.16 mmol). The reaction mixture was heated at 105 °C for 2 h. After being cooled down to ambient temperature, it was neutralized with 2 N hydrochloric acid (1.6 mL) and then directly purified by reverse-phase HPLC (TMC Pro-Pac C18; 0–40% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). Removal of the volatiles in vacuo afforded <b>12</b> as a white solid (0.10 g, 20% yield). LC/MS 155.1 (M+1)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.2 (s, 1H), 8.43 (s, 1H), 7.94 (d, <i>J</i> = 6.7 Hz, 1H), 6.43 (d, <i>J</i> = 6.6 Hz, 1H), 4.63 (s, 2H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 2-[2-Oxopyrimidin-1(2<i>H</i>)-yl]acetic Acid (<b>13</b>)</h4><div class="NLM_p last">2-Hydroxypyrimidine hydrochloride (1.00 g, 7.54 mmol) and chloroacetic acid (0.713 g, 7.54 mmol) were added to 5 N sodium hydroxide solution (4.5 mL). The reaction mixture was heated at 105 °C for 2 h. After being cooled down to ambient temperature and neutralized with 2 M hydrochloric acid (3.8 mL), the title compound was collected by crystallization and filtration to afford <b>13</b> as a pale yellow solid (417 mg, 36% yield). LC/MS 155.2 (M+1)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 13.2 (s, 1H), 8.59 (dd, <i>J</i> = 3.9, 3.0 Hz, 1H), 8.16 (dd, <i>J</i> = 6.4, 2.8 Hz, 1H), 6.46 (dd, <i>J</i> = 6.4, 4.1 Hz, 1H), 4.58 (s, 2H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-(Pyridazin-3-yloxy)propanoic Acid (<b>14</b>)</h4><div class="NLM_p last">To 3(2<i>H</i>)-pyridazinone (23.8 g, 248 mmol) in water (50 mL) was added lithium hydroxide (20.8 g, 495 mmol) followed by (2<i>R</i>)-bromopropionic acid (23.0 mL, 249 mmol), and the resulting mixture was heated at 70 °C for 2 h. The mixture was cooled and neutralized by the addition of concentrated HCl (20 mL). It was purified by reverse-phase HPLC (TMC Pro-Pac C18; 5–60% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient) to give the title compound <b>14</b> as a pale yellow solid (6.2 g, 15% yield). Some epimerization occurred during the reaction. LC/MS 169.1 (M+1)<sup>+</sup>. <sup>1</sup>H NMR (D<sub>2</sub>O): δ 8.07 (dd, <i>J</i> = 4.1, 1.6 Hz, 1H), 7.53 (dd, <i>J</i> = 9.3, 3.9 Hz, 1H), 7.09 (dd, <i>J</i> = 9.4, 1.6 Hz, 1H), 5.46 (m, 1H), 1.64 (d, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>S</i>)-5-Oxo-1,2,3,5-tetrahydroindolizine-3-carboxylic Acid (<b>15</b>)</h4><div class="NLM_p">To a stirred solution of 0.850 g (4.06 mmol) of (3<i>S</i>,8a<i>S</i>)-methyl-5-oxo-1,2,3,5,6,8a-hexahydroindolizine-3-carboxylate (<b>29</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> in 50 mL of dichloromethane was added 6.30 g (72.5 mmol) of manganese(IV) oxide, and the resulting mixture was stirred for 12 h at reflux. The reaction was cooled to ambient temperature and filtered through a pad of Celite, and the solid was then washed with 100 mL of dichloromethane. The filtrate was evaporated to dryness in vacuo, and the residue was purified by silica gel chromatography eluting with 10–50% ethyl acetate in hexanes gradient to afford the pyridone product as a clear gum (0.47 g, 55% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 194 (M+H)<sup>+</sup>.</div><div class="NLM_p last">To a stirred solution of 200 mg (1.00 mmol) of the above product (methyl-(3<i>S</i>)-5-oxo-1,2,3,5-tetrahydroindolizine-3-carboxylate) in 3 mL of THF was added 1.5 mL (1.5 mmol) of a 1.0 M aqueous LiOH solution. The resulting mixture was stirred for 2 h at ambient temperature then quenched with 2.0 mL (2.0 mmol) of a 1.0 M aqueous solution of hydrogen chloride. All volatiles were evaporated in vacuo, and the aqueous phase was extracted with a 30% IPA (isopropyl alcohol) in chloroform mixture (3 × 5 mL). The combined extract was washed with brine, dried over magnesium sulfate, filtered, and evaporated in vacuo to afford the title compound <b>15</b> as a white solid (0.17 g, 92% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 180 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.53 (dd, <i>J</i> = 8.9, 7.1 Hz, 1H), 6.38–6.35 (m, 2H), 5.11 (dd, <i>J</i> = 9.7, 2.7 Hz, 1H), 3.23–3.12 (m, 2H), 2.62–2.53 (m, 1H), 2.35–2.30 (m, 1H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>S</i>)-4-Oxo-4,6,7,8-tetrahydropyrrolo[1,2-<i>a</i>]pyrimidine-6-carboxylic Acid (<b>16</b>)</h4><div class="NLM_p">(<i>S</i>)-Methyl-5-methoxy-3,4-dihydro-2<i>H</i>-pyrrole-2-carboxylate (<b>31</b>) (4.19 g, 27 mmol) and 3-azatricyclo[4.2.1.0<sup>2,5</sup>]non-7-en-4-one (2.4 g, 17.8 mmol) were heated at 110 <span class="monospace">°</span>C overnight. Purification using a Biotage Horizon system (0–100% ethyl acetate/hexanes mixture) gave (<i>S</i>)-methyl 4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-<i>a</i>]pyrimidine-6-carboxylate and intermediate (1<i>S</i>,5<i>R</i>,8<i>S</i>)-methyl 9-oxo-1,2,3,4a,5,8,8a,9-octahydro-5,8-methanopyrrolo[2,1-<i>b</i>]quinazoline-1-carboxylate. The intermediate was heated at 150 <span class="monospace">°</span>C for 45 min to afford the product, which was used without further purification (2.5 g, 72% yield). LC/MS 195.2 (M+H)<sup>+</sup>.</div><div class="NLM_p last">To the above product, methyl-(<i>S</i>)-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-<i>a</i>]pyrimidine-6-carboxylate (7.30 g, 37.6 mmol) in tetrahydrofuran (35 mL), methanol (20 mL), and water (20 mL) was added to a solution of 5 M sodium hydroxide (11.3 mL). The reaction mixture was stirred at ambient temperature for 1.5 h. Hydrochloric acid (2 N, 28.2 mL) was added to neutralize the reaction mixture, which was then directly purified by reverse-phase HPLC (TMC Pro-Pac C18; 0–45% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). The pure fractions were collected and lyophilized to afford the title compound <b>16</b> as a pale yellow solid (5.8 g, 86% yield). LC/MS 181.2 (M+1)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.89 (d, <i>J</i> = 6.6 Hz, 1H), 6.24 (d, <i>J</i> = 6.6 Hz, 1H), 4.92 (dd, <i>J</i> = 10.0, 3.1 Hz, 1H), 3.12–2.99 (m, 2H), 2.52 (m, 1H), 2.11 (m, 1H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(4-oxoquinazolin-3(4<i>H</i>)-yl)acetamide (<b>17</b>)</h4><div class="NLM_p last">To aniline <b>8a</b> (350 mg, 0.915 mmol) and 4-oxo-3(4<i>H</i>)-quinazolineacetic acid <b>9</b> (193 mg, 0.945 mmol) in anhydrous <i>N,N</i>-dimethylformamide (10 mL) under an atmosphere of nitrogen was added 1-hydroxy-7-azabenzotriazole (10 mg, 0.073 mmol) followed by 1.1 equiv of 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (192 mg, 1 mmol). The reaction mixture was then quenched with water (100 mL), EtOAc (100 mL) was added, and the organic layer was separated. The aqueous layer was extracted with EtOAc (50 mL × 2), and the combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and evaporated in vacuo. The crude residue was purified by silica gel chromatography eluting with ethyl acetate in hexanes to afford the title compound (369 mg, 71% yield). To the purified product in 6 mL of methanol was added 6 mL of concentrated aqueous HCl, and the reaction mixture was stirred at room temperature overnight. The next day, the reaction was azeotroped with toluene (3×) to remove water. Purification of the crude material was performed by preparative TLC plates (4 × 1000 uM silica gel plates) eluting with 5% MeOH in dichloromethane to afford the product <b>17</b> as a crystalline hydrochloride salt (246 mg, 75% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 469.29 (M+H)<sup>+</sup>. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) δ 8.34 (s, 1H), 8.26 (d, <i>J</i> = 7.7 Hz, 1H), 7.88 (t, <i>J</i> = 7.6 Hz, 1H), 7.76 (d, <i>J</i> = 7.6 Hz, 1H), 7.63–7.56 (m, 3H), 7.46–7.42 (m, 3H), 7.41–7.37 (m, 2H), 7.27 (d, <i>J</i> = 7.8 Hz, 2H), 5.35 (br t, <i>J</i> = 6.8 Hz, 1H), 4.70 (d, <i>J</i> = 7.1 Hz, 1H), 4.37 (s, 2H), 3.76–3.66 (m, 2H), 3.07 (dd, <i>J</i> = 5.0, 13.5 Hz, 1H), 2.95 (dd, <i>J</i> = 9.7, 13.5 Hz, 1H), 2.66 (br s, 1H), 1.65–1.59 (m, 2H), 1.40–1.26 (m, 2H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(6-oxopyridazin-1(6<i>H</i>)-yl)acetamide (<b>18</b>)</h4><div class="NLM_p last">To a solution of aniline <b>8a</b> (4.00 g, 10.5 mmol) in DMF (30 mL) was added <b>11</b> (1.93 g, 12.6 mmol), 1-hydroxy-7-azabenzotriazole (1.84 g, 13.6 mmol), and 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (3.00 g, 15.6 mmol) followed by <i>N</i>,<i>N</i>-diisopropylethylamine (9.11 mL, 52.3 mmol). The reaction mixture was stirred at ambient temperature for 4 h and then quenched with water (120 mL), and EtOAc (120 mL) was added. The organic layer was separated, and the aqueous layer was extracted with EtOAc (50 mL × 2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated in vacuo. The crude residue was purified by silica gel chromatography, eluting with a 0–5% then 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to afford 4.89 g of the Boc-protected compounds as a white foam. The white foam was dissolved in <sup><i>i</i></sup>PrOH (20 mL) followed by 4 M HCl in dioxane solution (20 mL). The reaction mixture was stirred at ambient temperature for 2 h. LC-MS showed ∼60% completion. Fifteen mL of 4 M HCl dioxane solution was added, and the mixture was stirred for another 3.5 h. After removal of the volatiles and the solvent switch (CH<sub>3</sub>CN, 100 mL), the resulting ppt was collected by filtration (washed with <sup><i>i</i></sup>PrOH and CH<sub>3</sub>CN). The solid was dissolved in methanol again and then evaporated in vacuo, and ∼50 mL of CH<sub>3</sub>CN was added. Filtration afforded the title compound <b>18</b> as a white powder (3.27 g, 69% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 419.1 (M+H)<sup>+</sup>. HRMS (ESI-positive) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> calcd mass 419.2078, found 419.2073. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 9.47 (s, 1H), 8.73 (s, 1H), 7.92 (dd, <i>J</i> = 3.9, 1.6 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.45 (dd, <i>J</i> = 9.5, 3.9 Hz, 1H), 7.42–7.35 (m, 4H), 7.35–7.26 (m, 1H), 7.19 (d, <i>J</i> = 8.5 Hz, 2H), 6.97 (dd, <i>J</i> = 9.5, 1.6 Hz, 1H), 6.21 (d, <i>J</i> = 3.6 Hz, 1H), 4.87 (s, 2H), 4.73 (d, <i>J</i> = 9.4 Hz, 1H), 3.31 (s, 1H), 3.12 (dd, <i>J</i> = 13.6, 5.5 Hz, 1H), 2.87 (dd, <i>J</i> = 13.6, 9.4 Hz, 1H), 1.84 (q, <i>J</i> = 9.2 Hz, 1H), 1.67 (m, 2H), 1.54 (m, 1H).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(6-oxopyrimidin-1(6<i>H</i>)-yl)acetamide (<b>19</b>)</h4><div class="NLM_p last">To a solution of aniline <b>8a</b> (25 mg, 0.065 mmol) in DMF (0.6 mL) was added <b>12</b> (35.6 mg, 0.131 mmol), 1-hydroxy-7-azabenzotriazole (8.83 mg, 0.065 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (25.1 mg, 0.131 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.057 mL, 0.33 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was purified by reverse-phase HPLC (TMC Pro-Pac C18; 20–80% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight. The lyophilized product in 1 mL of DCM and 0.3 mL of TFA was stirred at ambient temperature for 2 h. After concentration, the residue was purified by reverse-phase HPLC (TMC Pro-Pac C18; 5–65% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight to afford the title compound <b>19</b> (25 mg, 59% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 419.2 (M+H)<sup>+</sup>. HRMS (ESI positive) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> calcd mass 419.2078, found 419.2076. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 9.41–9.45 (m, 1H), 8.44–8.50 (m, 1H), 8.42 (s, 1H), 7.95 (d, <i>J</i> = 6.6 Hz, 1H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.36–7.41 (m, 4H), 7.32–7.34 (m, 1H), 7.19 (d, <i>J</i> = 8.4 Hz, 2H), 6.42 (d, <i>J</i> = 6.7 Hz, 1H), 6.23 (br, 1H), 4.75 (s, 2H), 4.67 (d, <i>J</i> = 8.8 Hz, 1H), 3.61–3.63 (m, 2H), 3.08 (dd, <i>J</i> = 8.2, 5.5 Hz, 1H), 2.84 (dd, <i>J</i> = 9.6, 3.8 Hz, 1H), 1.82–1.87 (m, 1H), 1.63–1.67 (m, 2H), 1.55–1.61 (m, 1H).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(2-oxopyrimidin-1(2<i>H</i>)-yl)acetamide (<b>20</b>)</h4><div class="NLM_p last">To a solution of aniline <b>8a</b> (25 mg, 0.065 mmol) in DMF (0.6 mL) was added acid <b>13</b> (20.2 mg, 0.131 mmol), 1-hydroxy-7-azabenzotriazole (8.83 mg, 0.065 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (25.1 mg, 0.131 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.057 mL, 0.33 mmol). The reaction mixture was stirred at ambient temperature for 4 h. The mixture was purified by reverse-phase HPLC (TMC Pro-Pac C18; 25–85% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight. The lyophilized product in 1 mL of DCM and 0.3 mL of TFA was stirred at ambient temperature for 2 h. After concentration, the residue was purified by reverse-phase HPLC (TMC Pro-Pac C18; 5–65% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight to afford the title compound <b>20</b> (20 mg, 47% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 419.3 (M+H)<sup>+</sup>. HRMS (ESI positive) C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> calcd mass 419.2078, found 419.2075. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 9.45–9.46 (m, 1H), 8.59 (t, <i>J</i> = 3.4 Hz, 1H), 8.48–8.50 (m, 1H), 8.16 (dd, <i>J</i> = 3.7, 2.7 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.37–7.41 (m, 4H), 7.31–7.34 (m, 1H), 7.19 (d, <i>J</i> = 8.4 Hz, 2H), 6.48 (dd, <i>J</i> = 4.4, 2.1 Hz, 1H), 6.24 (br, 1H), 4.70 (s, 2H), 4.68 (d, <i>J</i> = 9.1 Hz, 1H), 3.61–3.63 (m, 2H), 3.09 (dd, <i>J</i> = 8.1, 5.4 Hz, 1H), 2.84 (dd, <i>J</i> = 9.5, 4.0 Hz, 1H), 1.82–1.87 (m, 1H), δ 1.61–1.70 (m, 2H), δ 1.54–1.59 (m, 1H).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(2-oxopyridin-1(2<i>H</i>)-yl)acetamide (<b>21</b>)</h4><div class="NLM_p last">To a solution of aniline <b>8a</b> (25 mg, 0.065 mmol) in DMF (0.6 mL) was added commercially available 2-(2-oxopyridin-1(2<i>H</i>)-yl)acetic acid (<b>10</b>) (20.0 mg, 0.131 mmol), 1-hydroxy-7-azabenzotriazole (8.83 mg, 0.065 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (25.1 mg, 0.131 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.057 mL, 0.33 mmol). The reaction mixture was stirred at ambient temperature for 4 h. The mixture was purified by reverse-phase HPLC (TMC Pro-Pac C18; 25–85% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight. The lyophilized product in 1 mL DCM and 0.3 mL TFA was stirred at ambient temperature for 2 h. After concentration, the residue was purified by reverse phase HPLC (TMC Pro-Pac C18; 5–65% 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight to afford the title compound <b>21</b> (20 mg, 47% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 418.4 (M+H)<sup>+</sup>. HRMS (ESI positive) C<sub>25</sub>H<sub>27</sub>N<sub>3</sub>O<sub>3</sub> (M + H)<sup>+</sup> calcd mass 418.2125, found 418.2118. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H), 9.42–9.46 (m, 1H), 8.47–8.55 (m, 1H), 7.64 (dd, <i>J</i> = 5.0, 1.8 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.45 (ddd, <i>J</i> = 4.6, 2.3, 2.0 Hz, 1H), 7.37–7.41 (m, 4H), 7.31–7.34 (m, 1H), 7.18 (d, <i>J</i> = 8.4 Hz, 2H), 6.37 (d, <i>J</i> = 9.2 Hz, 1H), 6.23 (dt, <i>J</i> = 5.5, 1.0 Hz, 2H), 4.71 (s, 2H), 4.67 (d, <i>J</i> = 8.9 Hz, 1H), 3.61–3.63 (m, 2H), 3.08 (dd, <i>J</i> = 8.1, 5.4 Hz, 1H), 2.84 (dd, <i>J</i> = 9.5, 3.9 Hz, 1H), 1.82–1.87 (m, 1H), 1.61–1.70 (m, 2H), 1.54–1.60 (m, 1H).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>S</i>)-<i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(6-oxopyridazin-1(6<i>H</i>)-yl)propanamide (<b>22</b>)</h4><div class="NLM_p">To a solution of aniline <b>8a</b> (3.23 g, 6.50 mmol) in DMF (20 mL) was added acid <b>14</b> (1.31 g, 7.80 mmol), 1-hydroxy-7-azabenzotriazole (1.32 g, 9.75 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (2.00 g, 10.4 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (5.66 mL, 32.5 mmol). The reaction mixture was stirred at ambient temperature for 2 h. After aqueous workup (EtOAc/water), the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel chromatography eluting with 0–80% gradient of ethyl acetate in hexanes to afford 1.96 g of pale yellow form as a mixture of two diastereomers. The two diastereomers were separated by chiral HPLC employing a ChiralCEL OD column (eluent: 10% IPA in heptane). The second eluting diastereomer (isomer <b>2</b>) was the desired diastereomer (white form, 0.876 g, 21% yield).</div><div class="NLM_p last">A solution of 0.87 g of isomer <b>2</b> from above (CH<sub>3</sub>CN, 6 mL), TFA (6 mL), and water (2 mL) was heated at 55 °C for 2 h. After concentration in vacuo, the crude reaction mixture was purified by reverse-phase HPLC (TMC Pro-Pac C18; 0–80% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). The pure fractions were lyophilized and then dissolved in a mixture of DCM and saturated aqueous bicarbonate solution. The aqueous phase was extracted with DCM, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Crystallization from EtOAc afforded the title compound as a white solid (370 mg, 63% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 433.4 (M+H)<sup>+</sup>. HRMS (ESI positive) C<sub>25</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> calcd mass 433.2234, found 433.2226. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.11 (s, 1H), 7.98 (dd, <i>J</i> = 3.9, 1.7 Hz, 1H), 7.49–7.41 (m, 3H), 7.34–7.24 (m, 4H), 7.21 (t, <i>J</i> = 6.9 Hz, 1H), 7.13 (d, <i>J</i> = 8.4 Hz, 2H), 6.95 (dd, <i>J</i> = 9.4, 1.7 Hz, 1H), 5.40 (q, <i>J</i> = 7.0 Hz, 1H), 4.21 (d, <i>J</i> = 7.2 Hz, 1H), 3.18 (m, 1H), 3.07 (q, <i>J</i> = 7.2 Hz, 1H), 2.63 (dd, <i>J</i> = 13.1, 6.8 Hz, 1H), 2.55 (dd, <i>J</i> = 13.2, 6.6 Hz, 1H), 1.58 (d, <i>J</i> = 7.1 Hz, 3H), 1.37 (m, 1H), 1.31–1.21 (m, 2H).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>S</i>)-<i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(pyridin-3-yl)methyl)pyrrolidin-2-yl)methyl)phenyl)-2-(6-oxopyridazin-1(6<i>H</i>)-yl)propanamide (<b>23</b>)</h4><div class="NLM_p">To a solution of aniline <b>8b</b> (50 mg, 0.13 mmol) in DMF (5 mL) was added acid <b>14</b> (39.2 mg, 0.235 mmol), 1-hydroxy-7-azabenzotriazole (261 μL of a 0.6 M DMF solution, 0.156 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (30 mg, 0.156 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.11 mL, 0.65 mmol). The reaction mixture was stirred at ambient temperature for 24 h. After aqueous workup (EtOAc/water), the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel chromatography eluting with 20–100% gradient of ethyl acetate in hexanes to afford 50 mg of the mixture of two diastereomers. The two diastereomers were separated by chiral HPLC employing a ChiralCEL AD column (eluent: 6% IPA in heptane). The second eluting diastereomer (isomer 2) was the desired diastereomer (white form, 15 mg 54% yield).</div><div class="NLM_p last">A solution of 15 mg of isomer <b>2</b> (CH<sub>3</sub>CN, 6 mL), TFA (6 mL), and water (2 mL) was heated at 55 °C for 2 h. After concentration in vacuo, the crude reaction mixture was purified by reverse-phase HPLC (TMC Pro-Pac C18; 0–80% 0.1% trifluoroacetic acid in acetonitrile/0.1% trifluoroacetic acid in water gradient). The pure fractions were lyophilized and then dissolved in a mixture of DCM and saturated aqueous bicarbonate solution. The aqueous phase was extracted with DCM, and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Crystallization from EtOAc afforded the title compound <b>23</b> as a white solid (8 mg, 70% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 433.0 (M+1). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.74 (s, 1H), 8.63 (d, <i>J</i> = 5.0 Hz, 1H), 8.17 (d, <i>J</i> = 7.8 Hz, 1H), 7.78 (d, <i>J</i> = 6.9 Hz, 1H), 7.69–7.66 (m, 1H), 7.54 (d, <i>J</i> = 8.5 Hz, 2H), 7.24 (d, <i>J</i> = 8.3 Hz, 2H), 6.56 (d, <i>J</i> = 9.1 Hz, 1H), 6.47 (t, 1H), 5.58 (q, <i>J</i> = 7.3 Hz, 1H), 4.92 (d, <i>J</i> = 8 Hz, 1H), 3.86–3.77 (m, 2H), 3.15–3.11 (m, 1H), 2.98–2.95 (m, 1H), 2.20–1.80 (m, 5H), 1.71 (d, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>S</i>)-<i>N</i>-(4-(((2<i>S</i>,5<i>R</i>)-5-((<i>R</i>)-Hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-5-oxo-1,2,3,5-tetrahydroindolizine-3-carboxamide (<b>24</b>)</h4><div class="NLM_p">To a solution of 0.610 g (1.60 mmol) of aniline <b>8a</b> and 0.300 g (1.67 mmol) of acid <b>15</b> in 3.2 mL of anhydrous <i>N,N</i>-dimethylformamide under an atmosphere of nitrogen was added 0.033 g (0.24 mmol) of 1-hydroxy-7-azabenzotriazole followed by 0.336 g (1.75 mmol) of 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride. The resulting suspension was stirred at ambient temperature for 30 min, quenched with water, and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and evaporated in vacuo. The crude residue was purified by silica gel chromatography eluting with a 50–100% gradient of ethyl acetate in hexanes to afford the title compounds as a mixture of diastereomers in a 97:3 ratio. The two diastereomers were separated by chiral HPLC employing a Daicel CHIRALPAK AD column (eluent: 40% IPA in heptane). The first eluting diastereomer isolated was the undesired R diastereomer (20 mg, 2.3%). LC-MS: <i>m</i>/<i>z</i> (ES) 544.2 (M+H)<sup>+</sup>. The second eluting diastereomer (isomer <b>2</b>) was the S diastereomer, and the major product of the reaction was isolated as a colorless solid (650 mg, 75% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 544.2 (M+H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of 0.500 g (0.920 mmol) of isomer <b>2</b> in 2 mL of isopropanol under an atmosphere of nitrogen was added 4.0 mL of a 4.0 M solution of anhydrous hydrogen chloride in 1,4-dioxane. The reaction mixture was stirred for 1 h and then evaporated to dryness in vacuo. The crude reaction mixture was purified by reverse-phase HPLC (TMC Pro-Pac C18; 0–75% 0.01% trifluoroacetic acid in acetonitrile/0.01% trifluoroacetic acid in water gradient). The pure fractions were lyophilized overnight and then dissolved in a mixture of 10 mL of chloroform and 4 mL of a saturated aqueous bicarbonate solution. The biphasic mixture was stirred vigorously for 10 min, and the layers were separated. The aqueous phase was extracted with chloroform (3 × 10 mL), and the combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and evaporated in vacuo to afford the title compound <b>24</b> as a white solid (390 mg, 95% yield). LC-MS: <i>m</i>/<i>z</i> (ES) 444.0 (M+H)<sup>+</sup>. HRMS (ESI positive) C<sub>27</sub>H<sub>29</sub>N<sub>3</sub>O<sub>3</sub> (M + H)<sup>+</sup> calcd mass 444.2282, found 444.2280. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.89 (s, 1 H), 7.54 (dd, <i>J</i> = 8.8, 7.2 Hz, 1H), 7.50 (d, <i>J</i> = 8.2 Hz, 2H), 7.34–7.29 (m, 4H), 7.26–7.23 (m, 1H), 7.20 (d, <i>J</i> = 8.2 Hz, 2H), 6.38–3.36 (m, 2H), 5.24 (dd, <i>J</i> = 9.4, 2.8 Hz, 1H), 4.20 (d, <i>J</i> = 7.8 Hz, 1H), 3.35–3.23 (m, 3H), 3.19–3.12 (m, 1H), 2.82–2.71 (m, 2H), 2.60–2.51 (m, 1H), 2.37–2.32 (m, 1H), 1.79–1.72 (m, 1H), 1.52–1.43 (m, 3H).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (6<i>S</i>)-<i>N</i>-[4-({(2<i>S</i>,5<i>R</i>)-5-[(<i>R</i>)-Hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]pyrimidine-6-carboxamide (<b>7</b>)</h4><div class="NLM_p">To a solution of <b>8a</b> (21.4 g, 55.9 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (100 mL) at 0 °C was added (6<i>S</i>)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-α]pyrimidine-6-carboxylic acid (<b>16</b>, 11.1 g, 61.5 mmol), followed by 1-hydroxybenzotriazole (7.55 g, 55.9 mmol), <i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (16.1 g, 84.0 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (29.2 mL, 168 mmol). The reaction mixture was stirred from 0 °C to ambient temperature for 2 h. Water (600 mL) was added, and it was extracted with dichloromethane (600 mL × 2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. After removal of the volatiles, the residue was purified by using a Biotage Horizon system (0–5% then 5% methanol with 10% ammonia/dichloromethane mixture) to afford the title compound, which contained 8% of the minor diastereomer. It was further purified by supercritical fluid chromatography (chiral AS column, 40% methanol) to afford the product as a pale yellow solid (22.0 g, 72% yield). LC-MS 567.4 (M+Na)<sup>+</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 9.61 (s, 1H), 7.93 (d, <i>J</i> = 6.6 Hz, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.35–7.28 (m, 5H), 7.13 (d, <i>J</i> = 8.5 Hz, 2H), 6.40 (d, <i>J</i> = 6.7 Hz, 1H), 5.36 (d, <i>J</i> = 8.6 Hz, 1H), 4.38 (m, 1H), 4.12–4.04 (m, 2H), 3.46 (m, 1H), 3.15–3.06 (m, 2H), 2.91 (dd, <i>J</i> = 13.1, 9.0 Hz, 1H), 2.55 (m, 1H), 2.38 (m, 1H), 1.71–1.49 (m, 13H).</div><div class="NLM_p last">To a solution of the above product (2.50 g, 4.59 mmol) in dichloromethane (40 mL) was added trifluoroacetic acid (15 mL). The reaction mixture was stirred at ambient temperature for 1.5 h. After removal of the volatiles, saturated NaHCO<sub>3</sub> was added to pH 8–9 to make the free base, and the mixture was then extracted with dichloromethane. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>. After concentration, crystallization from methanol/acetonitrile afforded the title compound <b>7</b> as a white solid (1.23 g, 60% yield). LC-MS 445.3 (M+1).<sup>+ 1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.40 (s, 1H), 7.91 (d, <i>J</i> = 6.7 Hz, 1H), 7.49 (d, <i>J</i> = 8.3 Hz, 2H), 7.32–7.26 (m, 4H), 7.21 (m, 1H), 7.15 (d, <i>J</i> = 8.4 Hz, 2H), 6.23 (d, <i>J</i> = 6.7 Hz, 1H), 5.11 (dd, <i>J</i> = 9.6, 2.9 Hz, 1H), 5.10 (br, 1H), 4.21 (d, <i>J</i> = 7.1 Hz, 1H), 3.20–3.00 (m, 4H), 2.66–2.51 (m, 3H), 2.16 (m, 1H), 1.57 (m, 1H), 1.38 (m, 1H), 1.29–1.23 (m, 2H).</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> β<sub>3</sub> cAMP Assay</h3><div class="NLM_p">CHO cells, stably transfected with the cloned β<sub>3</sub>-adrenergic receptor, were harvested after 3 days of subculturing. Harvesting of cells is done with Enzyme-free Dissociation Media (Specialty Media). Cells are then counted and resuspended in assay buffer (Hank’s balanced salt solution supplemented with 5 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES), 0.1% bovine serum albumin (BSA)) containing a phosphodiesterase inhibitor (IBMX, 0.6 mM). The reaction is initiated by mixing 6 000 cells in 6 μL with 6 μL of Alexa Fluor labeled cAMP antibody (LANCE kit), which is then added to an assay well containing 12 μL of compound (diluted in assay buffer to 2× final concentration). The reaction proceeds for 30 min at room temperature and is terminated by the addition of 24 μL of detection buffer (LANCE kit). The assay plate is then incubated for 1 h at room temperature, and time-resolved fluorescence is measured on a PerkinElmer Envision reader. The unknown cAMP level is determined by comparing fluorescence levels to a cAMP standard curve. The nonselective, full agonist β-adrenergic ligand isoproterenol is used to determine maximal stimulation. The human β<sub>3</sub>-adrenergic receptor selective ligand (<i>S</i>)-<i>N</i>-[4-[2[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide is used as a control. Isoproterenol is titrated at a final concentration in the assay of 10<sup>–10</sup>–10<sup>–5</sup> M, and the selective ligand (<i>S</i>)-<i>N</i>-[4-[2[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide is titrated at the β<sub>3</sub> receptor at a concentration of 10<sup>–10</sup>–10<sup>–5</sup> M. Unknown ligands are titrated at the β<sub>3</sub>-adrenergic receptor at a final concentration in the assay of 10<sup>–10</sup>–10<sup>–5</sup> M to determine the EC<sub>50</sub>. The EC<sub>50</sub> is defined as the concentration of compound that gives 50% activation of its own maximum. Data are analyzed using Microsoft Excel and Graphpad Prism, v4.</div><div class="NLM_p last">The cAMP functional assay employs a time-resolved fluorescence resonance energy transfer (TR-FRET) methodology. By incorporating a time-resolved measurement of fluorescence, short-lived background fluorescence (typical of compound interference) will be eliminated. A time delay of ∼50–150 μs between the system excitation and fluorescence measurement allows the signal to be cleared of all nonspecific short-lived emissions. In addition, we use a ratio metric measurement (excitation emission and acceptor emission) such that interference in either channel would be quickly identified. Finally, lead compounds are occasionally evaluated in a human β<sub>3</sub>-AR binding assay that uses a radio-ligand tracer to measure direct interaction with the receptor (see below). Compounds that are nonselectively interfering with the detection technology in the functional assay would show no direct binding to the human β<sub>3</sub>-AR.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> β<sub>1</sub> and β<sub>2</sub> Binding Assay</h3><div class="NLM_p last">CHO cells recombinantly expressing β<sub>1</sub> and β<sub>2</sub> receptors were grown for 3–4 days after splitting; the attached cells are washed with PBS and then lysed in 1 mM Tris, pH 7.2, for 10 min on ice. The flasks are scraped to remove the cells and then homogenized using a Teflon/glass homogenizer. Membranes are collected by centrifuging at 38 000<i>g</i> for 15 min at 4 °C. The pelleted membranes are resuspended in TME buffer (50 mM Tris, pH 7.4, 5 mM MgCl<sub>2</sub>, 2 mM EDTA) at a concentration of 1 mg of protein/mL. The binding assay is performed by incubating together membranes (2–5 μg of protein), the radiolabeled tracer <sup>125</sup>I-cyanopindolol (<sup>125</sup>I-CYP, 45 pM), 200 μg of WGA-PVT SPA beads (GE Healthcare), and the test compounds at final concentrations from 10<sup>–10</sup> to 10<sup>–5</sup> M in a final volume of 200 μL of TME buffer containing 0.1% BSA. The assay plate is incubated for 1 h with shaking at room temperature and then placed in a PerkinElmer Trilux scintillation counter. The plates are allowed to rest in the Trilux counter for ∼10 h in the dark prior to counting. Data are analyzed using a standard four-parameter nonlinear regression analysis using Graphpad Prism software, v4. The IC<sub>50</sub> is defined as the concentration of the title compound capable of inhibiting 50% of the binding of the radiolabeled tracer (<sup>125</sup>I-CYP).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> β<sub>3</sub> Binding Assay</h3><div class="NLM_p last">Membranes prepared from recombinant CHO cells overexpressing the human β<sub>3</sub>-AR are diluted in assay buffer (50 mM Tris pH 7.4, 5 mM MgCl<sub>2</sub>, 2 mM EDTA; Sigma) to a concentration of 50 μg/mL. Compounds to be tested are serially diluted in DMSO (typically half-log dilutions starting at 0.5 mM) at 50× the final concentration used in the binding assay. <sup>125</sup>I-CYP tracer (100 μCI/mL; NEN no. NEX189) is diluted in assay buffer to a concentration of 2.2 × 106 DPM/mL (∼400 pM stock solution). To each well of a 96-well plate, 46 μL of assay buffer, 4 μL of serially diluted compound, 50 μL of <sup>125</sup>I-CYP, and 100 μL of β<sub>3</sub> membranes is added. To determine total binding, DMSO is added instead of compound; to determine nonspecific binding, nonlabeled CYP (200 μM final) is added. The plate is then incubated at room temperature for 60 min while shaking on an orbital shaker. While the plates are incubating, GF/B filter plates (PerkinElmer) are presoaked in 0.1% polyethylenimine (Sigma) for at least 15 min prior to harvesting the assay. After the 1 h incubation, the assay was filtered using the presoaked filter plates and a Packard Harvester. The plates are washed 3 times with wash buffer (50 mM Tris pH 7.4; 500 mM NaCl) and dried overnight at room temperature. Once the plates are dry, 25 μL of Microscint-0 (PerkinElmer) is added to each well, and the plates are counted in a scintillation counter. Following counting, CPM is normalized to % inhibition using total binding (DMSO alone) and 100% inhibition (200 uM cold CYP). The % inhibition is then fitted to a standard four-parameter fit using a custom software package, and IC<sub>50</sub> is determined. The binding IC<sub>50</sub> of <b>7</b> to β<sub>3</sub>-AR was determined to be 295 nM ± 197 nM (<i>n</i> = 4).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Serotonin Transporter Assay</h3><div class="NLM_p last">HEK293 cells stably expressing the human serotonin transporter (SERT) are plated at a density of 20 000 cells/well in a 384-well plate (BD Biocoat no. 35663) and incubated overnight at 37 °C. The following day, growth media is removed and replaced with assay buffer (HBSS containing 20 mM HEPES and 0.1% BSA; Sigma). Compounds (serially diluted in DMSO at 100× final concentration) are added to appropriate assay wells, and the plate is incubated for 30 min at 37 °C. Fluorescent transporter substrate is prepared following the manufacturer’s instructions (neurotransmitter uptake kit, no. R8173, Molecular Probes) and added to the assay plate. The plate is then incubated for an additional 30 min at 37 °C. Uptake of the fluorescent dye is then determined by measuring fluorescence in a bottom read mode fluorescence plate reader (440 nm excitation, 520 nm emission wavelengths). Each plate includes 0% inhibition (DMSO only) and 100% inhibition (10 uM fluoxetine) control wells that are used to normalize the fluorescence data. Normalized data is then fit to a standard four-parameter curve, and IC<sub>50</sub> is determined.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Phospholipidosis Assay</h3><div class="NLM_p last">To assess the phospholipidosis potential of drug candidates, an in vitro screening assay was developed using the fluorescent labeled phospholipid probe NBD-PE.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> HepG2 cells are plated into Grenier glass-bottomed plates (no. 82050-792) at a concentration of 5 × 10<sup>4</sup> cells/well in standard growth media. The plates are then incubated for ∼24 h at 37 °C. Compounds are serially diluted in DMSO, and an aliquot along with the NBD-PE phospholipid probe is added to each well. The plates are then further incubated overnight at 37 °C. Following the overnight incubation, an aliquot of media from each well is removed for determination of cytotoxicity using a standard lactate dehydrogenase (LDH) cytotoxicity assay. The cells are then washed twice with media, 100 μL of fresh media is added to each well, and the plates are incubated for 30 min at 37 °C. The plates are then read in a SpectraMax fluorescent plate reader in a well scanning mode using 463 nm excitation and 536 nm emission. The relative potency of a compound to induce phospholipidosis was calculated by determining the concentration of test compound that produced the same normalized fluorescence response as one-half of the 10 μM amiodarone response (<i>A</i><sub>50</sub>). To determine <i>A</i><sub>50</sub> values for compounds, the measured fluorescence at each concentration tested is fitted to a standard dose–response curve (four-parameter fit). Drug concentrations at which the mean LDH activity was >1.74 times the mean untreated vehicle LDH were considered to be cytotoxic. These cytotoxic concentrations are not used for the NBD-PE measurement and plotting of regression curves for <i>A</i><sub>50</sub> determination. A compound was considered to be positive if an <i>A</i><sub>50</sub> value was obtained from the regression curves.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> General Procedure for Rat Acetic-Acid-Induced Hyperreflexia Studies</h3><div class="NLM_p last">Female Sprague–Dawley rats weighing 250–350 g were housed in a temperature-controlled and light-controlled (12-h light/dark cycle) room and were allowed access to food and water ad libitum. The animals were anesthetized with urethane (1.0 g/kg, i.p.). Supplemental urethane was given if necessary. A lower abdominal midline incision was made to expose the bladder, and a polyethylene catheter (PE-50) was inserted into the bladder dome for recording the intravesical pressure and intravesical infusion at the rate of 0.05 mL/min. An intravenous catheter (PE-10) was implanted into a femoral vein for drug administration. The intravesical pressure was measured using a pressure transducer, and signal was recorded using a multiple-channel data-acquisition system (Powerlab 16/30, AD Instruments) at a sampling rate of 10 Hz. After confirming stable intermicturition interval and micturition pressure by intravesical infusion of saline, 0.25% of acetic acid–saline solution was infused at the same infusion rate. After 30–60 min, drugs were intravenously infused using infusion pumps at a rate of 0.01 mL/min. Intermicturition interval (functional bladder capacity) and micturition pressure (maximum intravesical pressure) were obtained from micturitions prior to dosing (baseline) and between 30 and 45 min after starting drug infusion using Chart program (v5.5.4, AD Instruments), and the ratio to baseline was calculated. Blood samples were taken when drug infusion was stopped for measurements of plasma glycerol and drug levels. Compounds were dissolved with 5% ethanol–5% Tween80–distiled water. Blood was centrifuged, and the plasma was collected and either frozen immediately or used fresh. Plasma concentrations of the compounds were determined by liquid chromatography–tandem mass spectrometry on an Applied Biosystems API 4000 mass spectrometer.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> General Procedure for Rat Plasma Glycerol/FFA Measurements</h3><div class="NLM_p last">Female Sprague–Dawley rats weighing 250–350 g were anesthetized with urethane (1.0 g/kg, i.p.). An intravenous catheter (PE-10) was implanted into a femoral vein, and drugs were infused using infusion pumps at a rate of 0.01 mL/min. Blood samples were taken 45 min after initiation of drug infusion. Plasma glycerol and FFA levels were determined using commercially available kits (Sigma and NEFA-HR2, Wako, respectively) that rely on a series of enzyme-coupled reactions. Compounds were dissolved with 5% ethanol–5% Tween80–distilled water. Blood was centrifuged, and the plasma was collected and either frozen immediately or used fresh. Plasma concentrations of the compounds were determined by liquid chromatography–tandem mass spectrometry on an Applied Biosystems API 4000 mass spectrometer.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> In Vitro Permeability Analysis</h3><div class="NLM_p">To calculate permeability <i>P</i><sub>app</sub> for compound <b>7</b>, its bidirectional transport was evaluated in LLC-PK1 cells and in LLC-PK1 cells stably transfected with a human MDR1 cDNA (LLC-MDR1 cells). LLC-PK1, LLC-MDR1 cell lines were cultured in 24-well transwell culture plates. Compound <b>7</b> (5 μM) was prepared in Hank’s balanced salt solution with 10 mM HEPES. Substrate solution (500 μM) was added to either the apical (A) or the basolateral (B) compartment of the culture plate, and buffer (500 μM) was added to the compartment opposite that containing the compound. At <i>t</i> = 3 h, 100 μL of sample was taken out from both sides and internal standard (labetalol, 1 μM) was added for analysis. Verapamil (1 μM) was used as a positive control. The experiment was performed in triplicate.</div><div class="NLM_p last">Samples were analyzed quantitatively by LC/MS/MS using a SCIEX API 3000 triple quadruple mass spectrometer with a TurboIonSpray ion source in the positive ion mode. A PerkinElmer series 200 liquid chromatography system and a LEAP HTS PAL autosampler were compled to the PE-Sciex API 3000 with a flow rate of 800 μL/min to direct sample into the mass spectrometer. A Polaris C18 column was used for sample analysis. Mobile phase A consisted of 0.1% formic acid in water, and mobile phase B was acetonitrile with 0.1% formic acid. A gradient elution program was utilized where the solvent composition was held at 5% B for 0.5 min, changed from 5% B to 95% B at 0.6 min, and followed by a hold at 95% B for 0.5 min, then went back to 5% B at 1.1 min. The column was then reequilibrated at the original solvent composition, and the total run time was 1.5 min. Mass spectrometric detection was accomplished by multiple reaction monitoring of transitions unique to each compound. The transitions for the protonated precursor ions to the selected product ions of compound <b>7</b>, verapamil, and labetalol were <i>m</i>/<i>z</i> 445.2 to 135.2, 455.2 to 165.0, and 329.3 to 162.0, respectively. The <i>P</i><sub>app</sub> was calculated by the following formula for samples take at <i>t</i> = 3 h: <i>P</i><sub>app</sub> = ((volume of receptor chamber = 0.5 mL)/([area of membrane = 0.3 cm<sup>2</sup>][initial concentration in μM])) × (Δin concentration in μM/Δin time in s). The reported <i>P</i><sub>app</sub> is the average of <i>P</i><sub>app</sub> for transport from A to B and <i>P</i><sub>app</sub> for transport from B to A at <i>t</i> = 3 h.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Preclinical Toxicology</h3><div class="NLM_p">Compound <b>7</b> has been investigated in a variety of nonclinical studies as per ICHM3 (R2) to support the oral administration of this compound in humans. Compound <b>7</b> has been evaluated in a series of genetic toxicology studies (in in vitro microbial mutagenesis and chromosomal aberration assays and in in vivo assay for micronucleus induction in rat bone marrow) and demonstrated to be nongenotoxic and nonmutagenic.</div><div class="NLM_p">Repeat-dose oral toxicity studies were conducted up to 6 months in duration in Sprague–Dawley rats and up to 9 months of duration in Cynomolgus monkeys to support Phase 3 studies. Compound <b>7</b> was well-tolerated at adequate margins. Cynomolgus monkeys were chosen as the nonrodent species for repeat-dose toxicity studies with compound <b>7</b> because the cynomolgus monkey was the most sensitive species for the toxicity seen with compound <b>3</b>, which led to the discontinuation of its development. The oral repeated-dose toxicity studies in rats and monkeys were generally conducted at 3 doses and included assessment of antemortem parameters (physical signs, body weights, food consumption, ophthalmic examinations, hematological and serum biochemical examinations, urinalyses, and, in monkeys only, electrocardiograms) and post-mortem parameters (gross necropsy, organ weights, and histomorphologic evaluations from an extensive list of tissues). Blood samples were collected from control and treated animals for analyses of plasma concentrations of compound <b>7</b>. Extensive ophthalmic and electrocardiographic assessments were performed in the 3- and 9-month oral toxicity studies in monkeys. Compound <b>7</b> was also tested in CD1 mice in a 3-month study to support dose selection of a 2-year carcinogenicity study.</div><div class="NLM_p last">Additionally, embryo-fetal developmental was assessed in rats and rabbits following oral daily administration of compound <b>7</b> from gestation day 6 (rat) or 7 (rabbit) through gestation day 20. The potential effects of compound <b>7</b> on the fertility of male and female rats were also assessed with <b>7</b> as per ICHM3 (R2). To support long-term clinical studies with compound <b>7</b> coadministered with tolterodine (an antimuscarinic agent), a repeat-dose oral combination toxicity study of 3 months duration was conducted in monkeys with compound <b>7</b> coadministered with tolterodine.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01372">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01372" class="ext-link">10.1021/acs.jmedchem.5b01372</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystallographic information for compound <b>7</b> and the algorithm for determination of calculated Log <i>D </i>(cLogD) (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01372/suppl_file/jm5b01372_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01372/suppl_file/jm5b01372_si_001.pdf">jm5b01372_si_001.pdf (176.08 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01372" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08576" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08576" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott D. Edmondson</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1063737f64643e75747d7f7e74637f7e507d7562737b3e737f7d"><span class="__cf_email__" data-cfemail="5c2f3f332828723938313332382f33321c31392e3f37723f3331">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Zhu</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nam Fung Kar</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerry Di Salvo</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hiroshi Nagabukuro</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beatrice Sacre-Salem</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Dingley</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Berger</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen D. Goble</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregori Morriello</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bart Harper</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher R. Moyes</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dong-Ming Shen</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liping Wang</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Ball</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aileen Fitzmaurice</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tara Frenkl</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loise N. Gichuru</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sookhee Ha</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amanda L. Hurley</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nina Jochnowitz</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dorothy Levorse</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shruty Mistry</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Randy R. Miller</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James Ormes</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gino M. Salituro</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony Sanfiz</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andra S. Stevenson</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine Villa</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beata Zamlynny</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stuart Green</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Struthers</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ann E. Weber</span> - <span class="hlFld-Affiliation affiliation">Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d77e5813-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46363" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46363" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors wish to thank Dr. Charles W. Ross III for help with high-resolution mass spectroscopy, Dr. Mengfen Lin and Dr. Peter G. Dormer for NMR analysis to confirm N-alkylation of acids <b>26</b> and <b>27</b>, and Dr. Andrew Brunskill for the writeup of <a href="/doi/suppl/10.1021/acs.jmedchem.5b01372/suppl_file/jm5b01372_si_001.pdf" class="ext-link">Supporting Information</a> on the X-ray crystallographic analysis of compound <b>7</b>. We also wish to thank Dr. Prabha Karnachi for conversion of microsome stability data from % parent remaining to intrinsic clearance values illustrated in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Finally, the authors also wish to thank Drs. Caroline McGregor and Christopher Mortko for support with the physicochemical characterization of <b>7</b>.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i43" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i43"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i44" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i44"> Abbreviations Used</h2><tr><td class="NLM_term">β-AR</td><td class="NLM_def"><p class="first last">β-adrenergic receptor</p></td></tr><tr><td class="NLM_term">OAB</td><td class="NLM_def"><p class="first last">overactive bladder</p></td></tr><tr><td class="NLM_term">RHS</td><td class="NLM_def"><p class="first last">right-hand side</p></td></tr><tr><td class="NLM_term">PLDS</td><td class="NLM_def"><p class="first last">phospholipidosis</p></td></tr><tr><td class="NLM_term">Cl<sub>p</sub></td><td class="NLM_def"><p class="first last">total drug clearance in plasma</p></td></tr><tr><td class="NLM_term">Cl<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound drug clearance in plasma</p></td></tr><tr><td class="NLM_term">PO AUC<sub>N,total</sub></td><td class="NLM_def"><p class="first last">total dose normalized drug exposure after PO administration</p></td></tr><tr><td class="NLM_term">PO AUC<sub>N,u</sub></td><td class="NLM_def"><p class="first last">unbound dose normalized drug exposure after PO administration</p></td></tr><tr><td class="NLM_term">FFA</td><td class="NLM_def"><p class="first last">free fatty acid</p></td></tr><tr><td class="NLM_term">BDC</td><td class="NLM_def"><p class="first last">bile-duct cannulated</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">β<sub>3</sub>-Adrenergic receptor agonists for the treatment of obesity</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1016/S0065-7743(08)61084-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2FS0065-7743%2808%2961084-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1998&pages=193-202&author=A.+E.+Weber&title=%CE%B23-Adrenergic+receptor+agonists+for+the+treatment+of+obesity&doi=10.1016%2FS0065-7743%2808%2961084-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2961084-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252961084-2%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25CE%25B23-Adrenergic%2520receptor%2520agonists%2520for%2520the%2520treatment%2520of%2520obesity%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D1998%26volume%3D33%26spage%3D193%26epage%3D202%26doi%3D10.1016%2FS0065-7743%2808%2961084-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Cernecka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span> </span><span class="NLM_article-title">The Odd Sibling: Features of β<sub>3</sub>-Adrenoceptor Pharmacology</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1124/mol.114.092817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fmol.114.092817" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=479-484&author=H.+Cerneckaauthor=C.+Sandauthor=M.+C.+Michel&title=The+Odd+Sibling%3A+Features+of+%CE%B23-Adrenoceptor+Pharmacology&doi=10.1124%2Fmol.114.092817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.092817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.092817%26sid%3Dliteratum%253Aachs%26aulast%3DCernecka%26aufirst%3DH.%26aulast%3DSand%26aufirst%3DC.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DThe%2520Odd%2520Sibling%253A%2520Features%2520of%2520%25CE%25B23-Adrenoceptor%2520Pharmacology%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D86%26spage%3D479%26epage%3D484%26doi%3D10.1124%2Fmol.114.092817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Ursino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crema, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">The β<sub>3</sub>-Adrenoceptor as a Therapeutic Target: Current Perspectives</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.phrs.2009.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.phrs.2009.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=19429463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=221-234&author=M.+G.+Ursinoauthor=V.+Vasinaauthor=E.+Raschiauthor=F.+Cremaauthor=F.+De+Ponti&title=The+%CE%B23-Adrenoceptor+as+a+Therapeutic+Target%3A+Current+Perspectives&doi=10.1016%2Fj.phrs.2009.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The β3-adrenoceptor as a therapeutic target: Current perspectives</span></div><div class="casAuthors">Ursino, Maria Grazia; Vasina, Valentina; Raschi, Emanuel; Crema, Francesca; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-234</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  β3-Adrenoceptors (β3-ARs) are located not only on the plasma membrane of both white and brown adipocytes, but also exist in human heart, gall bladder, gastrointestinal tract, prostate, urinary bladder detrusor, brain and in near-term myometrium.  They are now recognized as an attractive target for drug discovery and several efforts have been made in this field to understand their function and regulation in different human tissues.  The aim of this review is to highlight the functional role of β3-ARs as well as to discuss their potential for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFwN6K0dBHLVg90H21EOLACvtfcHk0lixSd_SJL0X_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D&md5=0638652d4bb93a1e8b275aec8eb37575</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DUrsino%26aufirst%3DM.%2BG.%26aulast%3DVasina%26aufirst%3DV.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCrema%26aufirst%3DF.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DThe%2520%25CE%25B23-Adrenoceptor%2520as%2520a%2520Therapeutic%2520Target%253A%2520Current%2520Perspectives%26jtitle%3DPharmacol.%2520Res.%26date%3D2009%26volume%3D59%26spage%3D221%26epage%3D234%26doi%3D10.1016%2Fj.phrs.2009.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Baker, J. G.</span><span> </span><span class="NLM_article-title">The selectivity of β-adrenoceptor agonists at the human β <sub>1</sub>, β <sub>2</sub>, and β <sub>3</sub> adrenoceptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1111%2Fj.1476-5381.2010.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=20590599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1048-1061&author=J.+G.+Baker&title=The+selectivity+of+%CE%B2-adrenoceptor+agonists+at+the+human+%CE%B2+1%2C+%CE%B2+2%2C+and+%CE%B2+3+adrenoceptors&doi=10.1111%2Fj.1476-5381.2010.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors</span></div><div class="casAuthors">Baker, Jillian G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1061</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).  Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.  In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.  This study examd. the affinity and intrinsic efficacy of β-adrenoceptor agonists at the three human β-adrenoceptors to det. whether the current agonists are subtype selective because of affinity or intrinsic efficacy.  Stable clonal CHO-K1 cell lines, transfected with either the human β1, β2 or β3-adrenoceptor, were used, and whole-cell [3H]-CGP 12177 radioligand binding and [3H]-cAMP accumulation were measured.  Several agonists were highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2-adrenoceptor over the β1 or β3), while others (e.g. isoprenaline) had little affinity-selectivity.  However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.  Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype-selective intrinsic efficacy.  Several ligands appeared to activate two agonist conformations of the β1- and β3-adrenoceptors.  There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.  Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopuUPn04Hp7LVg90H21EOLACvtfcHk0lj2kMNYRvPHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D&md5=daff8f97b1dfc4732135d3aa79e7de0f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520selectivity%2520of%2520%25CE%25B2-adrenoceptor%2520agonists%2520at%2520the%2520human%2520%25CE%25B2%25201%252C%2520%25CE%25B2%25202%252C%2520and%2520%25CE%25B2%25203%2520adrenoceptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1048%26epage%3D1061%26doi%3D10.1111%2Fj.1476-5381.2010.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Tyagi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chancellor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">β<sub>3</sub>-Adrenoceptor Agonists for the Treatment of Overactive Bladder</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1358/dof.2009.034.08.1401947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1358%2Fdof.2009.034.08.1401947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1alsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=635-640&author=P.+Tyagiauthor=V.+Tyagiauthor=N.+Yoshimuraauthor=M.+Chancellorauthor=O.+Yamaguchi&title=%CE%B23-Adrenoceptor+Agonists+for+the+Treatment+of+Overactive+Bladder&doi=10.1358%2Fdof.2009.034.08.1401947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">β3-adrenoceptor agonists for the treatment of overactive bladder</span></div><div class="casAuthors">Tyagi, P.; Tyagi, V.; Yoshimura, N.; Chancellor, M.; Yamaguchi, O.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">635-640</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a medical condition that refers to the bothersome symptoms of increased frequency of voiding episodes and involuntary urinary urgency, with or without subsequent urinary incontinence and often assocd. with nocturia.  The disorder afflicts more than 17 million people of both genders in the United States, with a higher prevalence in the elderly population.  The etiol. of OAB is uncertain, but it is known that voiding in the healthy condition involves bladder contractions triggered by acetylcholine released from parasympathetic nerves, activating postjunctional muscarinic receptors in the detrusor.  Muscarinic receptor antagonists are therefore the most common form of therapy prescribed for treating OAB, but their assocn. with mechanistic side effects has prompted the search for new drugs.  Functional studies have demonstrated that adrenoceptor agonist-evoked bladder relaxation is mediated primarily by β3-adrenoceptors (β3-AR) in humans.  These receptors are an attractive target for the treatment of OAB because of their unique ability to produce detrusor relaxation only during the storage phase, which may allow unimpeded bladder voiding without the risk of urinary retention.  The recently completed phase II clin. proof-of-concept study BLOSSOM (Beta3-adrenoceptor agonist in Lowering OAB Symptoms Study compared to Oral anti-Muscarinic) revealed that a novel selective β3-AR agonist (YM-178) was well tolerated and effective in treating OAB symptoms, further supporting the β3-AR as a valid therapeutic target for OAB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV9XH3QG-GrrVg90H21EOLACvtfcHk0lj2kMNYRvPHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1alsA%253D%253D&md5=d286794d8362aa0757c85f75e95815a1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.08.1401947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.08.1401947%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DTyagi%26aufirst%3DV.%26aulast%3DYoshimura%26aufirst%3DN.%26aulast%3DChancellor%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3D%25CE%25B23-Adrenoceptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D635%26epage%3D640%26doi%3D10.1358%2Fdof.2009.034.08.1401947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gillespie, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouget, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granato, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korstanje, C.</span><span> </span><span class="NLM_article-title">Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">388</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1007/s00210-015-1136-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1007%2Fs00210-015-1136-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=26047780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2015&pages=719-726&author=J.+I.+Gillespieauthor=C.+Rougetauthor=S.+Paleaauthor=C.+Granatoauthor=C.+Korstanje&title=Beta+adrenergic+modulation+of+spontaneous+microcontractions+and+electrical+field-stimulated+contractions+in+isolated+strips+of+rat+urinary+bladder+from+normal+animals+and+animals+with+partial+bladder+outflow+obstruction&doi=10.1007%2Fs00210-015-1136-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction</span></div><div class="casAuthors">Gillespie, J. I.; Rouget, C.; Palea, S.; Granato, C.; Korstanje, C.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">719-726</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Spontaneous microcontractions and elec. field stimulation (EFS)-evoked contractions in isolated rat bladder strips from normal and from 6 wk partial bladder outflow obstruction (pBOO) animals were studied to identify the potential site of action for the β3-adrenoceptor (AR) agonist mirabegron in detrusor overactivity in rats.  For this, effects of the β-AR agonist isoprenaline and mirabegron were tested in presence or absence of selective antagonists for β-AR subtypes, namely CGP-20712A for β1-AR, ICI-118,551 for β2-AR, and L-748,337 for β3-AR.  In detrusor strips from both normal and obstructed animals, EFS-induced contractions were weakly affected by isoprenaline and even less so by mirabegron.  In contrast, microcontraction activity was more potently reduced by isoprenaline (pIC50 7.3; Emax ±85 %), whereas mirabegron showed a small effect.  In pBOO strips, concn. response curves for isoprenaline and mirabegron at inhibition of EFS and spontaneous microcontractions were similar to those in normal strips.  Isoprenaline-induced inhibition of microcontractions and EFS was antagonized by the β1-AR antagonist, but not by the β2- and β3-AR antagonists.  In the context of β3-AR-mediated bladder functions for mirabegron in other expts., the current data question a role for effects at spontaneous microcontractions, or neurogenic detrusor stimulation in the mode of action for mirabegron in vivo, since functional bladder effects for mirabegron are reported to occur at much lower concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ_lUBLqjTmLVg90H21EOLACvtfcHk0lj2kMNYRvPHAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtL%252FI&md5=b4a098d0377e2dc4e0cc9990bf660da2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs00210-015-1136-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-015-1136-z%26sid%3Dliteratum%253Aachs%26aulast%3DGillespie%26aufirst%3DJ.%2BI.%26aulast%3DRouget%26aufirst%3DC.%26aulast%3DPalea%26aufirst%3DS.%26aulast%3DGranato%26aufirst%3DC.%26aulast%3DKorstanje%26aufirst%3DC.%26atitle%3DBeta%2520adrenergic%2520modulation%2520of%2520spontaneous%2520microcontractions%2520and%2520electrical%2520field-stimulated%2520contractions%2520in%2520isolated%2520strips%2520of%2520rat%2520urinary%2520bladder%2520from%2520normal%2520animals%2520and%2520animals%2520with%2520partial%2520bladder%2520outflow%2520obstruction%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2015%26volume%3D388%26spage%3D719%26epage%3D726%26doi%3D10.1007%2Fs00210-015-1136-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Rouget, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camparo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rischmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westfall, T. D.</span><span> </span><span class="NLM_article-title">Modulation of nerve-evoked contractions by β<sub>3</sub>-Adrenoceptor Agonism in Human and Rat Isolated Urinary Bladder</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1016/j.phrs.2013.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.phrs.2013.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=24378642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFCisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=14-20&author=C.+Rougetauthor=M.+Rekikauthor=P.+Camparoauthor=H.+Bottoauthor=P.+Rischmannauthor=P.+Lluelauthor=S.+Paleaauthor=T.+D.+Westfall&title=Modulation+of+nerve-evoked+contractions+by+%CE%B23-Adrenoceptor+Agonism+in+Human+and+Rat+Isolated+Urinary+Bladder&doi=10.1016%2Fj.phrs.2013.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder</span></div><div class="casAuthors">Rouget, Celine; Rekik, Moez; Camparo, Philippe; Botto, Henry; Rischmann, Pascal; Lluel, Philippe; Palea, Stefano; Westfall, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-20</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activation of β3-adrenoceptors has been shown to have a direct relaxant effect on urinary bladder smooth muscle from both rats and humans, however there are very few studies investigating the effects of β3-adrenoceptor agonists on nerve-evoked bladder contractions.  Therefore in the current study, the role of β3-adrenoceptors in modulating efferent neurotransmission was evaluated.  The effects of β3-adrenoceptor agonism on neurogenic contractions induced by elec. field stimulation (EFS) were compared with effects on contractions induced by exogenous acetylcholine (Ach) and αβ-methylene ATP (αβ-meATP) in order to det. the site of action.  Isoproterenol inhibited EFS-induced neurogenic contractions of human bladder (pD2 = 6.79; Emax = 65%).  The effect of isoproterenol was selectively inhibited by the β3-adrenoceptor antagonist L-748,337 (pKB = 7.34).  Contractions induced by exogenous Ach (0.5-1 μM) were inhibited 25% by isoproterenol (3 μM) while contractions to 10 Hz in the same strip were inhibited 67%.  The selective β3-adrenoceptor agonist CL-316,243 inhibited EFS-induced neurogenic contractions of rat bladder (pD2 = 7.83; Emax = 65%).  The effects of CL-316,243 were inhibited in a concn. dependent manner by L-748,337 (pA2 = 6.42).  Contractions induced by exogenous Ach and αβ-meATP were significantly inhibited by CL-316,243, 29% and 40%, resp.  These results demonstrate that the activation of β3-adrenoceptors inhibits neurogenic contractions of both rat and human urinary bladder.  Contractions induced by exogenously applied parasympathetic neurotransmitters are also inhibited by β3-agonism however the effect is clearly less than on neurogenic contractions (particularly in human), suggesting that in addn. to a direct effect on smooth muscle, activation of prejunctional β3-adrenoceptors may inhibit neurotransmitter release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp501UAd-dGX7Vg90H21EOLACvtfcHk0lhGsufl5XXflw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFCisLY%253D&md5=15c0a2525492bac0f1b63e5af39f6883</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2013.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2013.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DRouget%26aufirst%3DC.%26aulast%3DRekik%26aufirst%3DM.%26aulast%3DCamparo%26aufirst%3DP.%26aulast%3DBotto%26aufirst%3DH.%26aulast%3DRischmann%26aufirst%3DP.%26aulast%3DLluel%26aufirst%3DP.%26aulast%3DPalea%26aufirst%3DS.%26aulast%3DWestfall%26aufirst%3DT.%2BD.%26atitle%3DModulation%2520of%2520nerve-evoked%2520contractions%2520by%2520%25CE%25B23-Adrenoceptor%2520Agonism%2520in%2520Human%2520and%2520Rat%2520Isolated%2520Urinary%2520Bladder%26jtitle%3DPharmacol.%2520Res.%26date%3D2014%26volume%3D80%26spage%3D14%26epage%3D20%26doi%3D10.1016%2Fj.phrs.2013.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Takasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasamata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), A Novel and Selective β<sub>3</sub>-Adrenoceptor Agonist, on Bladder Function</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span><span class="refDoi"> DOI: 10.1124/jpet.106.115840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fjpet.106.115840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17293563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=642-647&author=T.+Takasuauthor=M.+Ukaiauthor=S.+Satoauthor=T.+Matsuiauthor=I.+Nagaseauthor=T.+Maruyamaauthor=M.+Sasamataauthor=K.+Miyataauthor=H.+Uchidaauthor=O.+Yamaguchi&title=Effect+of+%28R%29-2-%282-Aminothiazol-4-yl%29-4%E2%80%B2-%7B2-%5B%282-hydroxy-2-phenylethyl%29amino%5Dethyl%7Dacetanilide+%28YM178%29%2C+A+Novel+and+Selective+%CE%B23-Adrenoceptor+Agonist%2C+on+Bladder+Function&doi=10.1124%2Fjpet.106.115840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function</span></div><div class="casAuthors">Takasu, Toshiyuki; Ukai, Masashi; Sato, Shuichi; Matsui, Tetsuo; Nagase, Itsuro; Maruyama, Tatsuya; Sasamata, Masao; Miyata, Keiji; Uchida, Hisashi; Yamaguchi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">642-647</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the pharmacol. characteristics of YM178.  YM178 increased cAMP accumulation in Chinese hamster ovary (CHO) cells expressing human β3-adrenoceptor (AR).  The half-maximal effective concn. (EC50) value was 22.4 nM.  EC50 values of YM178 for human β1- and β2-ARs were 10,000 nM or more, resp.  The ratio of intrinsic activities of YM178 vs. maximal response induced by isoproterenol (nonselective β-AR agonist) was 0.8 for human β3-ARs, 0.1 for human β1-ARs, and 0.1 for human β2-ARs.  The relaxant effects of YM178 were evaluated in rats and humans bladder strips precontracted with carbachol (CCh) and compared with those of isoproterenol and 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP-12177A) (β3-AR agonist).  EC50 values of YM178 and isoproterenol in rat bladder strips precontracted with 10-6 M CCh were 5.1 and 1.4 μM, resp., whereas those in human bladder strips precontracted with 10-7 M CCh were 0.78 and 0.28 μM, resp.  In in vivo study, YM178 at a dose of 3 mg/kg i.v. decreased the frequency of rhythmic bladder contraction induced by intravesical filling with saline without suppressing its amplitude in anesthetized rats.  These findings suggest the suitability of YM178 as a therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoYI45QFLfbVg90H21EOLACvtfcHk0lhGsufl5XXflw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D&md5=607d913d56ea8378fc9f22c767cbc599</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.115840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.115840%26sid%3Dliteratum%253Aachs%26aulast%3DTakasu%26aufirst%3DT.%26aulast%3DUkai%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DI.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DSasamata%26aufirst%3DM.%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DUchida%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3DEffect%2520of%2520%2528R%2529-2-%25282-Aminothiazol-4-yl%2529-4%25E2%2580%25B2-%257B2-%255B%25282-hydroxy-2-phenylethyl%2529amino%255Dethyl%257Dacetanilide%2520%2528YM178%2529%252C%2520A%2520Novel%2520and%2520Selective%2520%25CE%25B23-Adrenoceptor%2520Agonist%252C%2520on%2520Bladder%2520Function%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D642%26epage%3D647%26doi%3D10.1124%2Fjpet.106.115840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sadananda, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drake, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, J. F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, A. E.</span><span> </span><span class="NLM_article-title">A Functional Analysis of the Influence of β<sub>3</sub>-adrenoceptors on the Rat Micturition Cycle</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">506</span><span class="NLM_x">–</span> <span class="NLM_lpage">515</span><span class="refDoi"> DOI: 10.1124/jpet.113.207340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fjpet.113.207340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=24008334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSqsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=506-515&author=P.+Sadanandaauthor=M.+J.+Drakeauthor=J.+F.+R.+Patonauthor=A.+E.+Pickering&title=A+Functional+Analysis+of+the+Influence+of+%CE%B23-adrenoceptors+on+the+Rat+Micturition+Cycle&doi=10.1124%2Fjpet.113.207340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle</span></div><div class="casAuthors">Sadananda, Prajni; Drake, Marcus J.; Paton, Julian F. R.; Pickering, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">506-515</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dysfunctions of the lower urinary tract, such as overactive bladder syndrome and incontinence, are the product of storage failure.  Spontaneous regional bladder wall movements [nonmicturition contractions (NMCs)] are proposed to generate afferent activity that signals vol. status to the central nervous system.  The sympathetic nervous system, via activation of β-adrenoceptors (β-ARs), causes bladder relaxation and promotes urine storage.  We hypothesized that β-AR regulation of micturition is mediated by suppression of NMCs.  We used an unanesthetized, decerebrate, artificially perfused rat prepn. that allows simultaneous cystometry with external urethral sphincter and pelvic afferent nerve recordings.  Systemic isoprenaline (10 nM to 1 μM) increased intervoid interval and bladder compliance accompanied by a decrease in NMC amplitude, voiding pressure, and voiding threshold.  Isoprenaline also reduced arterial pressure and increased heart rate.  The β3-AR agonist Mirabegron (10-100 nM) increased intervoid interval and bladder compliance and reduced NMC amplitude, yet preserved active voiding function and had no effect on arterial pressure or heart rate.  All of these effects of Mirabegron were blocked by the selective β3-AR antagonist N-[[3-[(2S)-2-hydroxy-3-[[2-[4-[(phenylsulfonyl)amino] phenyl]ethyl]amino]propoxy]phenyl]methyl]-acetamide (L748,337), which alone shortened intervoid interval and decreased bladder compliance-suggesting the presence of a basal β3-AR-mediated sympathetic tone.  Similar effects of Mirabegron were seen in an acetic acid-sensitized bladder prepn. and in prepns. after loss of Spinobulbar reflex bladder control.  The β3-AR-mediated increase in intervoid interval correlated with increased bladder compliance but not with the decrease in NMC amplitude.  These findings indicate that β3-adrenoceptors have a selective effect that improves urine storage by increasing compliance without affecting the active components of voiding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK7hSOupzh7rVg90H21EOLACvtfcHk0lhGsufl5XXflw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSqsLrF&md5=8beefddf5895a91a9f9bb9a4da9ea96b</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207340%26sid%3Dliteratum%253Aachs%26aulast%3DSadananda%26aufirst%3DP.%26aulast%3DDrake%26aufirst%3DM.%2BJ.%26aulast%3DPaton%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DPickering%26aufirst%3DA.%2BE.%26atitle%3DA%2520Functional%2520Analysis%2520of%2520the%2520Influence%2520of%2520%25CE%25B23-adrenoceptors%2520on%2520the%2520Rat%2520Micturition%2520Cycle%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D506%26epage%3D515%26doi%3D10.1124%2Fjpet.113.207340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCafferty, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiyar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luce, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coatney, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westfall, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieble, J. P.</span><span> </span><span class="NLM_article-title">GW427353 (Solabegron), A Novel, Selective β<sub>3</sub>-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span><span class="refDoi"> DOI: 10.1124/jpet.107.125757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fjpet.107.125757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17626794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=202-209&author=A.+Hicksauthor=G.+P.+McCaffertyauthor=E.+Riedelauthor=N.+Aiyarauthor=M.+Pullenauthor=C.+Evansauthor=T.+D.+Luceauthor=R.+W.+Coatneyauthor=G.+C.+Riveraauthor=T.+D.+Westfallauthor=J.+P.+Hieble&title=GW427353+%28Solabegron%29%2C+A+Novel%2C+Selective+%CE%B23-Adrenergic+Receptor+Agonist%2C+Evokes+Bladder+Relaxation+and+Increases+Micturition+Reflex+Threshold+in+the+Dog&doi=10.1124%2Fjpet.107.125757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">GW427353 (solabegron), a novel, selective β3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog</span></div><div class="casAuthors">Hicks, Alexandra; McCafferty, Gerald P.; Riedel, Erin; Aiyar, Nambi; Pullen, Mark; Evans, Christopher; Luce, Trudy D.; Coatney, Robert W.; Rivera, Gian C.; Westfall, Timothy D.; Hieble, J. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Functional studies have demonstrated that adrenoceptor agonist-evoked relaxation is mediated primarily by β3-adrenergic receptors (ARs) in human bladder.  Thus, the use of selective β3-AR agonists in the pharmacol. treatment of overactive bladder is being explored.  The present studies investigated the effects of a novel selective β3-AR agonist, (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid (GW427353; solabegron) on bladder function in the dog using in vitro and in vivo techniques.  GW427353 stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 ± 6 nM and an intrinsic activity 90% of isoproterenol.  At concns. of 10,000 nM, GW427353 produced a minimal response in cells expressing either β1-ARs or β2-ARs (max. response <10% of that to isoproterenol).  In dog isolated bladder strips, GW427353 evoked relaxation that was attenuated by the non-selective β-AR antagonist bupranolol and 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol (SR59230A) (reported to have β3-AR antagonist activity).  The relaxation was unaffected by atenolol, a selective β1-AR antagonist, or (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI 118551), a selective β2-AR antagonist.  GW427353 increased the vol. required to evoke micturition in the anesthetized dog following acetic acid-evoked bladder irritation, without affecting the ability of the bladder to void.  GW427353-evoked effects on bladder parameters in vivo were inhibited by bupranolol.  The present study demonstrates that selective activation of β3-AR with GW427353 evokes bladder relaxation and facilitates bladder storage mechanisms in the dog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgB2WHHmcNBrVg90H21EOLACvtfcHk0ljZ2in8w1vWRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK&md5=360088edb870525e082f8379d1b21779</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.125757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.125757%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DMcCafferty%26aufirst%3DG.%2BP.%26aulast%3DRiedel%26aufirst%3DE.%26aulast%3DAiyar%26aufirst%3DN.%26aulast%3DPullen%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DC.%26aulast%3DLuce%26aufirst%3DT.%2BD.%26aulast%3DCoatney%26aufirst%3DR.%2BW.%26aulast%3DRivera%26aufirst%3DG.%2BC.%26aulast%3DWestfall%26aufirst%3DT.%2BD.%26aulast%3DHieble%26aufirst%3DJ.%2BP.%26atitle%3DGW427353%2520%2528Solabegron%2529%252C%2520A%2520Novel%252C%2520Selective%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonist%252C%2520Evokes%2520Bladder%2520Relaxation%2520and%2520Increases%2520Micturition%2520Reflex%2520Threshold%2520in%2520the%2520Dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D202%26epage%3D209%26doi%3D10.1124%2Fjpet.107.125757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulmsten, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kerrebroeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wein, A.</span><span> </span><span class="NLM_article-title">The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1002/nau.10052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1002%2Fnau.10052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=11857671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=167-178&author=P.+Abramsauthor=L.+Cardozoauthor=M.+Fallauthor=D.+Griffithsauthor=P.+Rosierauthor=U.+Ulmstenauthor=P.+van+Kerrebroeckauthor=A.+Victorauthor=A.+Wein&title=The+Standardisation+of+Terminology+of+Lower+Urinary+Tract+Function%3A+Report+from+the+Standardisation+Sub-Committee+of+the+International+Continence+Society&doi=10.1002%2Fnau.10052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</span></div><div class="casAuthors">Abrams Paul; Cardozo Linda; Fall Magnus; Griffiths Derek; Rosier Peter; Ulmsten Ulf; van Kerrebroeck Philip; Victor Arne; Wein Alan</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and urodynamics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-78</span>
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5XK5Z-KmPwRgd2Wuil24tfW6udTcc2ebwjEEL0HaVFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D&md5=bea718982e738444bc86683b568828fb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fnau.10052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.10052%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DFall%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DD.%26aulast%3DRosier%26aufirst%3DP.%26aulast%3DUlmsten%26aufirst%3DU.%26aulast%3Dvan%2BKerrebroeck%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DA.%26aulast%3DWein%26aufirst%3DA.%26atitle%3DThe%2520Standardisation%2520of%2520Terminology%2520of%2520Lower%2520Urinary%2520Tract%2520Function%253A%2520Report%2520from%2520the%2520Standardisation%2520Sub-Committee%2520of%2520the%2520International%2520Continence%2520Society%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2002%26volume%3D21%26spage%3D167%26epage%3D178%26doi%3D10.1002%2Fnau.10052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Irwin, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milsom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunskaar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herschorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artibani, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, P.</span><span> </span><span class="NLM_article-title">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1306</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span><span class="refDoi"> DOI: 10.1016/j.eururo.2006.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.eururo.2006.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17049716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1306-1315&author=D.+E.+Irwinauthor=I.+Milsomauthor=S.+Hunskaarauthor=K.+Reillyauthor=Z.+Koppauthor=S.+Herschornauthor=K.+Coyneauthor=C.+Kelleherauthor=C.+Hampelauthor=W.+Artibaniauthor=P.+Abrams&title=Population-based+survey+of+urinary+incontinence%2C+overactive+bladder%2C+and+other+lower+urinary+tract+symptoms+in+five+countries%3A+results+of+the+EPIC+study&doi=10.1016%2Fj.eururo.2006.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span></div><div class="casAuthors">Irwin Debra E; Milsom Ian; Hunskaar Steinar; Reilly Kate; Kopp Zoe; Herschorn Sender; Coyne Karin; Kelleher Con; Hampel Christian; Artibani Walter; Abrams Paul</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-14; discussion 1314-5</span>
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    </div><div class="casAbstract">OBJECTIVE:  Estimate the prevalence of urinary incontinence (UI), overactive bladder (OAB), and other lower urinary tract symptoms (LUTS) among men and women in five countries using the 2002 International Continence Society (ICS) definitions.  METHODS:  This population-based, cross-sectional survey was conducted between April and December 2005 in Canada, Germany, Italy, Sweden, and the United Kingdom using computer-assisted telephone interviews.  A random sample of men and women aged >/= 18 yr residing in the five countries and who were representative of the general populations in these countries was selected.  Using 2002 ICS definitions, the prevalence estimates of storage, voiding, and postmicturition LUTS were calculated.  Data were stratified by country, age cohort, and gender.  RESULTS:  A total of 19,165 individuals agreed to participate; 64.3% reported at least one LUTS.  Nocturia was the most prevalent LUTS (men, 48.6%; women, 54.5%).  The prevalence of storage LUTS (men, 51.3%; women, 59.2%) was greater than that for voiding (men, 25.7%; women, 19.5%) and postmicturition (men, 16.9%; women, 14.2%) symptoms combined.  The overall prevalence of OAB was 11.8%; rates were similar in men and women and increased with age.  OAB was more prevalent than all types of UI combined (9.4%).  CONCLUSIONS:  The EPIC study is the largest population-based survey to assess prevalence rates of OAB, UI, and other LUTS in five countries.  To date, this is the first study to evaluate these symptoms simultaneously using the 2002 ICS definitions.  The results indicate that these symptoms are highly prevalent in the countries surveyed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDX7KjsEQJ0vSAs_PE1QvifW6udTcc2ebsjLSeEsRWOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D&md5=8a24630cb261f6888e72b9dbd25ac55d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2006.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2006.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DD.%2BE.%26aulast%3DMilsom%26aufirst%3DI.%26aulast%3DHunskaar%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DK.%26aulast%3DKopp%26aufirst%3DZ.%26aulast%3DHerschorn%26aufirst%3DS.%26aulast%3DCoyne%26aufirst%3DK.%26aulast%3DKelleher%26aufirst%3DC.%26aulast%3DHampel%26aufirst%3DC.%26aulast%3DArtibani%26aufirst%3DW.%26aulast%3DAbrams%26aufirst%3DP.%26atitle%3DPopulation-based%2520survey%2520of%2520urinary%2520incontinence%252C%2520overactive%2520bladder%252C%2520and%2520other%2520lower%2520urinary%2520tract%2520symptoms%2520in%2520five%2520countries%253A%2520results%2520of%2520the%2520EPIC%2520study%26jtitle%3DEur.%2520Urol.%26date%3D2006%26volume%3D50%26spage%3D1306%26epage%3D1315%26doi%3D10.1016%2Fj.eururo.2006.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, K. E.</span><span> </span><span class="NLM_article-title">Muscarinic receptor antagonists for overactive bladder</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span><span class="refDoi"> DOI: 10.1111/j.1464-410X.2007.07205.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1111%2Fj.1464-410X.2007.07205.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17922784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=987-1006&author=P.+Abramsauthor=K.+E.+Andersson&title=Muscarinic+receptor+antagonists+for+overactive+bladder&doi=10.1111%2Fj.1464-410X.2007.07205.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic receptor antagonists for overactive bladder</span></div><div class="casAuthors">Abrams, Paul; Andersson, Karl-Erik</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-1006</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia.  OAB symptoms are often assocd. with detrusor overactivity (DO).  Like OAB symptoms, the prevalence of DO increases with age and can have a neurogenic and/or myogenic etiol.  Bladder outlet obstruction can be a contributing factor in DO, possibly through cholinergic denervation of the detrusor and supersensitivity of muscarinic receptors to acetylcholine, although the prevalence of OAB is similar in men and women across age groups.  Acetylcholine is the primary contractile neurotransmitter in the human detrusor, and antimuscarinics exert their effects on OAB/DO by inhibiting the binding of acetylcholine at muscarinic receptors M2 and M3 on detrusor smooth muscle cells and other structures within the bladder wall.  Worldwide, there are six antimuscarinic drugs currently marketed for the treatment of OAB: oxybutynin, tolterodine, propiverine, trospium, darifenacin, and solifenacin.  Each has demonstrated efficacy for the treatment of OAB symptoms, but their pharmacokinetic and adverse event profiles differ somewhat due to structural differences (tertiary vs quaternary amines), muscarinic receptor subtype selectivities, and organ selectivities.  Antimuscarinics are generally well tolerated, even in special populations (e.g. men with bladder outlet obstruction, elderly patients, children).  The most frequently reported adverse events in clin. studies of antimuscarinics are dry mouth, constipation, headache, and blurred vision; few patients withdraw from clin. trials because of adverse events.  Development of an antimuscarinic with functional selectivity for the bladder would reduce the occurrence of antimuscarinic adverse events.  The therapeutic potential of several other agents, such as α3-adrenoceptor agonists, purinergic receptor antagonists, phosphodiesterase inhibitors, neurokinin-1 receptor antagonists, opioids, and Rho-kinase inhibitors, is also under investigation for the treatment of OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo46uZDo-vaI7Vg90H21EOLACvtfcHk0lhyzxbD5TMC1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M&md5=ae74f99443663035095e793c43358bfa</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2007.07205.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2007.07205.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26atitle%3DMuscarinic%2520receptor%2520antagonists%2520for%2520overactive%2520bladder%26jtitle%3DBJU%2520Int.%26date%3D2007%26volume%3D100%26spage%3D987%26epage%3D1006%26doi%3D10.1111%2Fj.1464-410X.2007.07205.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Dmochowski, R.</span><span> </span><span class="NLM_article-title">Improving the tolerability of anticholinergic agents in the treatment of overactive bladder</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span><span class="refDoi"> DOI: 10.2165/00002018-200528070-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.2165%2F00002018-200528070-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=15963006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1eisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2005&pages=583-600&author=R.+Dmochowski&title=Improving+the+tolerability+of+anticholinergic+agents+in+the+treatment+of+overactive+bladder&doi=10.2165%2F00002018-200528070-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the tolerability of anticholinergic agents in the treatment of overactive bladder</span></div><div class="casAuthors">Dmochowski, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">583-600</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Pharmacol. treatment for overactive bladder has centered around the interruption of the detrusor activity that is central to urge and incontinence symptoms.  The majority of patients with this disorder are treated with antimus-carinic agents.  These drugs have been demonstrated to improve urgency, frequency of micturition and urge incontinence, all of which are primary symptoms of overactive bladder; however, they are also commonly assocd. with anticholin-ergic adverse effects, most notably dry mouth.  Attempts to increase tolerability have included the development of advanced formulations that regulate release of the active ingredient and the development of pharmacol. agents that target the desired bladder receptors more specifically and accurately.  Although all agents provide good efficacy, tolerability is greatly affected by the formulation used to deliver the active pharmacol. agent, as well as the specificity of the targeted receptors.  Clin. trials involving a transdermal formulation of oxybutynin have shown that this delivery method may be assocd. with a lower incidence of anticholinergic adverse events compared with both the immediate-release and the extended-release oral formulations of traditional agents, as well as the most recently approved agents - trospium chloride, solifenacin and darifenacin.  Much is still being learned about the function and specificity of muscarinic receptors, which will support the development of agents with sustained efficacy and enhanced tolerability compared with the available formulations to date.  These include the S-isomer of oxybutynin, as well as selective muscarinic M2 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJMlIaamoD7Vg90H21EOLACvtfcHk0lhyzxbD5TMC1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1eisr0%253D&md5=7ab864abf97cfabdd2c80804f154a758</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F00002018-200528070-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200528070-00003%26sid%3Dliteratum%253Aachs%26aulast%3DDmochowski%26aufirst%3DR.%26atitle%3DImproving%2520the%2520tolerability%2520of%2520anticholinergic%2520agents%2520in%2520the%2520treatment%2520of%2520overactive%2520bladder%26jtitle%3DDrug%2520Saf.%26date%3D2005%26volume%3D28%26spage%3D583%26epage%3D600%26doi%3D10.2165%2F00002018-200528070-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Chapple, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khullar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitoun, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, D.</span><span> </span><span class="NLM_article-title">The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1016/j.eururo.2008.06.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.eururo.2008.06.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=18599186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2008&pages=543-562&author=C.+R.+Chappleauthor=V.+Khullarauthor=Z.+Gabrielauthor=D.+Mustonauthor=C.+E.+Bitounauthor=D.+Weinstein&title=The+Effects+of+Antimuscarinic+Treatments+in+Overactive+Bladder%3A+An+Update+of+a+Systematic+Review+and+Meta-Analysis&doi=10.1016%2Fj.eururo.2008.06.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</span></div><div class="casAuthors">Chapple, Christopher R.; Khullar, Vik; Gabriel, Zahava; Muston, Dominic; Bitoun, Caty Ebel; Weinstein, David</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">543-562</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Context: Antimuscarinic agents are currently the first-line pharmacotherapy for overactive bladder.  Objectives: A systematic review published in 2005 was updated, including data on a newly licensed antimuscarinic (fesoterodine).  The primary aim of this study was to systematically review evidence on the efficacy of licensed administration of antimuscarinic treatments in overactive bladder from randomised controlled trials.  Secondary aims were to review evidence on tolerability and safety and health-related quality of life (HRQL).  Evidence acquisition: All relevant data sources from randomised controlled trials were searched, and two independent reviewers considered publications for inclusion and extd. relevant data.  Meta-anal. was used to pool efficacy, tolerability, safety, and HRQL outcomes by treatment.  Efficacy was measured by continent days, mean voided vol., urgency episodes, and micturition frequency.  Tolerability and safety were measured by means of adverse event and withdrawal rates.  HRQL was measured by various instruments.  Evidence synthesis: An addnl. 1118 refs. were retrieved with data on 83 studies extd.  Antimuscarinics were found to be more effective than placebo.  Tolerability was good; few of the antimuscarinics were found to have significantly higher withdrawal rates in comparison to placebo.  No serious adverse event for any product was statistically significant compared to placebo.  Dry mouth (mild, moderate, severe) was the most commonly reported adverse event (29.6% on treatment vs 7.9% on placebo), followed by pruritus (15.4% on treatment vs 5.2% on placebo).  Improvements were seen in HRQL with treatment by darifenacin, fesoterodine, oxybutynin transdermal delivery system, propiverine extended release (ER), solifenacin, tolterodine ER and immediate release, and trospium.  Limitations of the study include restrictions on the types of patients typically included in overactive bladder trials and topics that have not been adequately addressed in the current antimuscarinic literature.  Conclusions: Antimuscarinics are efficacious, safe, and well-tolerated treatments that improve HRQL.  Profiles of each drug and dosage differ and should be considered in making treatment choices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAxiEtWQKM7Vg90H21EOLACvtfcHk0lhyzxbD5TMC1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK&md5=5bfba69dca14592a3212db8ef9a69630</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2008.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2008.06.047%26sid%3Dliteratum%253Aachs%26aulast%3DChapple%26aufirst%3DC.%2BR.%26aulast%3DKhullar%26aufirst%3DV.%26aulast%3DGabriel%26aufirst%3DZ.%26aulast%3DMuston%26aufirst%3DD.%26aulast%3DBitoun%26aufirst%3DC.%2BE.%26aulast%3DWeinstein%26aufirst%3DD.%26atitle%3DThe%2520Effects%2520of%2520Antimuscarinic%2520Treatments%2520in%2520Overactive%2520Bladder%253A%2520An%2520Update%2520of%2520a%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DEur.%2520Urol.%26date%3D2008%26volume%3D54%26spage%3D543%26epage%3D562%26doi%3D10.1016%2Fj.eururo.2008.06.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasahara, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β<sub>3</sub>-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side-Effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6048</span><span class="NLM_x">–</span> <span class="NLM_lpage">6057</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00638</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6048-6057&author=Y.+Wadaauthor=H.+Shirahashiauthor=T.+Iwanamiauthor=M.+Ogawaauthor=S.+Nakanoauthor=A.+Morimotoauthor=K.-i.+Kasaharaauthor=E.+Tanakaauthor=Y.+Takadaauthor=S.+Ohashiauthor=M.+Moriauthor=S.+Shuto&title=Discovery+of+Novel+Indazole+Derivatives+as+Highly+Potent+and+Selective+Human+%CE%B23-Adrenergic+Receptor+Agonists+with+the+Possibility+of+Having+No+Cardiovascular+Side-Effects&doi=10.1021%2Facs.jmedchem.5b00638"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00638%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DY.%26aulast%3DShirahashi%26aufirst%3DH.%26aulast%3DIwanami%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DMorimoto%26aufirst%3DA.%26aulast%3DKasahara%26aufirst%3DK.-i.%26aulast%3DTanaka%26aufirst%3DE.%26aulast%3DTakada%26aufirst%3DY.%26aulast%3DOhashi%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%2520Indazole%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Human%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonists%2520with%2520the%2520Possibility%2520of%2520Having%2520No%2520Cardiovascular%2520Side-Effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6048%26epage%3D6057%26doi%3D10.1021%2Facs.jmedchem.5b00638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span> </span><span class="NLM_article-title">Absorption, Disposition, Metabolism, and Excretion of Ritobegron (KUC-7483), A Novel and Selective β<sub>3</sub> Adrenoceptor Agonist, in Rats</span> <span class="citation_source-journal">Pharmazie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=881-888&author=Y.+Abeauthor=E.+Otaauthor=T.+Endoauthor=M.+Murakamiauthor=M.+Kobayashi&title=Absorption%2C+Disposition%2C+Metabolism%2C+and+Excretion+of+Ritobegron+%28KUC-7483%29%2C+A+Novel+and+Selective+%CE%B23+Adrenoceptor+Agonist%2C+in+Rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DOta%26aufirst%3DE.%26aulast%3DEndo%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26atitle%3DAbsorption%252C%2520Disposition%252C%2520Metabolism%252C%2520and%2520Excretion%2520of%2520Ritobegron%2520%2528KUC-7483%2529%252C%2520A%2520Novel%2520and%2520Selective%2520%25CE%25B23%2520Adrenoceptor%2520Agonist%252C%2520in%2520Rats%26jtitle%3DPharmazie%26date%3D2014%26volume%3D69%26spage%3D881%26epage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jesudason, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaich, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahl, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriauciunas, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rito, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satterwhite, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinsley, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trankle, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuker, A. J.</span><span> </span><span class="NLM_article-title">Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1021/ml200071k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200071k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=583-586&author=C.+D.+Jesudasonauthor=J.+E.+Bakerauthor=R.+D.+Bryantauthor=J.+W.+Fisherauthor=L.+S.+O%E2%80%99Farrellauthor=G.+A.+Gaichauthor=M.+M.+Heauthor=S.+D.+Kahlauthor=A.+V.+Kriauciunasauthor=M.+L.+Heimanauthor=M.+A.+Petersauthor=C.+J.+Ritoauthor=J.+H.+Satterwhiteauthor=F.+C.+Tinsleyauthor=W.+G.+Trankleauthor=A.+J.+Shuker&title=Combination+of+a+Beta+Adrenoceptor+Modulator+and+a+Norepinephrine-Serotonin+Uptake+Inhibitor+for+the+Treatment+of+Obesity&doi=10.1021%2Fml200071k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fml200071k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200071k%26sid%3Dliteratum%253Aachs%26aulast%3DJesudason%26aufirst%3DC.%2BD.%26aulast%3DBaker%26aufirst%3DJ.%2BE.%26aulast%3DBryant%26aufirst%3DR.%2BD.%26aulast%3DFisher%26aufirst%3DJ.%2BW.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DL.%2BS.%26aulast%3DGaich%26aufirst%3DG.%2BA.%26aulast%3DHe%26aufirst%3DM.%2BM.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DKriauciunas%26aufirst%3DA.%2BV.%26aulast%3DHeiman%26aufirst%3DM.%2BL.%26aulast%3DPeters%26aufirst%3DM.%2BA.%26aulast%3DRito%26aufirst%3DC.%2BJ.%26aulast%3DSatterwhite%26aufirst%3DJ.%2BH.%26aulast%3DTinsley%26aufirst%3DF.%2BC.%26aulast%3DTrankle%26aufirst%3DW.%2BG.%26aulast%3DShuker%26aufirst%3DA.%2BJ.%26atitle%3DCombination%2520of%2520a%2520Beta%2520Adrenoceptor%2520Modulator%2520and%2520a%2520Norepinephrine-Serotonin%2520Uptake%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D583%26epage%3D586%26doi%3D10.1021%2Fml200071k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sacco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bientinesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tienforti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racioppi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Agostino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, P.</span><span> </span><span class="NLM_article-title">Discovery History and Clinical Development of Mirabegron for the Treatment of Overactive Bladder and Urinary Incontinence</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1517/17460441.2014.892923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1517%2F17460441.2014.892923" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=433-448&author=E.+Saccoauthor=R.+Bientinesiauthor=D.+Tienfortiauthor=M.+Racioppiauthor=G.+Gulinoauthor=D.+D%E2%80%99Agostinoauthor=M.+Vittoriauthor=P.+Bassi&title=Discovery+History+and+Clinical+Development+of+Mirabegron+for+the+Treatment+of+Overactive+Bladder+and+Urinary+Incontinence&doi=10.1517%2F17460441.2014.892923"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.892923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.892923%26sid%3Dliteratum%253Aachs%26aulast%3DSacco%26aufirst%3DE.%26aulast%3DBientinesi%26aufirst%3DR.%26aulast%3DTienforti%26aufirst%3DD.%26aulast%3DRacioppi%26aufirst%3DM.%26aulast%3DGulino%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DD.%26aulast%3DVittori%26aufirst%3DM.%26aulast%3DBassi%26aufirst%3DP.%26atitle%3DDiscovery%2520History%2520and%2520Clinical%2520Development%2520of%2520Mirabegron%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%2520and%2520Urinary%2520Incontinence%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D433%26epage%3D448%26doi%3D10.1517%2F17460441.2014.892923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bragg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vouri, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlick, J. M.</span><span> </span><span class="NLM_article-title">Mirabegron: A Beta-3 Agonist for Overactive Bladder</span> <span class="citation_source-journal">Consult. Pharmacist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">823</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span><span class="refDoi"> DOI: 10.4140/TCP.n.2014.823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.4140%2FTCP.n.2014.823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=25521658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=823-837&author=R.+Braggauthor=D.+Hebelauthor=S.+M.+Vouriauthor=J.+M.+Pitlick&title=Mirabegron%3A+A+Beta-3+Agonist+for+Overactive+Bladder&doi=10.4140%2FTCP.n.2014.823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron: a Beta-3 agonist for overactive bladder</span></div><div class="casAuthors">Bragg Rebecca; Hebel Danielle; Vouri Scott Martin; Pitlick Jamie M</div><div class="citationInfo"><span class="NLM_cas:title">The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">823-37</span>
        ISSN:<span class="NLM_cas:issn">0888-5109</span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB).  DATA SOURCES:  A literature search was performed using MEDLINE (PubMed) prior to December 31, 2013, using the terms "mirabegron" and "randomized-controlled trial."  STUDY SELECTION/DATA EXTRACTION:  All published, double-blind, randomized-controlled trials assessing mirabegron were included.  Articles were reviewed and included if mirabegron was used as monotherapy and if the primary outcome analyzed drug efficacy.  DATA SYNTHESIS:  The efficacy of mirabegron for the treatment of OAB has been demonstrated in the selected five randomized, placebo-controlled trials.  The majority of these trials lasted 12 weeks and compared various doses of mirabegron with placebo and/or tolterodine extended-release (ER).  Primary efficacy outcomes for the trials included mean number of micturitions per 24 hours and mean number of incontinence episodes per 24 hours.  Included trials showed statistically significant reductions in both efficacy outcomes for various doses of mirabegron when compared with placebo.  CONCLUSION:  Based on the trials reviewed, mirabegron has been efficacious in reducing mean number of micturitions and incontinence episodes per 24 hours, as well as in improving other secondary outcomes such as OAB symptoms and quality-of-life measures.  Common adverse drug events seen with mirabegron include: hypertension, nasopharyngitis, urinary tract infections, headache, constipation, upper respiratory tract infection, arthralgia, diarrhea, tachycardia, abdominal pain, and fatigue.  Given the efficacy and safety data currently available, mirabegron represents a reasonable alternative to antimuscarinics for patients with OAB.  Future studies are needed to determine the utility of mirabegron for OAB in a variety of demographics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8R_CrClfSRxWfpMXQLRstfW6udTcc2earzqAsobj2fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D&md5=77c9f399bbcc48ffc99b3a39fc075116</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.4140%2FTCP.n.2014.823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4140%252FTCP.n.2014.823%26sid%3Dliteratum%253Aachs%26aulast%3DBragg%26aufirst%3DR.%26aulast%3DHebel%26aufirst%3DD.%26aulast%3DVouri%26aufirst%3DS.%2BM.%26aulast%3DPitlick%26aufirst%3DJ.%2BM.%26atitle%3DMirabegron%253A%2520A%2520Beta-3%2520Agonist%2520for%2520Overactive%2520Bladder%26jtitle%3DConsult.%2520Pharmacist%26date%3D2014%26volume%3D29%26spage%3D823%26epage%3D837%26doi%3D10.4140%2FTCP.n.2014.823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Martin, M.; Von Keitz, A.; Ohlstein, E.</span> <span class="citation_source-book">Abstracts of Papers</span>, Americal Urological Association’s 2012 Annual Meeting, Atlanta, GA; <span class="NLM_publisher-name">American Urological Association</span>: <span class="NLM_publisher-loc">Linthicum, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Abstract 520.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Martin&author=A.+Von+Keitz&author=E.+Ohlstein&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Urological%2520Association%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ellsworth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantasia, J.</span><span> </span><span class="NLM_article-title">Solabegron: A Potential Future Addition to the β<sub>3</sub> Adrenoceptor Agonist Armamentarium for the Management of Overactive Bladder</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1001836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1517%2F13543784.2015.1001836" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=413-419&author=P.+Ellsworthauthor=J.+Fantasia&title=Solabegron%3A+A+Potential+Future+Addition+to+the+%CE%B23+Adrenoceptor+Agonist+Armamentarium+for+the+Management+of+Overactive+Bladder&doi=10.1517%2F13543784.2015.1001836"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1001836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1001836%26sid%3Dliteratum%253Aachs%26aulast%3DEllsworth%26aufirst%3DP.%26aulast%3DFantasia%26aufirst%3DJ.%26atitle%3DSolabegron%253A%2520A%2520Potential%2520Future%2520Addition%2520to%2520the%2520%25CE%25B23%2520Adrenoceptor%2520Agonist%2520Armamentarium%2520for%2520the%2520Management%2520of%2520Overactive%2520Bladder%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D413%26epage%3D419%26doi%3D10.1517%2F13543784.2015.1001836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mathvink, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candelore, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colwell, L. F.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Discovery of a potent, orally bioavailable β<sub>3</sub> adrenergic receptor agonist, (R)-<i>N</i>-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3832</span><span class="NLM_x">–</span> <span class="NLM_lpage">3836</span><span class="refDoi"> DOI: 10.1021/jm000286i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000286i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3832-3836&author=R.+J.+Mathvinkauthor=J.+S.+Tolmanauthor=D.+Chittyauthor=M.+R.+Candeloreauthor=M.+A.+Cascieriauthor=L.+F.+Colwellauthor=L.+Dengauthor=W.+P.+Feeneyauthor=M.+J.+Forrestauthor=G.+J.+Homauthor=D.+E.+MacIntyreauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=L.+Totaauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=A.+E.+Weber&title=Discovery+of+a+potent%2C+orally+bioavailable+%CE%B23+adrenergic+receptor+agonist%2C+%28R%29-N-%5B4-%5B2-%5B%5B2-hydroxy-2-%283-pyridinyl%29ethyl%5Damino%5Dethyl%5Dphenyl%5D-4-%5B4-%5B4-%28trifluoromethyl%29phenyl%5Dthiazol-2-yl%5Dbenzenesulfonamide&doi=10.1021%2Fjm000286i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm000286i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000286i%26sid%3Dliteratum%253Aachs%26aulast%3DMathvink%26aufirst%3DR.%2BJ.%26aulast%3DTolman%26aufirst%3DJ.%2BS.%26aulast%3DChitty%26aufirst%3DD.%26aulast%3DCandelore%26aufirst%3DM.%2BR.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DColwell%26aufirst%3DL.%2BF.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DFeeney%26aufirst%3DW.%2BP.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DHom%26aufirst%3DG.%2BJ.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DTota%26aufirst%3DL.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520orally%2520bioavailable%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonist%252C%2520%2528R%2529-N-%255B4-%255B2-%255B%255B2-hydroxy-2-%25283-pyridinyl%2529ethyl%255Damino%255Dethyl%255Dphenyl%255D-4-%255B4-%255B4-%2528trifluoromethyl%2529phenyl%255Dthiazol-2-yl%255Dbenzenesulfonamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3832%26epage%3D3836%26doi%3D10.1021%2Fjm000286i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Van Baak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hul, G. B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toubro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSmet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saris, W. H. M.</span><span> </span><span class="NLM_article-title">Acute Effect of L-796568, A Novel β<sub>3</sub>-Adrenergic Receptor Agonist, on Energy Expenditure in Obese Men</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1067/mcp.2002.122527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1067%2Fmcp.2002.122527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=11956510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjs1ersbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=272-279&author=M.+A.+Van+Baakauthor=G.+B.+J.+Hulauthor=S.+Toubroauthor=A.+Astrupauthor=K.+M.+Gottesdienerauthor=M.+DeSmetauthor=W.+H.+M.+Saris&title=Acute+Effect+of+L-796568%2C+A+Novel+%CE%B23-Adrenergic+Receptor+Agonist%2C+on+Energy+Expenditure+in+Obese+Men&doi=10.1067%2Fmcp.2002.122527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men</span></div><div class="casAuthors">Van Baak, Marleen A.; Hul, Gabby B. J.; Toubro, Soren; Astrup, Arne; Gottesdiener, Keith M.; DeSmet, Marina; Saris, Wim H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">272-279</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Our objective was to investigate the thermogenic efficacy of single oral doses of the novel β3-adrenergic receptor agonist L-796568 [(R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl) ethyl]amino]ethyl]-phenyl] -4-[4-[4-(trifluoromethyl)phenyl] thiazol-2-yl]-benzenesulfonamide, dihydrochloride] in humans.  Twelve healthy overweight to obese men participated in this 2-center, 3-period, randomized, placebo-controlled, crossover trial.  In each period subjects received 250 mg L-796568, 1000 mg L-796568, or placebo.  Energy expenditure and RQ were detd. by indirect calorimetry; blood samples were taken; and ear temp., heart rate, and blood pressure were measured at baseline and during the 4-h period after administration.  Energy expenditure increased significantly after the 1000-mg dose (about 8%) and this was accompanied by an increase in plasma glycerol and free fatty acid concns.  Systolic blood pressure also increased significantly.  No changes in heart rate, diastolic blood pressure, ear temp., plasma catecholamine, potassium, or leptin were found.  Single-dose administration of 1000 mg of the novel β3-adrenergic receptor agonist L-796568 increased lipolysis and energy expenditure in overweight men.  This is the first study to show such an effect of β3-adrenergic receptor agonists in humans without significant evidence for β2-adrenergic receptor involvement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtaP0O2WKbrVg90H21EOLACvtfcHk0li4c7vGYRAw2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjs1ersbc%253D&md5=3435a2e5dec16a4f2d408d19836b2509</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.122527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.122527%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBaak%26aufirst%3DM.%2BA.%26aulast%3DHul%26aufirst%3DG.%2BB.%2BJ.%26aulast%3DToubro%26aufirst%3DS.%26aulast%3DAstrup%26aufirst%3DA.%26aulast%3DGottesdiener%26aufirst%3DK.%2BM.%26aulast%3DDeSmet%26aufirst%3DM.%26aulast%3DSaris%26aufirst%3DW.%2BH.%2BM.%26atitle%3DAcute%2520Effect%2520of%2520L-796568%252C%2520A%2520Novel%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonist%252C%2520on%2520Energy%2520Expenditure%2520in%2520Obese%2520Men%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D71%26spage%3D272%26epage%3D279%26doi%3D10.1067%2Fmcp.2002.122527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Larsen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toubro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Baak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saris, W. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astrup, A.</span><span> </span><span class="NLM_article-title">Effects of a 28-d Treatment with L-796568, A Novel β<sub>3</sub>-Adrenergic Receptor Agonist, on Energy Expenditure and Body Composition in Obese Men</span> <span class="citation_source-journal">Am. J. Clin. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=12324291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD38Xns1eqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=780-788&author=T.+M.+Larsenauthor=S.+Toubroauthor=M.+van+Baakauthor=K.+M.+Gottesdienerauthor=P.+Larsonauthor=W.+H.+M.+Sarisauthor=A.+Astrup&title=Effects+of+a+28-d+Treatment+with+L-796568%2C+A+Novel+%CE%B23-Adrenergic+Receptor+Agonist%2C+on+Energy+Expenditure+and+Body+Composition+in+Obese+Men"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men</span></div><div class="casAuthors">Larsen, Thomas M.; Toubro, Soren; van Baak, Marleen A.; Gottesdiener, Keith M.; Larson, Patrick; Saris, Wim H. M.; Astrup, Arne</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Nutrition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">780-788</span>CODEN:
                <span class="NLM_cas:coden">AJCNAC</span>;
        ISSN:<span class="NLM_cas:issn">0002-9165</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Nutrition</span>)
        </div><div class="casAbstract">Stimulation of energy expenditure (EE) with selective thermogenic β-adrenergic agonists may be a promising approach for treating obesity.  We analyzed the effects of the highly selective human β3-adrenergic agonist L-796568 on 24-h EE, substrate oxidn., and body compn. in obese, wt.-stable men.  In this 2-center, double-blind, randomized, parallel-group study, we measured 24-h EE before and after 28 d of treatment with L-796568 (375 mg/d) or placebo during wt. maintenance (ie, without dietary intervention) in nondiabetic, nonsmoking men aged 25-49 yr with body mass index (in kg/m2) of 28-35 (n = 10 subjects per treatment group).  The mean change in 24-h EE from before to after treatment did not differ significantly between groups (92±586 and 86±512 kJ/24 h for the L-796568 and placebo groups, resp.).  The change in 24-h nonprotein RQ from before to after treatment did not differ significantly between groups (0.009±0.021 and 0.009±0.029, resp.).  No changes in glucose tolerance were obsd., but triacylglycerol concns. decreased significantly with L-796568 treatment compared with placebo (-0.76±0.76 and 0.42±0.31 mmol/L, resp.; P < 0.002).  Overall, treatment-related changes in body compn. were not obsd., but higher plasma L-796568 concns. in the L-796568 group were assocd. with greater decreases in fat mass (r = -0.69, P < 0.03).  Treatment with L-796568 for 28 d had no major lipolytic or thermogenic effect but it lowered triacylglycerol concns.  This lack of chronic effect on energy balance is likely explained by insufficient recruitment of β3-responsive tissues in humans, down-regulation of the β3-adrenergic receptor-mediated effects with chronic dosing, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogKuqIefRBVbVg90H21EOLACvtfcHk0li4c7vGYRAw2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xns1eqsLg%253D&md5=a1437ac79c034a5eb3ea710bb556b356</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DT.%2BM.%26aulast%3DToubro%26aufirst%3DS.%26aulast%3Dvan%2BBaak%26aufirst%3DM.%26aulast%3DGottesdiener%26aufirst%3DK.%2BM.%26aulast%3DLarson%26aufirst%3DP.%26aulast%3DSaris%26aufirst%3DW.%2BH.%2BM.%26aulast%3DAstrup%26aufirst%3DA.%26atitle%3DEffects%2520of%2520a%252028-d%2520Treatment%2520with%2520L-796568%252C%2520A%2520Novel%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonist%252C%2520on%2520Energy%2520Expenditure%2520and%2520Body%2520Composition%2520in%2520Obese%2520Men%26jtitle%3DAm.%2520J.%2520Clin.%2520Nutr.%26date%3D2002%26volume%3D76%26spage%3D780%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zinner, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattiasson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, S. L.</span><span> </span><span class="NLM_article-title">Efficacy, Safety, and Tolerability of Extended-Release Once-Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients</span> <span class="citation_source-journal">J. Am. Geriatr. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1046/j.1532-5415.2002.50203.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1046%2Fj.1532-5415.2002.50203.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=12028164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BD383osFSrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2002&pages=799-807&author=N.+R.+Zinnerauthor=A.+Mattiassonauthor=S.+L.+Stanton&title=Efficacy%2C+Safety%2C+and+Tolerability+of+Extended-Release+Once-Daily+Tolterodine+Treatment+for+Overactive+Bladder+in+Older+versus+Younger+Patients&doi=10.1046%2Fj.1532-5415.2002.50203.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients</span></div><div class="casAuthors">Zinner Norman R; Mattiasson Anders; Stanton Stuart L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Geriatrics Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">799-807</span>
        ISSN:<span class="NLM_cas:issn">0002-8614</span>.
    </div><div class="casAbstract">OBJECTIVES:  To evaluate the efficacy, safety, and tolerability of a new, once-daily extended-release (ER) formulation of tolterodine in treating overactive bladder in older (> or =65) and younger (<65) patients.  DESIGN:  A 12-week double-blind, placebo-controlled clinical trial.  SETTING:  An international study conducted at 167 medical centers.  PARTICIPANTS:  One thousand fifteen patients (43.1% aged > or =65) with urge incontinence and urinary frequency.  INTERVENTION:  Patients were randomized to treatment with tolterodine ER 4 mg once daily (qd) (n = 507) or placebo (n = 508) for 12 weeks.  MEASUREMENTS:  Efficacy, measured with micturition charts (incontinence episodes, micturitions, volume voided per micturition) and subjective patient assessments, safety, and tolerability endpoints were evaluated, relative to placebo, according to two age cohorts: younger than 65 and 65 and older.  RESULTS:  Mean age in the older and younger patient cohorts was 74 (range 65-93) and 51 (range 20-64), respectively.  Compared with placebo, significant improvements in micturition chart variables with tolterodine ER showed no age-related differences.  Irrespective of age, significantly more tolterodine ER recipients than placebo recipients reported an improvement in urgency symptoms.  After 12 weeks of treatment with tolterodine ER, a fivefold increase in the percentage of patients able to finish tasks before voiding in response to urgency was noted in both age groups (<65: from 6.5-32.8%, > or =65: from 5.1-26.2%).  Tolterodine ER recipients, irrespective of age, also had significant improvements in their bladder condition than did placebo recipients.  Overall, a greater percentage of patients, irrespective of age, perceived any benefit with tolterodine ER than with placebo (P <.001).  Dry mouth (of any severity) was the most common adverse event in both the tolterodine ER and placebo treatment arms, irrespective of age (<65: ER 22.7%, placebo 8.1%; > or =65: ER 24.3%, placebo 7.2%).  Few patients (<2%) experienced severe dry mouth.  No central nervous system, visual, cardiac (per electrocardiogram), or laboratory safety concerns were noted.  Withdrawal rates due to adverse events on tolterodine ER 4 mg qd were comparable in the two age cohorts (<65: 5.5%; > or =65: 5.1%; P =.87).  CONCLUSIONS:  The new, once-daily ER formulation of tolterodine is efficacious, safe, and well tolerated in the treatment of patients with symptoms of overactive bladder, irrespective of age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn9iue94-DWw5nADWVYHg1fW6udTcc2eYSxIGtYo-_KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD383osFSrtQ%253D%253D&md5=7d852994f4dd4a731df09d4b90a05121</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1046%2Fj.1532-5415.2002.50203.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1532-5415.2002.50203.x%26sid%3Dliteratum%253Aachs%26aulast%3DZinner%26aufirst%3DN.%2BR.%26aulast%3DMattiasson%26aufirst%3DA.%26aulast%3DStanton%26aufirst%3DS.%2BL.%26atitle%3DEfficacy%252C%2520Safety%252C%2520and%2520Tolerability%2520of%2520Extended-Release%2520Once-Daily%2520Tolterodine%2520Treatment%2520for%2520Overactive%2520Bladder%2520in%2520Older%2520versus%2520Younger%2520Patients%26jtitle%3DJ.%2520Am.%2520Geriatr.%2520Soc.%26date%3D2002%26volume%3D50%26spage%3D799%26epage%3D807%26doi%3D10.1046%2Fj.1532-5415.2002.50203.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="citation_source-book">Detrol LA, tolterodine tartrate, extended release capsules</span>; Pharmacia & Upjohn Company: 2004; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21228se8-006_detrol_lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21228se8-006_detrol_lbl.pdf</a> (accessed November<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Detrol+LA%2C+tolterodine+tartrate%2C+extended+release+capsules%3B+Pharmacia+%26+Upjohn+Company%3A+2004%3B+U.S.+Food+and+Drug+Administration%2C+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2004%2F21228se8-006_detrol_lbl.pdf+%28accessed+November+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDetrol%2520LA%252C%2520tolterodine%2520tartrate%252C%2520extended%2520release%2520capsules%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandrell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennie, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, A.</span><span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lhANBkhZIXFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, S. J. F.</span><span> </span><span class="NLM_article-title">The Impact of Aromatic Ring Compound Developability – Are too Many Aromatic Rings A Liability in Drug Design?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-20&author=T.+J.+Ritchieauthor=S.+J.+F.+MacDonald&title=The+Impact+of+Aromatic+Ring+Compound+Developability+%E2%80%93+Are+too+Many+Aromatic+Rings+A+Liability+in+Drug+Design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacDonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520Impact%2520of%2520Aromatic%2520Ring%2520Compound%2520Developability%2520%25E2%2580%2593%2520Are%2520too%2520Many%2520Aromatic%2520Rings%2520A%2520Liability%2520in%2520Drug%2520Design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D20%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwei, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Metabolism of a thiazole benzenesulfonamide derivative, a potent and selective agonist of the human β<sub>3</sub>-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">778</span><span class="NLM_x">–</span> <span class="NLM_lpage">787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=778-787&author=W.+Tangauthor=R.+A.+Stearnsauthor=R.+R.+Millerauthor=J.+S.+Nguiauthor=R.+J.+Mathvinkauthor=A.+E.+Weberauthor=G.+Y.+Kweiauthor=J.+R.+Straussauthor=C.+A.+Keohaneauthor=G.+A.+Dossauthor=S.+H.+Chiuauthor=T.+A.+Baillie&title=Metabolism+of+a+thiazole+benzenesulfonamide+derivative%2C+a+potent+and+selective+agonist+of+the+human+%CE%B23-adrenergic+receptor%2C+in+rats%3A+identification+of+a+novel+isethionic+acid+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DNgui%26aufirst%3DJ.%2BS.%26aulast%3DMathvink%26aufirst%3DR.%2BJ.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DKwei%26aufirst%3DG.%2BY.%26aulast%3DStrauss%26aufirst%3DJ.%2BR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DChiu%26aufirst%3DS.%2BH.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMetabolism%2520of%2520a%2520thiazole%2520benzenesulfonamide%2520derivative%252C%2520a%2520potent%2520and%2520selective%2520agonist%2520of%2520the%2520human%2520%25CE%25B23-adrenergic%2520receptor%252C%2520in%2520rats%253A%2520identification%2520of%2520a%2520novel%2520isethionic%2520acid%2520conjugate%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D778%26epage%3D787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Morriello, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feighner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hreniuk, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galloway, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGettigan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laws, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKnight, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streckfuss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β<sub>3</sub> adrenergic receptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1865</span><span class="NLM_x">–</span> <span class="NLM_lpage">1870</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.bmcl.2010.12.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1865-1870&author=G.+J.+Morrielloauthor=H.+R.+Wendtauthor=A.+Bansalauthor=J.+Di+Salvoauthor=S.+Feighnerauthor=J.+Heauthor=A.+L.+Hurleyauthor=D.+L.+Hreniukauthor=G.+M.+Salituroauthor=M.+V.+Reddyauthor=S.+M.+Gallowayauthor=K.+K.+McGettiganauthor=G.+Lawsauthor=C.+McKnightauthor=G.+A.+Dossauthor=N.+N.+Tsouauthor=R.+M.+Blackauthor=J.+Morrisauthor=R.+G.+Ballauthor=A.+T.+Sanfizauthor=E.+Streckfussauthor=M.+Struthersauthor=S.+D.+Edmondson&title=Design+of+a+novel+pyrrolidine+scaffold+utilized+in+the+discovery+of+potent+and+selective+human+%CE%B23+adrenergic+receptor+agonists&doi=10.1016%2Fj.bmcl.2010.12.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DMorriello%26aufirst%3DG.%2BJ.%26aulast%3DWendt%26aufirst%3DH.%2BR.%26aulast%3DBansal%26aufirst%3DA.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DFeighner%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DHreniuk%26aufirst%3DD.%2BL.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DGalloway%26aufirst%3DS.%2BM.%26aulast%3DMcGettigan%26aufirst%3DK.%2BK.%26aulast%3DLaws%26aufirst%3DG.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DBlack%26aufirst%3DR.%2BM.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DSanfiz%26aufirst%3DA.%2BT.%26aulast%3DStreckfuss%26aufirst%3DE.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDesign%2520of%2520a%2520novel%2520pyrrolidine%2520scaffold%2520utilized%2520in%2520the%2520discovery%2520of%2520potent%2520and%2520selective%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1865%26epage%3D1870%26doi%3D10.1016%2Fj.bmcl.2010.12.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Moyes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goble, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingley, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzmaurice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gichuru, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochnowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagabukuro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamlynny, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β<sub>3</sub> Adrenergic Receptor Agonists for the Treatment of Overactive Bladder</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1021/jm4017224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1437-1453&author=C.+R.+Moyesauthor=R.+Bergerauthor=S.+D.+Gobleauthor=B.+Harperauthor=D.-M.+Shenauthor=L.+Wangauthor=A.+Bansalauthor=P.+N.+Brownauthor=A.+S.+Chenauthor=K.+H.+Dingleyauthor=J.+Di+Salvoauthor=A.+Fitzmauriceauthor=L.+N.+Gichuruauthor=A.+L.+Hurleyauthor=N.+Jochnowitzauthor=R.+R.+Millerauthor=S.+Mistryauthor=H.+Nagabukuroauthor=G.+M.+Salituroauthor=A.+Sanfizauthor=A.+S.+Stevensonauthor=K.+Villaauthor=B.+Zamlynnyauthor=M.+Struthersauthor=A.+E.+Weberauthor=S.+D.+Edmondson&title=Design%2C+Synthesis%2C+and+Evaluation+of+Conformationally+Restricted+Acetanilides+as+Potent+and+Selective+%CE%B23+Adrenergic+Receptor+Agonists+for+the+Treatment+of+Overactive+Bladder&doi=10.1021%2Fjm4017224"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm4017224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017224%26sid%3Dliteratum%253Aachs%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DD.-M.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBansal%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DP.%2BN.%26aulast%3DChen%26aufirst%3DA.%2BS.%26aulast%3DDingley%26aufirst%3DK.%2BH.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DGichuru%26aufirst%3DL.%2BN.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520Conformationally%2520Restricted%2520Acetanilides%2520as%2520Potent%2520and%2520Selective%2520%25CE%25B23%2520Adrenergic%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1437%26epage%3D1453%26doi%3D10.1021%2Fjm4017224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hanessian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sailes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, E.</span><span> </span><span class="NLM_article-title">Synthesis of Diversely Functionalized Indolizidinones and Related Bicyclic Lactams Using Intramolecular Grubbs Olefin Metathesis and Dieckmann Condensation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">7219</span><span class="NLM_x">–</span> <span class="NLM_lpage">7233</span><span class="refDoi"> DOI: 10.1021/jo030145z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo030145z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1eqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=7219-7233&author=S.+Hanessianauthor=H.+Sailesauthor=A.+Munroauthor=E.+Therrien&title=Synthesis+of+Diversely+Functionalized+Indolizidinones+and+Related+Bicyclic+Lactams+Using+Intramolecular+Grubbs+Olefin+Metathesis+and+Dieckmann+Condensation&doi=10.1021%2Fjo030145z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diversely Functionalized Indolizidinones and Related Bicyclic Lactams Using Intramolecular Grubbs Olefin Metathesis and Dieckmann Condensation</span></div><div class="casAuthors">Hanessian, Stephen; Sailes, Helen; Munro, Alexander; Therrien, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7219-7233</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bicyclic 1-aza-2-oxo ring systems with versatile functionality were synthesized from the Grubbs olefin metathesis of appropriate olefinic precursors, starting with L-pyroglutamic acid.  The carbocyclization products were further functionalized utilizing the double bond or by enolate chem. of the corresponding β,γ-unsatd. bicyclic lactam.  In an alternative strategy, indolizidinones were synthesized by application of an intramol. Dieckmann cyclization.  A constrained peptidomimetic thrombin inhibitor was prepd. from one of the bicyclic indolizidinones.  Mol. structures of (-)-(3S,6S,9S)-6-azido-3-[[(tert-butyldiphenylsilyl)oxy]methyl]hexahydro-5-indolizinone, (-)-(1R,3S,7S,8R,9S)-1-benzyl-7,8-oxa-5-oxooctahydroindolizine-3-carboxylic acid Me ester, (-)-(3S,6R,9S)-3-[[[(tert-butyldiphenyl)silyl]oxy]methyl]-6-azido-6-benzylhexahydroindolzin-5-one were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRe4oebr4irVg90H21EOLACvtfcHk0liZGx1tsMiB_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1eqsbw%253D&md5=a2e80c567a34037d9cfdfe263f8affc7</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fjo030145z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030145z%26sid%3Dliteratum%253Aachs%26aulast%3DHanessian%26aufirst%3DS.%26aulast%3DSailes%26aufirst%3DH.%26aulast%3DMunro%26aufirst%3DA.%26aulast%3DTherrien%26aufirst%3DE.%26atitle%3DSynthesis%2520of%2520Diversely%2520Functionalized%2520Indolizidinones%2520and%2520Related%2520Bicyclic%2520Lactams%2520Using%2520Intramolecular%2520Grubbs%2520Olefin%2520Metathesis%2520and%2520Dieckmann%2520Condensation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D7219%26epage%3D7233%26doi%3D10.1021%2Fjo030145z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vaswani, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlin, R.</span><span> </span><span class="NLM_article-title">Stereocontrolled Total Synthesis of (−)-Kaitocephalin</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1661</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span><span class="refDoi"> DOI: 10.1021/jo702329z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702329z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=1661-1681&author=R.+G.+Vaswaniauthor=R.+Chamberlin&title=Stereocontrolled+Total+Synthesis+of+%28%E2%88%92%29-Kaitocephalin&doi=10.1021%2Fjo702329z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fjo702329z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702329z%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DChamberlin%26aufirst%3DR.%26atitle%3DStereocontrolled%2520Total%2520Synthesis%2520of%2520%2528%25E2%2588%2592%2529-Kaitocephalin%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D1661%26epage%3D1681%26doi%3D10.1021%2Fjo702329z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Fülöp, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palkó, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernáth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohár, P.</span><span> </span><span class="NLM_article-title">Synthesis and Retro Diels-Alder Decomposition of 1,4-Methanopyrrolo-,1,4-Methanoazepino[2,1-b]-quinazolinones</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1080/00397919708005019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1080%2F00397919708005019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=195-203&author=F.+F%C3%BCl%C3%B6pauthor=M.+Palk%C3%B3author=G.+Bern%C3%A1thauthor=P.+Soh%C3%A1r&title=Synthesis+and+Retro+Diels-Alder+Decomposition+of+1%2C4-Methanopyrrolo-%2C1%2C4-Methanoazepino%5B2%2C1-b%5D-quinazolinones&doi=10.1080%2F00397919708005019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F00397919708005019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919708005019%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCl%25C3%25B6p%26aufirst%3DF.%26aulast%3DPalk%25C3%25B3%26aufirst%3DM.%26aulast%3DBern%25C3%25A1th%26aufirst%3DG.%26aulast%3DSoh%25C3%25A1r%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520Retro%2520Diels-Alder%2520Decomposition%2520of%25201%252C4-Methanopyrrolo-%252C1%252C4-Methanoazepino%255B2%252C1-b%255D-quinazolinones%26jtitle%3DSynth.%2520Commun.%26date%3D1997%26volume%3D27%26spage%3D195%26epage%3D203%26doi%3D10.1080%2F00397919708005019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><div class="note"><p class="first last">The reason for comparing β<sub>3</sub>-AR EC<sub>50</sub>’s and β<sub>1</sub>-AR and β<sub>2</sub>-AR IC<sub>50</sub>’s as an assessment of selectivity is described in</p></div><span class="NLM_contrib-group">Mathvink, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candelore, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colwell, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Potent, selective 3-pyridylethanoloamine β<sub>3</sub> adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1971</span><span class="NLM_x">–</span> <span class="NLM_lpage">1973</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00390-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2FS0960-894X%2800%2900390-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=1971-1973&author=R.+J.+Mathvinkauthor=J.+S.+Tolmanauthor=D.+Chittyauthor=M.+R.+Candeloreauthor=M.+A.+Cascieriauthor=L.+F.+Colwellauthor=L.+Dengauthor=W.+P.+Feeneyauthor=M.+J.+Forrestauthor=G.+J.+Homauthor=E.+MacIntyreauthor=L.+Totaauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=A.+E.+Weber&title=Potent%2C+selective+3-pyridylethanoloamine+%CE%B23+adrenergic+receptor+agonists+possessing+a+thiazole+benzenesulfonamide+pharmacophore&doi=10.1016%2FS0960-894X%2800%2900390-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900390-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900390-5%26sid%3Dliteratum%253Aachs%26aulast%3DMathvink%26aufirst%3DR.%2BJ.%26aulast%3DTolman%26aufirst%3DJ.%2BS.%26aulast%3DChitty%26aufirst%3DD.%26aulast%3DCandelore%26aufirst%3DM.%2BR.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DColwell%26aufirst%3DL.%2BF.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DFeeney%26aufirst%3DW.%2BP.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DHom%26aufirst%3DG.%2BJ.%26aulast%3DMacIntyre%26aufirst%3DE.%26aulast%3DTota%26aufirst%3DL.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DPotent%252C%2520selective%25203-pyridylethanoloamine%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%2520possessing%2520a%2520thiazole%2520benzenesulfonamide%2520pharmacophore%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D1971%26epage%3D1973%26doi%3D10.1016%2FS0960-894X%2800%2900390-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lynch, J. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stupienski, R. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beare, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleby, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkiewicz, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. B.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=7802864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1KmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=541-554&author=J.+J.+Lynchauthor=A.+A.+Wallaceauthor=R.+F.+Stupienskiauthor=E.+P.+Baskinauthor=C.+M.+Beareauthor=S.+D.+Applebyauthor=J.+J.+Salataauthor=N.+K.+Jurkiewiczauthor=M.+C.+Sanguinettiauthor=R.+B.+Stein&title=Cardiac+electrophysiologic+and+antiarrhythmic+actions+of+two+long-acting+spirobenzopyran+piperidine+class+III+agents%2C+L-702%2C958+and+L-706%2C000+%5BMK-499%5D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]</span></div><div class="casAuthors">Lynch, Joseph J., Jr.; Wallace, Audrey A.; Stupienski, Raymond F., III; Baskin, Elizabeth P.; Beare, Carolann M.; Appleby, Sandra D.; Salata, Joseph J.; Jurkiewicz, Nancy K.; Sanguinetti, Michael; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">541-54</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The cardiac electrophysiol. and antiarrhythmic actions of two Class III ketone- and alc.-contg. spirobenzopyran piperidine analogs, L-702,958 and L-706,000 [MK-499], resp., were assessed in vitro and in vivo.  L-702,958 and L-706,000 [MK-499] selectively blocked the rapidly activating component of the delayed rectifier K+ current in guinea pig isolated ventricular myocytes (IC50 values, 14.6 and 43.9 nM, resp.), and prolonged effective refractory period in ferret isolated papillary muscles (EC25 values, 10.5 and 53.8 nM, resp.).  In anesthetized dogs, L-702,958 and L-706,000 [MK-499] increased ventricular refractory periods (ED20 values, 3.3 and 9.2 μg/kg i.v., resp.) and concomitantly increased ECG QT interval and left ventricular + dP/dt.  Cumulative i.v. administrations of ≤100 μg/kg of L-702,958 and 300 μg/kg L-706,000 [MK-499] in anesthetized dogs increased atrial and ventricular refractoriness and prolonged the ECG QT interval, but did not alter atrial, atrioventricular nodal, His-Purkinje or ventricular conduction indexes.  In anesthetized dogs studied chronically (9.2 days) after anterior myocardial infarction, the cumulative i.v. administrations of 100 μg/kg of L-702,958 and 300 μg/kg L-706,000 [MK-499] suppressed the induction of ventricular tachyarrhythmia by programmed ventricular stimulation (suppression rates: 8 of 10, 80% and 9 of 11, 82%, resp.) and reduced the incidence of lethal ventricular arrhythmias (incidences of lethal ischemic arrhythmias: 4 of 10, 40% and 1 of 11 9%, resp., compared to 34 of 40, 85%, in vehicle controls).  L-702,958 and L-706,000 [MK-499] (cumulative 100 and 300 μg/kg i.v., resp.) did not facilitate the induction of arrhythmias by programmed ventricular stimulation in postinfarction dogs.  After equivalently effective p.o. doses in conscious dogs, L-702,958 (10 μg/kg) and L-706,000 [MK-499] (30 μg/kg) increased ECG QT interval with long durations of action of approx. 9 and 14 h, resp.  L-706,000 [MK-499] elicited a more consistent and sustained prolongation of the QT interval than L-702,958.  These findings show that both L-702,958 and L-706,000 [MK-499] are potentially useful agents for the prevention of malignant ventricular arrhythmias in the setting of myocardial ischemic injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoodlHaDa4-FrVg90H21EOLACvtfcHk0ljZ-fAWI2GPvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1KmtLY%253D&md5=b13505c41ffd30d723860c4b9e13dfb8</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DWallace%26aufirst%3DA.%2BA.%26aulast%3DStupienski%26aufirst%3DR.%2BF.%26aulast%3DBaskin%26aufirst%3DE.%2BP.%26aulast%3DBeare%26aufirst%3DC.%2BM.%26aulast%3DAppleby%26aufirst%3DS.%2BD.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26aulast%3DJurkiewicz%26aufirst%3DN.%2BK.%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DStein%26aufirst%3DR.%2BB.%26atitle%3DCardiac%2520electrophysiologic%2520and%2520antiarrhythmic%2520actions%2520of%2520two%2520long-acting%2520spirobenzopyran%2520piperidine%2520class%2520III%2520agents%252C%2520L-702%252C958%2520and%2520L-706%252C000%2520%255BMK-499%255D%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1994%26volume%3D269%26spage%3D541%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schoemaker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, S.</span><span> </span><span class="NLM_article-title">Calcium Channel Receptor Binding Studies for Diltiazem and Its Major Metabolites: Fuctional Correlation to Inhibition of Portal Vein Myogenic Activity</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1097/00005344-198702000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1097%2F00005344-198702000-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1987&pages=173-180&author=H.+Schoemakerauthor=P.+Hicksauthor=S.+Langer&title=Calcium+Channel+Receptor+Binding+Studies+for+Diltiazem+and+Its+Major+Metabolites%3A+Fuctional+Correlation+to+Inhibition+of+Portal+Vein+Myogenic+Activity&doi=10.1097%2F00005344-198702000-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1097%2F00005344-198702000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-198702000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DSchoemaker%26aufirst%3DH.%26aulast%3DHicks%26aufirst%3DP.%26aulast%3DLanger%26aufirst%3DS.%26atitle%3DCalcium%2520Channel%2520Receptor%2520Binding%2520Studies%2520for%2520Diltiazem%2520and%2520Its%2520Major%2520Metabolites%253A%2520Fuctional%2520Correlation%2520to%2520Inhibition%2520of%2520Portal%2520Vein%2520Myogenic%2520Activity%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1987%26volume%3D9%26spage%3D173%26epage%3D180%26doi%3D10.1097%2F00005344-198702000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hartmann, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedeman, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, G. E.</span><span> </span><span class="NLM_article-title">Effects of III-IV Linker Mutations on Human Heart Na<sup>+</sup> Channel Inactivation Gating</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1161/01.RES.75.1.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1161%2F01.RES.75.1.114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1994&pages=114-122&author=H.+A.+Hartmannauthor=A.+A.+Tiedemanauthor=S.+F.+Chenauthor=A.+M.+Brownauthor=G.+E.+Kirsch&title=Effects+of+III-IV+Linker+Mutations+on+Human+Heart+Na%2B+Channel+Inactivation+Gating&doi=10.1161%2F01.RES.75.1.114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1161%2F01.RES.75.1.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.75.1.114%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DH.%2BA.%26aulast%3DTiedeman%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26aulast%3DKirsch%26aufirst%3DG.%2BE.%26atitle%3DEffects%2520of%2520III-IV%2520Linker%2520Mutations%2520on%2520Human%2520Heart%2520Na%252B%2520Channel%2520Inactivation%2520Gating%26jtitle%3DCirc.%2520Res.%26date%3D1994%26volume%3D75%26spage%3D114%26epage%3D122%26doi%3D10.1161%2F01.RES.75.1.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bhandari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueroa, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhold, D. L.</span><span> </span><span class="NLM_article-title">Phospholipidosis Assay in HepG2 Cells and Rat or Rhesus Hepatocytes Using Phospholipid Probe NBD-PE</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span><span class="refDoi"> DOI: 10.1089/adt.2007.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1089%2Fadt.2007.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=18537465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFCgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=407-420&author=N.+Bhandariauthor=D.+J.+Figueroaauthor=J.+W.+Lawrenceauthor=D.+L.+Gerhold&title=Phospholipidosis+Assay+in+HepG2+Cells+and+Rat+or+Rhesus+Hepatocytes+Using+Phospholipid+Probe+NBD-PE&doi=10.1089%2Fadt.2007.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phospholipidosis Assay in HepG2 Cells and Rat or Rhesus Hepatocytes Using Phospholipid Probe NBD-PE</span></div><div class="casAuthors">Bhandari, Neetesh; Figueroa, David J.; Lawrence, Jeffrey W.; Gerhold, David Lee</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Phospholipidosis (PLD) is an accumulation of phospholipids in lysosome-derived multilamellar vesicles.  More than 50 com. drugs are known to cause PLD.  In vitro screening assays were developed in HepG2 cells, rat primary hepatocytes, and rhesus monkey hepatocytes using the fluorescent-labeled phospholipid probe N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE) or Nile Red lipid stain.  The assays were qualified using amiodarone and fluoxetine as pos. controls and precocene and valproic acid as neg. controls.  NBD-PE accumulation and Nile Red staining were first measured using fluorescence microscopy with morphometric anal., and the throughput of the NBD-PE assay in HepG2 cells was increased by measuring fluorescence with a multiwell spectrofluorometer.  The PLD potential values obtained for the tested compds. from the morphometric anal. were similar to the values obtained from the spectrofluorometer, suggesting the plate reader assay was effective at measuring the induction of NBD-PE accumulation.  Fifteen com. compds. were evaluated using the NBD-PE assay in HepG2 cells, rat primary hepatocytes, and rhesus monkey hepatocytes.  The relative NBD-PE accumulation and PLD potentials of the evaluated compds. were similar and comparable to the values obsd. from other in vitro PLD assays referenced in the literature using different probes and cell lines.  NBD-PE accumulations obsd. in rat hepatocytes after drug treatments were similar to those in HepG2 cells.  NBD-PE accumulation potential obsd. in rhesus monkey hepatocytes after drug treatment was different for tamoxifen, perhexiline, clomipramine, and haloperidol.  These agents caused potent NBD-PE accumulation in HepG2 cells, but minimal or no activity was obsd. in rhesus monkey hepatocytes.  These data suggest that the NBD-PE spectrofluorometer assay in HepG2 cells has the speed and throughput to sensitively and quant. det. the PLD potential of various drug candidates.  In addn., these data demonstrate the species differences in PLD potential between rat and monkey hepatocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyDkd0BQfYSbVg90H21EOLACvtfcHk0ljZ-fAWI2GPvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFCgsrk%253D&md5=9776b2e6b248258d65c2668c29f599e0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.119%26sid%3Dliteratum%253Aachs%26aulast%3DBhandari%26aufirst%3DN.%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DLawrence%26aufirst%3DJ.%2BW.%26aulast%3DGerhold%26aufirst%3DD.%2BL.%26atitle%3DPhospholipidosis%2520Assay%2520in%2520HepG2%2520Cells%2520and%2520Rat%2520or%2520Rhesus%2520Hepatocytes%2520Using%2520Phospholipid%2520Probe%2520NBD-PE%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2008%26volume%3D6%26spage%3D407%26epage%3D420%26doi%3D10.1089%2Fadt.2007.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Goble, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockunier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiSalvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feighner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hreniuk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streckfuss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Heterocyclic Acetamide and Benzamide Derivatives as potent and selective β<sub>3</sub>-adrenergic receptor agonists with improved rodent pharmacokinetic profiles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1899</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.bmcl.2010.01.130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1895-1899&author=S.+D.+Gobleauthor=L.+Wangauthor=K.+L.+Howellauthor=A.+Bansalauthor=R.+Bergerauthor=L.+Brockunierauthor=J.+DiSalvoauthor=S.+Feighnerauthor=B.+Harperauthor=J.+Heauthor=A.+Hurleyauthor=D.+Hreniukauthor=E.+Parmeeauthor=M.+Robbinsauthor=G.+Salituroauthor=A.+Sanfizauthor=E.+Streckfussauthor=E.+Watkinsauthor=A.+E.+Weberauthor=M.+Struthersauthor=S.+D.+Edmondson&title=Heterocyclic+Acetamide+and+Benzamide+Derivatives+as+potent+and+selective+%CE%B23-adrenergic+receptor+agonists+with+improved+rodent+pharmacokinetic+profiles&doi=10.1016%2Fj.bmcl.2010.01.130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.130%26sid%3Dliteratum%253Aachs%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHowell%26aufirst%3DK.%2BL.%26aulast%3DBansal%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBrockunier%26aufirst%3DL.%26aulast%3DDiSalvo%26aufirst%3DJ.%26aulast%3DFeighner%26aufirst%3DS.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHurley%26aufirst%3DA.%26aulast%3DHreniuk%26aufirst%3DD.%26aulast%3DParmee%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DM.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStreckfuss%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DHeterocyclic%2520Acetamide%2520and%2520Benzamide%2520Derivatives%2520as%2520potent%2520and%2520selective%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520improved%2520rodent%2520pharmacokinetic%2520profiles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1895%26epage%3D1899%26doi%3D10.1016%2Fj.bmcl.2010.01.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liggett, S. B.</span><span> </span><span class="NLM_article-title">Functional Properties of the Rat and Human β<sub>3</sub>-Adrenergic Receptors: Differential Agonist Activation of Recombinant Receptors in Chinese Hamster Ovary Cells</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1992&pages=634-637&author=S.+B.+Liggett&title=Functional+Properties+of+the+Rat+and+Human+%CE%B23-Adrenergic+Receptors%3A+Differential+Agonist+Activation+of+Recombinant+Receptors+in+Chinese+Hamster+Ovary+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26atitle%3DFunctional%2520Properties%2520of%2520the%2520Rat%2520and%2520Human%2520%25CE%25B23-Adrenergic%2520Receptors%253A%2520Differential%2520Agonist%2520Activation%2520of%2520Recombinant%2520Receptors%2520in%2520Chinese%2520Hamster%2520Ovary%2520Cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1992%26volume%3D42%26spage%3D634%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vrydag, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span> </span><span class="NLM_article-title">Tools to Study β<sub>3</sub>-Adrenoceptors</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1007/s00210-006-0127-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1007%2Fs00210-006-0127-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17211601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVersrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2007&pages=385-98&author=W.+Vrydagauthor=M.+C.+Michel&title=Tools+to+Study+%CE%B23-Adrenoceptors&doi=10.1007%2Fs00210-006-0127-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Tools to study β3-adrenoceptors</span></div><div class="casAuthors">Vrydag, Wim; Michel, Martin C.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">385-398</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  β3-Adrenoceptors mediate some of the effects of catecholamines on tissues such as blood vessels or the urinary bladder and are putative targets for the treatment of diseases such as the overactive bladder syndrome.  Progress in the understanding of the presence, function, and regulation of β3-adrenoceptors has been hampered by a lack of highly specific tools.  "Classical" β3-adrenoceptor agonists such as BRL 37,344 [(R*, R*)-(±)-4[2-[(3-chlorophenyl)-2-hydroxyethyl amino] propyl] phenoxyacetic acid] and CGP 12,177 [(±)-4-(3-t-butylamino-2-hydroxypropoxy)benzimidazol-2-one] are only partial agonists in many settings, have limited selectivity over other β-adrenoceptor subtypes, and may addnl. act on receptors other than β-adrenoceptors.  More efficacious and more selective agonists have been reported and, in some cases, are in clin. development but are not widely available for exptl. studies.  The widely used antagonist SR 59,230 [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronaphth-1-ylamino]-2S-2-propanoloxalate] is not selective for β3-adrenoceptors, at least in humans, and may actually be a partial agonist.  Radioligands, which are suitable either for the selective labeling of β3-adrenoceptors or for the nonselective labeling of all β-adrenoceptor subtypes, are also missing. β3- and β1/β2 double knockout mice have been reported, but their usefulness for extrapolations in humans is questionable based upon major differences between humans and rodents with regard to the ligand recognition and expression profiles of β3-adrenoceptors.  While the common availability of more selective agonists and antagonists at the β3-adrenoceptor is urgently awaited, the limitations of the currently available tools need to be considered in studies of β3-adrenoceptor for the time being.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFuFA8A8dRELVg90H21EOLACvtfcHk0lgQyiIuXmu1QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVersrs%253D&md5=46ae123b753946122873eaea5adaf76e</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1007%2Fs00210-006-0127-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-006-0127-5%26sid%3Dliteratum%253Aachs%26aulast%3DVrydag%26aufirst%3DW.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DTools%2520to%2520Study%2520%25CE%25B23-Adrenoceptors%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2007%26volume%3D374%26spage%3D385%26epage%3D98%26doi%3D10.1007%2Fs00210-006-0127-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Birder, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groat, W. C.</span><span> </span><span class="NLM_article-title">Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4878</span><span class="NLM_x">–</span> <span class="NLM_lpage">4889</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1464772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADyaK3sXht1aht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1992&pages=4878-4889&author=L.+A.+Birderauthor=W.+C.+de+Groat&title=Increased+c-fos+expression+in+spinal+neurons+after+irritation+of+the+lower+urinary+tract+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat</span></div><div class="casAuthors">Birder, Lori A.; De Groat, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4878-89</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    </div><div class="casAbstract">This study utilized neuronal c-fos expression to examine the spinal pathways involved in processing nociceptive and non-nociceptive afferent input from the lower urinary tract (LUT) of the urethane-anesthetized rat.  C-fos protein was detected immunocytochem. in only a small no. of cells (<2 cells/L6 section) in control animals.  However, chem. irritation with 1% acetic acid or mech. stimulation of the LUT markedly increased the no. of c-fos-pos. neurons (56-180 cells/L6 section) in four regions of the caudal lumbosacral (L6-S1) spinal cord: medial dorsal horn (MDH), lateral dorsal horn, dorsal commissure (DCM), and sacral parasympathetic nucleus (SPN).  Only small nos. of c-fos-pos. cells were detected in rostral lumbar segments, a region that is though to receive nociceptive input from the LUT via afferent pathways in sympathetic nerves.  The distribution of c-fos-pos. cells in the L6 spinal cord varied according to the stimulus (i.e., urethral catheter, bladder distension, or chem. irritation).  Distension of the urinary bladder increased the no. of c-fos-pos. cells mainly in DCM and SPN regions of the cord.  In contrast, irritation of the LUT increased c-fos expression largely in DCM and MDH areas.  Spinal cord transection (T8 level) did not alter the c-fos expression induced by a catheter or chem. irritation, indicating that gene expression was mediated by spinal pathways.  Denervation expts. showed that c-fos expression was induced by activation of afferent pathways in the pelvic and pudendal nerves.  These results suggest that neurons in several regions of the spinal cord are involved in processing afferent input from different parts of the LUT.  Neurons in the DCM appear to have an important role since they respond to both nociceptive and non-nociceptive inputs and to visceral (pelvic nerve) and somatic (pudendal nerve) afferent pathways.  Thus, these neurons may be involved in the mechanisms of visceral-somatic referred pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23_bMKp_6CbVg90H21EOLACvtfcHk0lgQyiIuXmu1QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXht1aht7o%253D&md5=89d69a06b5be4eff23c8e3b34d8e8804</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBirder%26aufirst%3DL.%2BA.%26aulast%3Dde%2BGroat%26aufirst%3DW.%2BC.%26atitle%3DIncreased%2520c-fos%2520expression%2520in%2520spinal%2520neurons%2520after%2520irritation%2520of%2520the%2520lower%2520urinary%2520tract%2520in%2520the%2520rat%26jtitle%3DJ.%2520Neurosci.%26date%3D1992%26volume%3D12%26spage%3D4878%26epage%3D4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Nagabukuro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gichuru, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochnowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbadie, C.</span><span> </span><span class="NLM_article-title">Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats</span> <span class="citation_source-journal">Auton. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1016/j.autneu.2010.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.autneu.2010.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=20335078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1aqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2010&pages=19-26&author=H.+Nagabukuroauthor=A.+Degenhardtauthor=K.+L.+Villaauthor=S.+L.+Mistryauthor=L.+Gichuruauthor=N.+Jochnowitzauthor=C.+Abbadie&title=Correlation+between+pharmacologically-induced+changes+in+cystometric+parameters+and+spinal+c-Fos+expression+in+rats&doi=10.1016%2Fj.autneu.2010.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats</span></div><div class="casAuthors">Nagabukuro, Hiroshi; Degenhardt, Amanda; Villa, Katherine L.; Mistry, Shruti L.; Gichuru, Loise; Jochnowitz, Nina; Abbadie, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Autonomic Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">ANUEB2</span>;
        ISSN:<span class="NLM_cas:issn">1566-0702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The inhibition of bladder sensory transmission is crit. for the pharmacotherapy of urine storage symptoms.  The purpose of this study is to examine the correlation between pharmacol.-induced changes in cystometric parameters and spinal c-Fos expression in anesthetized rats with bladder hyperactivity induced by the intravesical infusion of acetic acid.  Animals were i.v. infused with either oxybutynin (OXY), a muscarinic receptor antagonist, tamsulosin (TAM), an α1-adrenoceptor antagonist, CL316243 (CL), a β3-adrenoceptor agonist, or saline.  Morphine (MOR) treatment served as a pos. control to inhibit bladder afferent activity.  Intermicturition intervals, micturition pressure and pressure threshold were measured after intravesical acetic acid infusion.  Animals were then perfused and spinal cords were removed.  Sections from the L6 spinal cord were immunostained with an anti-c-Fos antibody, and c-Fos pos. cells in the dorsal region were counted.  CL and MOR significantly increased intermicturition intervals, whereas OXY and TAM had no significant effect on intermicturition intervals.  While TAM and MOR did not affect the micturition pressure, OXY and CL caused a significant decrease.  Pressure threshold was significantly decreased by CL and increased by MOR.  All drugs significantly decreased the no. of c-Fos pos. cells with the following order of efficacy: MOR > CL > OXT > TAM.  The no. of c-Fos pos. cells in each animal from all treatment groups was neg. correlated with its av. intermicturition interval and pressure threshold, but not with its micturition pressure.  Bladder afferent activity is suppressed by several clin. proven mechanisms as measured by c-Fos expression, despite the varied effects on cystometric parameters of each pharmacol. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OrWBZy2DaLVg90H21EOLACvtfcHk0lh7KppPPsStqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1aqsrc%253D&md5=ba706884210b87c5c212b4b44335023a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.autneu.2010.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.autneu.2010.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DDegenhardt%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DK.%2BL.%26aulast%3DMistry%26aufirst%3DS.%2BL.%26aulast%3DGichuru%26aufirst%3DL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DAbbadie%26aufirst%3DC.%26atitle%3DCorrelation%2520between%2520pharmacologically-induced%2520changes%2520in%2520cystometric%2520parameters%2520and%2520spinal%2520c-Fos%2520expression%2520in%2520rats%26jtitle%3DAuton.%2520Neurosci.%26date%3D2010%26volume%3D156%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.autneu.2010.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="note"><p class="first last">For lead references to rodent lipolytic effects of β<sub>3</sub>-AR agonists, see</p></div><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautier, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danforth, E.,  Jr.</span><span> </span><span class="NLM_article-title">Development of Beta3-Adrenoceptor Agonists for the Treatment of Obesity and Diabetes – An Update</span> <span class="citation_source-journal">Diabetes Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10335419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADyaK1MXjt1Cruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1999&pages=11-21&author=C.+Weyerauthor=J.+F.+Gautierauthor=E.+Danforth&title=Development+of+Beta3-Adrenoceptor+Agonists+for+the+Treatment+of+Obesity+and+Diabetes+%E2%80%93+An+Update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development of beta3-adrenoceptor agonists for the treatment of obesity and diabetes - an update</span></div><div class="casAuthors">Weyer, C.; Gautier, J. F.; Danforth, E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & Metabolism</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">DIMEFW</span>;
        ISSN:<span class="NLM_cas:issn">1262-3636</span>.
    
            (<span class="NLM_cas:orgname">Masson Editeur</span>)
        </div><div class="casAbstract">A review with 94 refs.  Beta3-adrenoceptor (β3-AR) agonists were found to have remarkable anti-obesity and anti-diabetic effects in rodents shortly after their discovery in the early 1980s.  Despite these promising qualities, several pharmaceutical problems and theor. concerns have slowed the development of these products as therapeutic agents in humans during the last 15 yr.  To date, the pharmaceutical industry has not been successful in developing a β3-AR agonist for use in the treatment of human obesity and type 2 diabetes.  Pharmaceutical problems in this area concern important differences between rodent and human β3-AR and the difficulty in finding a compd. with sufficient bioavailability that is a highly selective and full agonist at the human receptor.  Some of these problems seem to have been solved with the cloning of the human β3-AR, which has made it possible to develop novel compds. directly and specifically against the human receptor.  However, several theor. concerns still remain.  These include the major question as to whether the no. of biol. active β3-ARs in adult humans is sufficient to produce relevant metabolic effects and, if so, whether their long-term stimulation is safe and free of unwarranted side effects.  In addn., the mechanisms of action of β3-AR agonists remain poorly understood.  Recent studies using CL 316,243, a highly selective β3-adrenergic compd., have provided new insights into the potential mechanisms of action of these drugs in rodents as well as the first evidence that treatment with a highly selective β3-AR agonist exerts relevant metabolic effects in humans.  It appears that chronic β3-adrenergic stimulation in white adipose tissue increases the expression of newly discovered mitochondrial uncoupling proteins (UCP 2 and 3) and a "reawakening" of dormant brown adipocytes.  In addn., β3-ARs may be present in skeletal muscle where ectopic expression of UCP-1 has been reported.  If these findings are confirmed, tissues other than brown fat may play an important role in mediating β3-adrenergic effects on thermogenesis and substrate oxidn.  In humans, treatment with CL 316,243 for 8 wk, in spite of limited bioavailability, induced marked plasma concn.-dependent increases in insulin sensitivity, lipolysis, and fat oxidn. in lean volunteers, without causing β1-, or β2-mediated side effects.  These results clearly indicate that favorable metabolic effects can be achieved by selective β3-AR stimulation in humans.  The compds. of the next generation currently emerging from preclin. development are full agonists at the human β3-AR.  These agents have demonstrated promising results in non-human primates.  It will be interesting to see whether their efficacy in clin. trials is superior to that achieved with previous (rodent) β3-AR agonists and, if so, whether their effects will eventually translate into wt. loss and improved metabolic control that could facilitate their use as effective drugs for the treatment of obesity and Type 2 diabetes in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLau4LifmzNbVg90H21EOLACvtfcHk0lh7KppPPsStqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjt1Cruro%253D&md5=85718d61dafe1aac00e999e5ef3cb48b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DGautier%26aufirst%3DJ.%2BF.%26aulast%3DDanforth%26aufirst%3DE.%26atitle%3DDevelopment%2520of%2520Beta3-Adrenoceptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Obesity%2520and%2520Diabetes%2520%25E2%2580%2593%2520An%2520Update%26jtitle%3DDiabetes%2520Metab.%26date%3D1999%26volume%3D25%26spage%3D11%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vose, C. W.; Ings, R. M. J.</span><span> </span><span class="NLM_article-title">Drug Metabolism</span>. In  <span class="citation_source-book">The Handbook of Medicinal Chemistry: Principles and Practice</span>; <span class="NLM_contrib-group">Davis, A.; Ward, S. E.</span>, Eds; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=184-207&author=C.+W.+Vose&author=R.+M.+J.+Ingsauthor=A.+Davis&author=S.+E.+Ward&title=The+Handbook+of+Medicinal+Chemistry%3A+Principles+and+Practice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVose%26aufirst%3DC.%2BW.%26atitle%3DDrug%2520Metabolism%26btitle%3DThe%2520Handbook%2520of%2520Medicinal%2520Chemistry%253A%2520Principles%2520and%2520Practice%26aulast%3DDavis%26aufirst%3DA.%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2014%26spage%3D184%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zientek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, K.</span><span> </span><span class="NLM_article-title">Reaction phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug Metabolizing Enzymes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1124/dmd.114.058750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fdmd.114.058750" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=163-81&author=M.+A.+Zientekauthor=K.+Youdim&title=Reaction+phenotyping%3A+Advances+in+the+Experimental+Strategies+Used+to+Characterize+the+Contribution+of+Drug+Metabolizing+Enzymes&doi=10.1124%2Fdmd.114.058750"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.058750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.058750%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%2BA.%26aulast%3DYoudim%26aufirst%3DK.%26atitle%3DReaction%2520phenotyping%253A%2520Advances%2520in%2520the%2520Experimental%2520Strategies%2520Used%2520to%2520Characterize%2520the%2520Contribution%2520of%2520Drug%2520Metabolizing%2520Enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D163%26epage%3D81%26doi%3D10.1124%2Fdmd.114.058750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahi, J.</span><span> </span><span class="NLM_article-title">Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclnical and Clinical</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span><span class="refDoi"> DOI: 10.1208/s12248-008-9037-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1208%2Fs12248-008-9037-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=391-400&author=M.+Sinzauthor=G.+Wallaceauthor=J.+Sahi&title=Current+Industrial+Practices+in+Assessing+CYP450+Enzyme+Induction%3A+Preclnical+and+Clinical&doi=10.1208%2Fs12248-008-9037-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1208%2Fs12248-008-9037-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-008-9037-4%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DWallace%26aufirst%3DG.%26aulast%3DSahi%26aufirst%3DJ.%26atitle%3DCurrent%2520Industrial%2520Practices%2520in%2520Assessing%2520CYP450%2520Enzyme%2520Induction%253A%2520Preclnical%2520and%2520Clinical%26jtitle%3DAAPS%2520J.%26date%3D2008%26volume%3D10%26spage%3D391%26epage%3D400%26doi%3D10.1208%2Fs12248-008-9037-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nettleton, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span> </span><span class="NLM_article-title">Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">382</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span><span class="refDoi"> DOI: 10.2174/156802611794480882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.2174%2F156802611794480882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=21320066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=382-403&author=D.+O.+Nettletonauthor=H.+J.+Einolf&title=Assessment+of+Cytochrome+P450+Enzyme+Inhibition+and+Inactivation+in+Drug+Discovery+and+Development&doi=10.2174%2F156802611794480882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of cytochrome P450 enzyme inhibition and inactivation in drug discovery and development</span></div><div class="casAuthors">Nettleton, David O.; Einolf, Heidi J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">382-403</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Evaluation of the potential of a drug candidate to inhibit or inactivate cytochrome P 450 (CYP) enzymes remains an important part of pharmaceutical drug Discovery and Development programs.  CYP enzymes are considered to be one of the most important enzyme families involved in the metabolic clearance of the vast majority of prescribed drugs.  Clin. drug-drug interactions (DDI) involving inhibition or time-dependent inactivation of these enzymes can result in dangerous side effects resulting from reduced clearance/increased exposure of the drug being affected (the "victim" drug).  In this regard, pharmaceutical companies have become quite vigilant in mitigating CYP inhibition/inactivation liabilities of drug candidates early in Discovery including continued risk assessment throughout Development.  In this review, common strategies and decision making processes for the assessment of DDI risk in the different stages of pharmaceutical development are discussed.  In addn., in vitro study designs, anal., and interpretation of CYP inhibition and inactivation data are described in stage appropriate context.  The in vitro tools and knowledge available now enable the Discovery Chemist to place the potential CYP DDI liability of a drug candidate into perspective and to aid in the optimization of chem. drug design to further mitigate this risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnthGt_UtSfLVg90H21EOLACvtfcHk0lh7KppPPsStqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnur8%253D&md5=985d26afbff18426f2dc6e4559addde1</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.2174%2F156802611794480882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480882%26sid%3Dliteratum%253Aachs%26aulast%3DNettleton%26aufirst%3DD.%2BO.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26atitle%3DAssessment%2520of%2520Cytochrome%2520P450%2520Enzyme%2520Inhibition%2520and%2520Inactivation%2520in%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D382%26epage%3D403%26doi%3D10.2174%2F156802611794480882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit38"><span>U.S. Department of Health & Human Services, U.S. Food and Drug Administration, The Biopharmaceutics Classification System (BCS) Guidance. <a href="http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219" class="extLink">http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219</a> (accessed November<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Department+of+Health+%26+Human+Services%2C+U.S.+Food+and+Drug+Administration%2C+The+Biopharmaceutics+Classification+System+%28BCS%29+Guidance.+http%3A%2F%2Fwww.fda.gov%2FAboutFDA%2FCentersOffices%2FOfficeofMedicalProductsandTobacco%2FCDER%2Fucm128219+%28accessed+November+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span><span class="refDoi"> DOI: 10.1021/tx200211v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&author=N.+A.+Meanwell&title=Improving+Drug+Candidates+by+Design%3A+A+Focus+on+Physicochemical+Properties+as+a+Means+of+Improving+Compound+Disposition+and+Safety&doi=10.1021%2Ftx200211v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0ljdXn2M54OeWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Candidates%2520by%2520Design%253A%2520A%2520Focus%2520on%2520Physicochemical%2520Properties%2520as%2520a%2520Means%2520of%2520Improving%2520Compound%2520Disposition%2520and%2520Safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1420%26epage%3D1456%26doi%3D10.1021%2Ftx200211v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">High-Resolution Crystal Structure of an Engineered Human β<sub>2</sub>-Adrenergic G Protein–Coupled Receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1258</span><span class="refDoi"> DOI: 10.1126/science.1150577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.+J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-Resolution+Crystal+Structure+of+an+Engineered+Human+%CE%B22-Adrenergic+G+Protein%E2%80%93Coupled+Receptor&doi=10.1126%2Fscience.1150577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the β2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human β2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the β2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0ljdXn2M54OeWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-Resolution%2520Crystal%2520Structure%2520of%2520an%2520Engineered%2520Human%2520%25CE%25B22-Adrenergic%2520G%2520Protein%25E2%2580%2593Coupled%2520Receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26doi%3D10.1126%2Fscience.1150577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Warne, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Vega, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moukhametzianov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schertler, G. F. X.</span><span> </span><span class="NLM_article-title">Structure of β<sub>1</sub>-Adrenergic G Protein-Coupled Receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1038/nature07101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnature07101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2008&pages=486-91&author=T.+Warneauthor=M.+J.+Serrano-Vegaauthor=J.+G.+Bakerauthor=R.+Moukhametzianovauthor=P.+C.+E.+Edwardsauthor=R.+Hendersonauthor=A.+G.+W.+Leslieauthor=C.+G.+Tateauthor=G.+F.+X.+Schertler&title=Structure+of+%CE%B21-Adrenergic+G+Protein-Coupled+Receptor&doi=10.1038%2Fnature07101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1038%2Fnature07101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07101%26sid%3Dliteratum%253Aachs%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DSerrano-Vega%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DMoukhametzianov%26aufirst%3DR.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%2BE.%26aulast%3DHenderson%26aufirst%3DR.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26atitle%3DStructure%2520of%2520%25CE%25B21-Adrenergic%2520G%2520Protein-Coupled%2520Receptor%26jtitle%3DNature%26date%3D2008%26volume%3D454%26spage%3D486%26epage%3D91%26doi%3D10.1038%2Fnature07101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit41c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lebon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1016/j.sbi.2012.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.sbi.2012.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=22480933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVeit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lebon%2C+G.%3B+Warne%2C+T.%3B+Tate%2C+C.+G.Curr.+Opin.+Struct.+Biol.+2012%2C+22%2C+482%E2%80%9390+10.1016%2Fj.sbi.2012.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41cR"><div class="casContent"><span class="casTitleNuber">41c</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-bound structures of G protein-coupled receptors</span></div><div class="casAuthors">Lebon, Guillaume; Warne, Tony; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-490</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) play a major role in intercellular communication by binding small diffusible ligands (agonists) at the extracellular surface.  Agonist-binding induces a conformational change in the receptor, which results in the binding and activation of heterotrimeric G proteins within the cell.  Ten agonist-bound structures of non-rhodopsin GPCRs published last year defined for the 1st time the mol. details of receptor activated states and how inverse agonists, partial agonists, and full agonists bind to produce different effects on the receptor.  In addn., the structure of the β2-adrenoceptor coupled to a heterotrimeric G protein showed how the opening of a cleft in the cytoplasmic face of the receptor as a consequence of agonist binding results in G protein coupling and activation of the G protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9IZFD6OPS4bVg90H21EOLACvtfcHk0lggGnQK1PxHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVeit7g%253D&md5=9d9a390eca0636d08918938c7a7e2eea</span></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2012.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2012.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DLebon%26aufirst%3DG.%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DTate%26aufirst%3DC.%2BG.%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2012%26volume%3D22%26spage%3D482%26epage%3D90%26doi%3D10.1016%2Fj.sbi.2012.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Klebe, G.</span><span> </span><span class="NLM_article-title">Applying Thermodynamic Profiling in Lead Finding and Optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1038/nrd4486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnrd4486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=25614222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVemtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=95-110&author=G.+Klebe&title=Applying+Thermodynamic+Profiling+in+Lead+Finding+and+Optimization&doi=10.1038%2Fnrd4486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Applying thermodynamic profiling in lead finding and optimization</span></div><div class="casAuthors">Klebe, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-110</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery involves the optimization of various physicochem. properties of a ligand, particularly its binding affinity for its target receptor (or receptors).  In recent years, there has been growing interest in using thermodn. profiling of ligand-receptor interactions in order to select and optimize those ligands that might be most likely to become drug candidates with desirable physicochem. properties.  The thermodn. of binding is influenced by multiple factors, including hydrogen bonding and hydrophobic interactions, desolvation, residual mobility, dynamics and the local water structure.  This article discusses key issues in understanding the effects of these factors and applying this knowledge in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqtHj7SsL6rrVg90H21EOLACvtfcHk0lggGnQK1PxHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVemtr4%253D&md5=c2e12760623de81335ce252cb804c602</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd4486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4486%26sid%3Dliteratum%253Aachs%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DApplying%2520Thermodynamic%2520Profiling%2520in%2520Lead%2520Finding%2520and%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D95%26epage%3D110%26doi%3D10.1038%2Fnrd4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Morgan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Graaf, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Street, S. D. A.</span><span> </span><span class="NLM_article-title">Can the Flow of Medicines be Improved? Fundamental Pharmacokinetic and Pharmacological Principles Toward Improving Phase II Survival</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1016/j.drudis.2011.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.drudis.2011.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=22227532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=419-424&author=P.+Morganauthor=P.+H.+Van+Der+Graafauthor=J.+Arrowsmithauthor=D.+E.+Feltnerauthor=K.+S.+Drummondauthor=C.+D.+Wegnerauthor=S.+D.+A.+Street&title=Can+the+Flow+of+Medicines+be+Improved%3F+Fundamental+Pharmacokinetic+and+Pharmacological+Principles+Toward+Improving+Phase+II+Survival&doi=10.1016%2Fj.drudis.2011.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival</span></div><div class="casAuthors">Morgan, Paul; Van Der Graaf, Piet H.; Arrowsmith, John; Feltner, Doug E.; Drummond, Kira S.; Wegner, Craig D.; Street, Steve D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">419-424</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In an effort to uncover systematic learnings that can be applied to improve compd. survival, an anal. was performed on data from Phase II decisions for 44 programs at Pfizer.  It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large no. of cases (43%), it was not possible to conclude whether the mechanism had been tested adequately.  A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacol. activity (termed together as the three Pillars of survival') all det. the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFyWWmU_ARMLVg90H21EOLACvtfcHk0lggGnQK1PxHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D&md5=18816036124edb3d50c4e063fdc40614</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DVan%2BDer%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DFeltner%26aufirst%3DD.%2BE.%26aulast%3DDrummond%26aufirst%3DK.%2BS.%26aulast%3DWegner%26aufirst%3DC.%2BD.%26aulast%3DStreet%26aufirst%3DS.%2BD.%2BA.%26atitle%3DCan%2520the%2520Flow%2520of%2520Medicines%2520be%2520Improved%253F%2520Fundamental%2520Pharmacokinetic%2520and%2520Pharmacological%2520Principles%2520Toward%2520Improving%2520Phase%2520II%2520Survival%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D419%26epage%3D424%26doi%3D10.1016%2Fj.drudis.2011.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Cook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">March, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satterthwaite, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangalos, M. N.</span><span> </span><span class="NLM_article-title">Lessons Learned from the Fate of AstraZeneca’s Drug Pipeline: A Five-Dimensional Framework</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+AstraZeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0lggGnQK1PxHcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520AstraZeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30a','cit30b','cit30c'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34'],'ref35':['cit35'],'ref39':['cit39'],'ref36':['cit36a','cit36b'],'ref37':['cit37a','cit37b'],'ref38':['cit38'],'ref40':['cit40'],'ref41':['cit41a','cit41b','cit41c'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 41 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Junichi Sonehara, Hidetoshi Isawa, Kiyoshi Kasai, Norihiko Kikuchi, Takehiro Ishikawa, Masahiro Kobayashi, Tetsuji Ozawa, Ritsu Suzuki, Makoto Kobayashi, Takayuki Ainai, Masayuki Nishimura, Yohei Saito, <span class="NLM_string-name hlFld-ContribAuthor">Kyoko Nakagawa-Goto</span>. </span><span class="cited-content_cbyCitation_article-title">Development of an Efficient Scale-Up Synthesis Method for a β3-Adrenergic Receptor Agonist, Ritobegron Ethyl Hydrochloride. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (9)
                                     , 1675-1682. <a href="https://doi.org/10.1021/acs.oprd.0c00278" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00278</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00278%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ban%252BEfficient%252BScale-Up%252BSynthesis%252BMethod%252Bfor%252Ba%252B%2525CE%2525B23-Adrenergic%252BReceptor%252BAgonist%25252C%252BRitobegron%252BEthyl%252BHydrochloride%26aulast%3DSonehara%26aufirst%3DJunichi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11062020%26date%3D13082020%26date%3D31072020%26volume%3D24%26issue%3D9%26spage%3D1675%26epage%3D1682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasuhiro  Wada</span>, <span class="hlFld-ContribAuthor ">Seiji  Nakano</span>, <span class="hlFld-ContribAuthor ">Akifumi  Morimoto</span>, <span class="hlFld-ContribAuthor ">Ken-ichi  Kasahara</span>, <span class="hlFld-ContribAuthor ">Takahiko  Hayashi</span>, <span class="hlFld-ContribAuthor ">Yoshio  Takada</span>, <span class="hlFld-ContribAuthor ">Hiroko  Suzuki</span>, <span class="hlFld-ContribAuthor ">Michiko  Niwa-Sakai</span>, <span class="hlFld-ContribAuthor ">Shigeki  Ohashi</span>, <span class="hlFld-ContribAuthor ">Mutsuhiro  Mori</span>, <span class="hlFld-ContribAuthor ">Takatsugu  Hirokawa</span>, and <span class="hlFld-ContribAuthor ">Satoshi  Shuto</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (8)
                                     , 3252-3265. <a href="https://doi.org/10.1021/acs.jmedchem.6b01197" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01197</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01197%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BIndazole%252BDerivatives%252Bas%252BOrally%252BAvailable%252B%2525CE%2525B23-Adrenergic%252BReceptor%252BAgonists%252BLacking%252BOff-Target-Based%252BCardiovascular%252BSide%252BEffects%26aulast%3DWada%26aufirst%3DYasuhiro%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D09082016%26date%3D11042017%26date%3D27042017%26date%3D29032017%26volume%3D60%26issue%3D8%26spage%3D3252%26epage%3D3265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Masayuki  Takeda</span>, <span class="hlFld-ContribAuthor ">Momokazu  Gotoh</span>, <span class="hlFld-ContribAuthor ">Osamu  Yokoyama</span>, <span class="hlFld-ContribAuthor ">Hidehiro  Kakizaki</span>, <span class="hlFld-ContribAuthor ">Satoru  Takahashi</span>, <span class="hlFld-ContribAuthor ">Naoya  Masumori</span>, <span class="hlFld-ContribAuthor ">Shinji  Nagai</span>, <span class="hlFld-ContribAuthor ">Kazuyoshi  Minemura</span>. </span><span class="cited-content_cbyCitation_article-title">Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study. </span><span class="cited-content_cbyCitation_journal-name">Neurourology and Urodynamics</span><span> <strong>2021,</strong> <em>40 </em>
                                    (6)
                                     , 1651-1660. <a href="https://doi.org/10.1002/nau.24732" title="DOI URL">https://doi.org/10.1002/nau.24732</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/nau.24732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fnau.24732%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurourology%2520and%2520Urodynamics%26atitle%3DCardiovascular%252Bsafety%252Bof%252Bvibegron%25252C%252Ba%252Bnew%252B%2525CE%2525B23%2525E2%252580%252590adrenoceptor%252Bagonist%25252C%252Bin%252Bolder%252Bpatients%252Bwith%252Boveractive%252Bbladder%25253A%252BPost%2525E2%252580%252590hoc%252Banalysis%252Bof%252Ba%252Brandomized%25252C%252Bplacebo%2525E2%252580%252590controlled%25252C%252Bdouble%2525E2%252580%252590blind%252Bcomparative%252Bphase%252B3%252Bstudy%26aulast%3DYoshida%26aufirst%3DMasaki%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D6%26spage%3D1651%26epage%3D1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Yong-Qiang  Luo</span>, <span class="hlFld-ContribAuthor ">Jia-Hui  Zuo</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Fang  Li</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">New drug approvals for 2020: Synthesis and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113284. <a href="https://doi.org/10.1016/j.ejmech.2021.113284" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113284%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Bdrug%252Bapprovals%252Bfor%252B2020%25253A%252BSynthesis%252Band%252Bclinical%252Bapplications%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2021%26volume%3D215%26spage%3D113284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susann  Varano</span>, <span class="hlFld-ContribAuthor ">David  Staskin</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Frankel</span>, <span class="hlFld-ContribAuthor ">Denise  Shortino</span>, <span class="hlFld-ContribAuthor ">Rachael  Jankowich</span>, <span class="hlFld-ContribAuthor ">Paul N.  Mudd</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. </span><span class="cited-content_cbyCitation_journal-name">Drugs & Aging</span><span> <strong>2021,</strong> <em>38 </em>
                                    (2)
                                     , 137-146. <a href="https://doi.org/10.1007/s40266-020-00829-z" title="DOI URL">https://doi.org/10.1007/s40266-020-00829-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40266-020-00829-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40266-020-00829-z%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2520%2526%2520Aging%26atitle%3DEfficacy%252Band%252BSafety%252Bof%252BOnce-Daily%252BVibegron%252Bfor%252BTreatment%252Bof%252BOveractive%252BBladder%252Bin%252BPatients%252BAged%252B%2525E2%252589%2525A565%252Band%252B%2525E2%252589%2525A575%252BYears%25253A%252BSubpopulation%252BAnalysis%252Bfrom%252Bthe%252BEMPOWUR%252BRandomized%25252C%252BInternational%25252C%252BPhase%252BIII%252BStudy%26aulast%3DVarano%26aufirst%3DSusann%26date%3D2021%26date%3D2021%26volume%3D38%26issue%3D2%26spage%3D137%26epage%3D146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tomasz  Rechberger</span>, <span class="hlFld-ContribAuthor ">Andrzej  Wróbel</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluating vibegron for the treatment of overactive bladder. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     , 9-17. <a href="https://doi.org/10.1080/14656566.2020.1809652" title="DOI URL">https://doi.org/10.1080/14656566.2020.1809652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2020.1809652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2020.1809652%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DEvaluating%252Bvibegron%252Bfor%252Bthe%252Btreatment%252Bof%252Boveractive%252Bbladder%26aulast%3DRechberger%26aufirst%3DTomasz%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D9%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shunye  Su</span>, <span class="hlFld-ContribAuthor ">Liqin  Liang</span>, <span class="hlFld-ContribAuthor ">Jinlei  Lin</span>, <span class="hlFld-ContribAuthor ">Ludong  Liu</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder. </span><span class="cited-content_cbyCitation_journal-name">Medicine</span><span> <strong>2021,</strong> <em>100 </em>
                                    (5)
                                     , e23171. <a href="https://doi.org/10.1097/MD.0000000000023171" title="DOI URL">https://doi.org/10.1097/MD.0000000000023171</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/MD.0000000000023171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FMD.0000000000023171%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%26atitle%3DSystematic%252Breview%252Band%252Bmeta-analysis%252Bof%252Bthe%252Befficacy%252Band%252Bsafety%252Bof%252Bvibegron%252Bvs%252Bantimuscarinic%252Bmonotherapy%252Bfor%252Boveractive%252Bbladder%26aulast%3DSu%26aufirst%3DShunye%26date%3D2021%26date%3D2021%26volume%3D100%26issue%3D5%26spage%3De23171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gary  Chinigo</span>, <span class="hlFld-ContribAuthor ">Yiqing  Feng</span>, <span class="hlFld-ContribAuthor ">Susan  Hoy</span>, <span class="hlFld-ContribAuthor ">Ricardo  Lira</span>, <span class="hlFld-ContribAuthor ">Matthew  Perry</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridazines and Their Benzo Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00082-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00082-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00082-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00082-2%26sid%3Dliteratum%253Aachs%26atitle%3DPyridazines%252Band%252BTheir%252BBenzo%252BDerivatives%26aulast%3DChinigo%26aufirst%3DGary%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cora  Fogaing</span>, <span class="hlFld-ContribAuthor ">Abubakr H.  Mossa</span>, <span class="hlFld-ContribAuthor ">Lysanne  Campeau</span>. </span><span class="cited-content_cbyCitation_article-title">Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?. </span><span class="cited-content_cbyCitation_journal-name">Current Urology Reports</span><span> <strong>2020,</strong> <em>21 </em>
                                    (12)
                                     <a href="https://doi.org/10.1007/s11934-020-01003-z" title="DOI URL">https://doi.org/10.1007/s11934-020-01003-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11934-020-01003-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11934-020-01003-z%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Urology%2520Reports%26atitle%3DAre%252BBeta%252B3%252BAdrenergic%252BAgonists%252BNow%252Bthe%252BPreferred%252BPharmacologic%252BManagement%252Bof%252BOveractive%252BBladder%25253F%26aulast%3DFogaing%26aufirst%3DCora%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongyu  Jian</span>, <span class="hlFld-ContribAuthor ">Chi  Yuan</span>, <span class="hlFld-ContribAuthor ">Hong  Li</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Kunjie  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. </span><span class="cited-content_cbyCitation_journal-name">International Urology and Nephrology</span><span> <strong>2020,</strong> <em>52 </em>
                                    (12)
                                     , 2215-2221. <a href="https://doi.org/10.1007/s11255-020-02536-5" title="DOI URL">https://doi.org/10.1007/s11255-020-02536-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11255-020-02536-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11255-020-02536-5%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Urology%2520and%2520Nephrology%26atitle%3DVibegron%252B50%2525C2%2525A0mg%252Bis%252Bthe%252Boptimal%252Balgorithm%252Bin%252Bthe%252Bpharmacologic%252Bmanagement%252Bof%252Boveractive%252Bbladder%25253A%252Boutcomes%252Bfrom%252Ba%252Bsystematic%252Breview%252Band%252Bmeta-analysis%26aulast%3DJian%26aufirst%3DZhongyu%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D12%26spage%3D2215%26epage%3D2221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin M.  Brucker</span>, <span class="hlFld-ContribAuthor ">Richard K.  Lee</span>, <span class="hlFld-ContribAuthor ">Diane K.  Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing Nonsurgical Treatments of Overactive Bladder in the United States. </span><span class="cited-content_cbyCitation_journal-name">Urology</span><span> <strong>2020,</strong> <em>145 </em>, 52-59. <a href="https://doi.org/10.1016/j.urology.2020.06.017" title="DOI URL">https://doi.org/10.1016/j.urology.2020.06.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.urology.2020.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.urology.2020.06.017%26sid%3Dliteratum%253Aachs%26jtitle%3DUrology%26atitle%3DOptimizing%252BNonsurgical%252BTreatments%252Bof%252BOveractive%252BBladder%252Bin%252Bthe%252BUnited%252BStates%26aulast%3DBrucker%26aufirst%3DBenjamin%2BM.%26date%3D2020%26volume%3D145%26spage%3D52%26epage%3D59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Akira  Furuta</span>, <span class="hlFld-ContribAuthor ">Yasuyuki  Suzuki</span>, <span class="hlFld-ContribAuthor ">Taro  Igarashi</span>, <span class="hlFld-ContribAuthor ">Yusuke  Koike</span>, <span class="hlFld-ContribAuthor ">Takahiro  Kimura</span>, <span class="hlFld-ContribAuthor ">Shin  Egawa</span>, <span class="hlFld-ContribAuthor ">Naoki  Yoshimura</span>. </span><span class="cited-content_cbyCitation_article-title">Additive effects of intravenous and intravesical application of vibegron, a β3-adrenoceptor agonist, on bladder function in rats with bladder overactivity. </span><span class="cited-content_cbyCitation_journal-name">Naunyn-Schmiedeberg's Archives of Pharmacology</span><span> <strong>2020,</strong> <em>393 </em>
                                    (11)
                                     , 2073-2080. <a href="https://doi.org/10.1007/s00210-020-01921-2" title="DOI URL">https://doi.org/10.1007/s00210-020-01921-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00210-020-01921-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00210-020-01921-2%26sid%3Dliteratum%253Aachs%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Archives%2520of%2520Pharmacology%26atitle%3DAdditive%252Beffects%252Bof%252Bintravenous%252Band%252Bintravesical%252Bapplication%252Bof%252Bvibegron%25252C%252Ba%252B%2525CE%2525B23-adrenoceptor%252Bagonist%25252C%252Bon%252Bbladder%252Bfunction%252Bin%252Brats%252Bwith%252Bbladder%252Boveractivity%26aulast%3DFuruta%26aufirst%3DAkira%26date%3D2020%26date%3D2020%26volume%3D393%26issue%3D11%26spage%3D2073%26epage%3D2080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongbin  Shi</span>, <span class="hlFld-ContribAuthor ">Hongyan  Chen</span>, <span class="hlFld-ContribAuthor ">Yong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanshan  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials. </span><span class="cited-content_cbyCitation_journal-name">Neurourology and Urodynamics</span><span> <strong>2020,</strong> <em>39 </em>
                                    (5)
                                     , 1255-1263. <a href="https://doi.org/10.1002/nau.24387" title="DOI URL">https://doi.org/10.1002/nau.24387</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/nau.24387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fnau.24387%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurourology%2520and%2520Urodynamics%26atitle%3DThe%252Befficacy%252Band%252Bsafety%252Bof%252BVibegron%252Bin%252Btreating%252Boveractive%252Bbladder%25253A%252BA%252Bsystematic%252Breview%252Band%252Bpooled%252Banalysis%252Bof%252Brandomized%252Bcontrolled%252Btrials%26aulast%3DShi%26aufirst%3DHongbin%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D5%26spage%3D1255%26epage%3D1263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Masayuki  Takeda</span>, <span class="hlFld-ContribAuthor ">Momokazu  Gotoh</span>, <span class="hlFld-ContribAuthor ">Osamu  Yokoyama</span>, <span class="hlFld-ContribAuthor ">Hidehiro  Kakizaki</span>, <span class="hlFld-ContribAuthor ">Satoru  Takahashi</span>, <span class="hlFld-ContribAuthor ">Naoya  Masumori</span>, <span class="hlFld-ContribAuthor ">Shinji  Nagai</span>, <span class="hlFld-ContribAuthor ">Kazuyoshi  Minemura</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder:
              post hoc
              analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. </span><span class="cited-content_cbyCitation_journal-name">BJU International</span><span> <strong>2020,</strong> <em>125 </em>
                                    (5)
                                     , 709-717. <a href="https://doi.org/10.1111/bju.15020" title="DOI URL">https://doi.org/10.1111/bju.15020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bju.15020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbju.15020%26sid%3Dliteratum%253Aachs%26jtitle%3DBJU%2520International%26atitle%3DEfficacy%252Bof%252Bvibegron%25252C%252Ba%252Bnovel%252B%2525CE%2525B23-adrenoreceptor%252Bagonist%25252C%252Bon%252Bsevere%252Burgency%252Burinary%252Bincontinence%252Brelated%252Bto%252Boveractive%252Bbladder%25253A%252Bpost%252Bhoc%252Banalysis%252Bof%252Ba%252Brandomized%25252C%252Bplacebo-controlled%25252C%252Bdouble-blind%25252C%252Bcomparative%252Bphase%252B3%252Bstudy%26aulast%3DYoshida%26aufirst%3DMasaki%26date%3D2020%26date%3D2020%26volume%3D125%26issue%3D5%26spage%3D709%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Osamu  Nakanishi</span>, <span class="hlFld-ContribAuthor ">Yoshikazu  Fujimori</span>, <span class="hlFld-ContribAuthor ">Naoki  Aizawa</span>, <span class="hlFld-ContribAuthor ">Takemitsu  Hayashi</span>, <span class="hlFld-ContribAuthor ">Akane  Matsuzawa</span>, <span class="hlFld-ContribAuthor ">Jun-ichi  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Hideaki  Hirasawa</span>, <span class="hlFld-ContribAuthor ">Yosuke  Mutai</span>, <span class="hlFld-ContribAuthor ">Fumiya  Tanada</span>, <span class="hlFld-ContribAuthor ">Yasuhiko  Igawa</span>. </span><span class="cited-content_cbyCitation_article-title">KPR-5714, a Novel Transient Receptor Potential Melastatin 8 Antagonist, Improves Overactive Bladder via Inhibition of Bladder Afferent Hyperactivity in Rats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2020,</strong> <em>373 </em>
                                    (2)
                                     , 239-247. <a href="https://doi.org/10.1124/jpet.119.263616" title="DOI URL">https://doi.org/10.1124/jpet.119.263616</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.263616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.263616%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DKPR-5714%25252C%252Ba%252BNovel%252BTransient%252BReceptor%252BPotential%252BMelastatin%252B8%252BAntagonist%25252C%252BImproves%252BOveractive%252BBladder%252Bvia%252BInhibition%252Bof%252BBladder%252BAfferent%252BHyperactivity%252Bin%252BRats%26aulast%3DNakanishi%26aufirst%3DOsamu%26date%3D2020%26date%3D2020%26volume%3D373%26issue%3D2%26spage%3D239%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alana E.  O’Mara</span>, <span class="hlFld-ContribAuthor ">James W.  Johnson</span>, <span class="hlFld-ContribAuthor ">Joyce D.  Linderman</span>, <span class="hlFld-ContribAuthor ">Robert J.  Brychta</span>, <span class="hlFld-ContribAuthor ">Suzanne  McGehee</span>, <span class="hlFld-ContribAuthor ">Laura A.  Fletcher</span>, <span class="hlFld-ContribAuthor ">Yael A.  Fink</span>, <span class="hlFld-ContribAuthor ">Devika  Kapuria</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Cassimatis</span>, <span class="hlFld-ContribAuthor ">Nathan  Kelsey</span>, <span class="hlFld-ContribAuthor ">Cheryl  Cero</span>, <span class="hlFld-ContribAuthor ">Zahraa Abdul  Sater</span>, <span class="hlFld-ContribAuthor ">Francesca  Piccinini</span>, <span class="hlFld-ContribAuthor ">Alison S.  Baskin</span>, <span class="hlFld-ContribAuthor ">Brooks P.  Leitner</span>, <span class="hlFld-ContribAuthor ">Hongyi  Cai</span>, <span class="hlFld-ContribAuthor ">Corina M.  Millo</span>, <span class="hlFld-ContribAuthor ">William  Dieckmann</span>, <span class="hlFld-ContribAuthor ">Mary  Walter</span>, <span class="hlFld-ContribAuthor ">Norman B.  Javitt</span>, <span class="hlFld-ContribAuthor ">Yaron  Rotman</span>, <span class="hlFld-ContribAuthor ">Peter J.  Walter</span>, <span class="hlFld-ContribAuthor ">Marilyn  Ader</span>, <span class="hlFld-ContribAuthor ">Richard N.  Bergman</span>, <span class="hlFld-ContribAuthor ">Peter  Herscovitch</span>, <span class="hlFld-ContribAuthor ">Kong Y.  Chen</span>, <span class="hlFld-ContribAuthor ">Aaron M.  Cypess</span>. </span><span class="cited-content_cbyCitation_article-title">Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Investigation</span><span> <strong>2020,</strong> <em>130 </em>
                                    (5)
                                     , 2209-2219. <a href="https://doi.org/10.1172/JCI131126" title="DOI URL">https://doi.org/10.1172/JCI131126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/JCI131126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2FJCI131126%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Investigation%26atitle%3DChronic%252Bmirabegron%252Btreatment%252Bincreases%252Bhuman%252Bbrown%252Bfat%25252C%252BHDL%252Bcholesterol%25252C%252Band%252Binsulin%252Bsensitivity%26aulast%3DO%25E2%2580%2599Mara%26aufirst%3DAlana%2BE.%26date%3D2020%26date%3D2020%26volume%3D130%26issue%3D5%26spage%3D2209%26epage%3D2219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeffrey S.  Flier</span>. </span><span class="cited-content_cbyCitation_article-title">Might β3-adrenergic receptor agonists be useful in disorders of glucose homeostasis?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Investigation</span><span> <strong>2020,</strong> <em>130 </em>
                                    (5)
                                     , 2180-2182. <a href="https://doi.org/10.1172/JCI136476" title="DOI URL">https://doi.org/10.1172/JCI136476</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/JCI136476&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2FJCI136476%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Investigation%26atitle%3DMight%252B%2525CE%2525B23-adrenergic%252Breceptor%252Bagonists%252Bbe%252Buseful%252Bin%252Bdisorders%252Bof%252Bglucose%252Bhomeostasis%25253F%26aulast%3DFlier%26aufirst%3DJeffrey%2BS.%26date%3D2020%26date%3D2020%26volume%3D130%26issue%3D5%26spage%3D2180%26epage%3D2182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">King C.  Lee</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  Weiss</span>. </span><span class="cited-content_cbyCitation_article-title">Management and treatment. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 71-106. <a href="https://doi.org/10.1016/B978-0-12-820097-1.00006-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-820097-1.00006-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820097-1.00006-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820097-1.00006-8%26sid%3Dliteratum%253Aachs%26atitle%3DManagement%252Band%252Btreatment%26aulast%3DLee%26aufirst%3DKing%2BC.%26date%3D2020%26spage%3D71%26epage%3D106%26pub%3DElsevier%26atitle%3DNocturia%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">King C.  Lee</span>, <span class="hlFld-ContribAuthor ">Jeffrey P.  Weiss</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging novel therapies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 107-131. <a href="https://doi.org/10.1016/B978-0-12-820097-1.00007-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-820097-1.00007-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820097-1.00007-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820097-1.00007-X%26sid%3Dliteratum%253Aachs%26atitle%3DEmerging%252Bnovel%252Btherapies%26aulast%3DLee%26aufirst%3DKing%2BC.%26date%3D2020%26spage%3D107%26epage%3D131%26pub%3DElsevier%26atitle%3DNocturia%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">George  Araklitis</span>, <span class="hlFld-ContribAuthor ">Georgina  Baines</span>, <span class="hlFld-ContribAuthor ">Ana Sofia  da Silva</span>, <span class="hlFld-ContribAuthor ">Dudley  Robinson</span>, <span class="hlFld-ContribAuthor ">Linda  Cardozo</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in managing overactive bladder. </span><span class="cited-content_cbyCitation_journal-name">F1000Research</span><span> <strong>2020,</strong> <em>9 </em>, 1125. <a href="https://doi.org/10.12688/f1000research.26607.1" title="DOI URL">https://doi.org/10.12688/f1000research.26607.1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12688/f1000research.26607.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12688%2Ff1000research.26607.1%26sid%3Dliteratum%253Aachs%26jtitle%3DF1000Research%26atitle%3DRecent%252Badvances%252Bin%252Bmanaging%252Boveractive%252Bbladder%26aulast%3DAraklitis%26aufirst%3DGeorge%26date%3D2020%26date%3D2020%26volume%3D9%26spage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasuhiko  Igawa</span>, <span class="hlFld-ContribAuthor ">Naoki  Aizawa</span>, <span class="hlFld-ContribAuthor ">Martin C.  Michel</span>. </span><span class="cited-content_cbyCitation_article-title">β
              3
              ‐Adrenoceptors in the normal and diseased urinary bladder—What are the open questions?. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2019,</strong> <em>176 </em>
                                    (14)
                                     , 2525-2538. <a href="https://doi.org/10.1111/bph.14658" title="DOI URL">https://doi.org/10.1111/bph.14658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14658%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3D%2525CE%2525B2%252B3%252B%2525E2%252580%252590Adrenoceptors%252Bin%252Bthe%252Bnormal%252Band%252Bdiseased%252Burinary%252Bbladder%2525E2%252580%252594What%252Bare%252Bthe%252Bopen%252Bquestions%25253F%26aulast%3DIgawa%26aufirst%3DYasuhiko%26date%3D2019%26date%3D2019%26volume%3D176%26issue%3D14%26spage%3D2525%26epage%3D2538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anca-Elena  Dascalu</span>, <span class="hlFld-ContribAuthor ">Alina  Ghinet</span>, <span class="hlFld-ContribAuthor ">Emmanuelle  Lipka</span>, <span class="hlFld-ContribAuthor ">Marion  Collinet</span>, <span class="hlFld-ContribAuthor ">Benoit  Rigo</span>, <span class="hlFld-ContribAuthor ">Muriel  Billamboz</span>. </span><span class="cited-content_cbyCitation_article-title">Cesium salts as superior catalysts for solvent-free modifications of biosourced pterolactam. </span><span class="cited-content_cbyCitation_journal-name">Molecular Catalysis</span><span> <strong>2019,</strong> <em>470 </em>, 32-39. <a href="https://doi.org/10.1016/j.mcat.2019.03.003" title="DOI URL">https://doi.org/10.1016/j.mcat.2019.03.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.mcat.2019.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.mcat.2019.03.003%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Catalysis%26atitle%3DCesium%252Bsalts%252Bas%252Bsuperior%252Bcatalysts%252Bfor%252Bsolvent-free%252Bmodifications%252Bof%252Bbiosourced%252Bpterolactam%26aulast%3DDascalu%26aufirst%3DAnca-Elena%26date%3D2019%26volume%3D470%26spage%3D32%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Masayuki  Takeda</span>, <span class="hlFld-ContribAuthor ">Momokazu  Gotoh</span>, <span class="hlFld-ContribAuthor ">Osamu  Yokoyama</span>, <span class="hlFld-ContribAuthor ">Hidehiro  Kakizaki</span>, <span class="hlFld-ContribAuthor ">Satoru  Takahashi</span>, <span class="hlFld-ContribAuthor ">Naoya  Masumori</span>, <span class="hlFld-ContribAuthor ">Shinji  Nagai</span>, <span class="hlFld-ContribAuthor ">Keita  Hashimoto</span>, <span class="hlFld-ContribAuthor ">Kazuyoshi  Minemura</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of novel β
              3
              ‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Urology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (3)
                                     , 369-375. <a href="https://doi.org/10.1111/iju.13877" title="DOI URL">https://doi.org/10.1111/iju.13877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/iju.13877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fiju.13877%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Urology%26atitle%3DEfficacy%252Bof%252Bnovel%252B%2525CE%2525B2%252B3%252B%2525E2%252580%252590adrenoreceptor%252Bagonist%252Bvibegron%252Bon%252Bnocturia%252Bin%252Bpatients%252Bwith%252Boveractive%252Bbladder%25253A%252BA%252Bpost%2525E2%252580%252590hoc%252Banalysis%252Bof%252Ba%252Brandomized%25252C%252Bdouble%2525E2%252580%252590blind%25252C%252Bplacebo%2525E2%252580%252590controlled%252Bphase%252B3%252Bstudy%26aulast%3DYoshida%26aufirst%3DMasaki%26date%3D2019%26date%3D2018%26volume%3D26%26issue%3D3%26spage%3D369%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karl-Erik  Andersson</span>. </span><span class="cited-content_cbyCitation_article-title">Future Considerations in Overactive Bladder Pharmacotherapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 219-229. <a href="https://doi.org/10.1007/978-3-319-97265-7_13" title="DOI URL">https://doi.org/10.1007/978-3-319-97265-7_13</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-97265-7_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-97265-7_13%26sid%3Dliteratum%253Aachs%26atitle%3DFuture%252BConsiderations%252Bin%252BOveractive%252BBladder%252BPharmacotherapy%26aulast%3DAndersson%26aufirst%3DKarl-Erik%26date%3D2019%26date%3D2018%26spage%3D219%26epage%3D229%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DContemporary%252BPharmacotherapy%252Bof%252BOveractive%252BBladder%26aulast%3DCox%26aufirst%3DLindsey%26date%3D2019%26volume%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karl-Erik  Andersson</span>, <span class="hlFld-ContribAuthor ">Helmut  Madersbacher</span>, <span class="hlFld-ContribAuthor ">Waleed  Altaweel</span>, <span class="hlFld-ContribAuthor ">Pawan  Vasudeva</span>, <span class="hlFld-ContribAuthor ">Yasuhiko  Igawa</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Treatment. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 231-259. <a href="https://doi.org/10.1007/978-94-017-7509-0_27" title="DOI URL">https://doi.org/10.1007/978-94-017-7509-0_27</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-94-017-7509-0_27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-94-017-7509-0_27%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BTreatment%26aulast%3DAndersson%26aufirst%3DKarl-Erik%26date%3D2019%26date%3D2019%26spage%3D231%26epage%3D259%26pub%3DSpringer%2520Netherlands%26atitle%3DNeurourology%26aulast%3DLiao%26aufirst%3DLimin%26date%3D2019%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Riccardo  Bientinesi</span>, <span class="hlFld-ContribAuthor ">Emilio  Sacco</span>. </span><span class="cited-content_cbyCitation_article-title">Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2018,</strong> <em>19 </em>
                                    (18)
                                     , 1989-1997. <a href="https://doi.org/10.1080/14656566.2018.1532502" title="DOI URL">https://doi.org/10.1080/14656566.2018.1532502</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2018.1532502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2018.1532502%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DManaging%252Burinary%252Bincontinence%252Bin%252Bwomen%252B-%252Ba%252Breview%252Bof%252Bnew%252Band%252Bemerging%252Bpharmacotherapy%26aulast%3DBientinesi%26aufirst%3DRiccardo%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D18%26spage%3D1989%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susan J.  Keam</span>. </span><span class="cited-content_cbyCitation_article-title">Vibegron: First Global Approval. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2018,</strong> <em>78 </em>
                                    (17)
                                     , 1835-1839. <a href="https://doi.org/10.1007/s40265-018-1006-3" title="DOI URL">https://doi.org/10.1007/s40265-018-1006-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-018-1006-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-018-1006-3%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DVibegron%25253A%252BFirst%252BGlobal%252BApproval%26aulast%3DKeam%26aufirst%3DSusan%2BJ.%26date%3D2018%26date%3D2018%26volume%3D78%26issue%3D17%26spage%3D1835%26epage%3D1839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Hidehiro  Kakizaki</span>, <span class="hlFld-ContribAuthor ">Satoru  Takahashi</span>, <span class="hlFld-ContribAuthor ">Shinji  Nagai</span>, <span class="hlFld-ContribAuthor ">Takafumi  Kurose</span>. </span><span class="cited-content_cbyCitation_article-title">Long-term safety and efficacy of the novel β
              3
              -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Urology</span><span> <strong>2018,</strong> <em>25 </em>
                                    (7)
                                     , 668-675. <a href="https://doi.org/10.1111/iju.13596" title="DOI URL">https://doi.org/10.1111/iju.13596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/iju.13596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fiju.13596%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Urology%26atitle%3DLong-term%252Bsafety%252Band%252Befficacy%252Bof%252Bthe%252Bnovel%252B%2525CE%2525B2%252B3%252B-adrenoreceptor%252Bagonist%252Bvibegron%252Bin%252BJapanese%252Bpatients%252Bwith%252Boveractive%252Bbladder%25253A%252BA%252Bphase%252BIII%252Bprospective%252Bstudy%26aulast%3DYoshida%26aufirst%3DMasaki%26date%3D2018%26date%3D2018%26volume%3D25%26issue%3D7%26spage%3D668%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Xu</span>, <span class="hlFld-ContribAuthor ">Birgit  Kosjek</span>, <span class="hlFld-ContribAuthor ">Fabien L.  Cabirol</span>, <span class="hlFld-ContribAuthor ">Haibin  Chen</span>, <span class="hlFld-ContribAuthor ">Richard  Desmond</span>, <span class="hlFld-ContribAuthor ">Jeonghan  Park</span>, <span class="hlFld-ContribAuthor ">Anupam P.  Gohel</span>, <span class="hlFld-ContribAuthor ">Steven J.  Collier</span>, <span class="hlFld-ContribAuthor ">Derek J.  Smith</span>, <span class="hlFld-ContribAuthor ">Zhuqing  Liu</span>, <span class="hlFld-ContribAuthor ">Jacob M.  Janey</span>, <span class="hlFld-ContribAuthor ">John Y. L.  Chung</span>, <span class="hlFld-ContribAuthor ">Oscar  Alvizo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (23)
                                     , 6979-6983. <a href="https://doi.org/10.1002/ange.201802791" title="DOI URL">https://doi.org/10.1002/ange.201802791</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201802791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201802791%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DSynthesis%252Bof%252BVibegron%252BEnabled%252Bby%252Ba%252BKetoreductase%252BRationally%252BDesigned%252Bfor%252BHigh%2525E2%252580%252585pH%252BDynamic%252BKinetic%252BReduction%26aulast%3DXu%26aufirst%3DFeng%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D23%26spage%3D6979%26epage%3D6983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Xu</span>, <span class="hlFld-ContribAuthor ">Birgit  Kosjek</span>, <span class="hlFld-ContribAuthor ">Fabien L.  Cabirol</span>, <span class="hlFld-ContribAuthor ">Haibin  Chen</span>, <span class="hlFld-ContribAuthor ">Richard  Desmond</span>, <span class="hlFld-ContribAuthor ">Jeonghan  Park</span>, <span class="hlFld-ContribAuthor ">Anupam P.  Gohel</span>, <span class="hlFld-ContribAuthor ">Steven J.  Collier</span>, <span class="hlFld-ContribAuthor ">Derek J.  Smith</span>, <span class="hlFld-ContribAuthor ">Zhuqing  Liu</span>, <span class="hlFld-ContribAuthor ">Jacob M.  Janey</span>, <span class="hlFld-ContribAuthor ">John Y. L.  Chung</span>, <span class="hlFld-ContribAuthor ">Oscar  Alvizo</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (23)
                                     , 6863-6867. <a href="https://doi.org/10.1002/anie.201802791" title="DOI URL">https://doi.org/10.1002/anie.201802791</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201802791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201802791%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DSynthesis%252Bof%252BVibegron%252BEnabled%252Bby%252Ba%252BKetoreductase%252BRationally%252BDesigned%252Bfor%252BHigh%2525E2%252580%252585pH%252BDynamic%252BKinetic%252BReduction%26aulast%3DXu%26aufirst%3DFeng%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D23%26spage%3D6863%26epage%3D6867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Yoshida</span>, <span class="hlFld-ContribAuthor ">Masayuki  Takeda</span>, <span class="hlFld-ContribAuthor ">Momokazu  Gotoh</span>, <span class="hlFld-ContribAuthor ">Shinji  Nagai</span>, <span class="hlFld-ContribAuthor ">Takafumi  Kurose</span>. </span><span class="cited-content_cbyCitation_article-title">Vibegron, a Novel Potent and Selective β 3 -Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study. </span><span class="cited-content_cbyCitation_journal-name">European Urology</span><span> <strong>2018,</strong> <em>73 </em>
                                    (5)
                                     , 783-790. <a href="https://doi.org/10.1016/j.eururo.2017.12.022" title="DOI URL">https://doi.org/10.1016/j.eururo.2017.12.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.eururo.2017.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.eururo.2017.12.022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Urology%26atitle%3DVibegron%25252C%252Ba%252BNovel%252BPotent%252Band%252BSelective%252B%2525CE%2525B2%252B3%252B-Adrenoreceptor%252BAgonist%25252C%252Bfor%252Bthe%252BTreatment%252Bof%252BPatients%252Bwith%252BOveractive%252BBladder%25253A%252BA%252BRandomized%25252C%252BDouble-blind%25252C%252BPlacebo-controlled%252BPhase%252B3%252BStudy%26aulast%3DYoshida%26aufirst%3DMasaki%26date%3D2018%26volume%3D73%26issue%3D5%26spage%3D783%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcos  Lorca</span>, <span class="hlFld-ContribAuthor ">Cesar  Morales-Verdejo</span>, <span class="hlFld-ContribAuthor ">David  Vásquez-Velásquez</span>, <span class="hlFld-ContribAuthor ">Juan  Andrades-Lagos</span>, <span class="hlFld-ContribAuthor ">Javier  Campanini-Salinas</span>, <span class="hlFld-ContribAuthor ">Jorge  Soto-Delgado</span>, <span class="hlFld-ContribAuthor ">Gonzalo  Recabarren-Gajardo</span>, <span class="hlFld-ContribAuthor ">Jaime  Mella</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2018,</strong> <em>23 </em>
                                    (5)
                                     , 1191. <a href="https://doi.org/10.3390/molecules23051191" title="DOI URL">https://doi.org/10.3390/molecules23051191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules23051191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules23051191%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DStructure-Activity%252BRelationships%252BBased%252Bon%252B3D-QSAR%252BCoMFA%25252FCoMSIA%252Band%252BDesign%252Bof%252BAryloxypropanol-Amine%252BAgonists%252Bwith%252BSelectivity%252Bfor%252Bthe%252BHuman%252B%2525CE%2525B23-Adrenergic%252BReceptor%252Band%252BAnti-Obesity%252Band%252BAnti-Diabetic%252BProfiles%26aulast%3DLorca%26aufirst%3DMarcos%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D5%26spage%3D1191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benoit  Peyronnet</span>, <span class="hlFld-ContribAuthor ">Benjamin M.  Brucker</span>, <span class="hlFld-ContribAuthor ">Martin C.  Michel</span>. </span><span class="cited-content_cbyCitation_article-title">Lower Urinary Tract Symptoms: What’s New in Medical Treatment?. </span><span class="cited-content_cbyCitation_journal-name">European Urology Focus</span><span> <strong>2018,</strong> <em>4 </em>
                                    (1)
                                     , 17-24. <a href="https://doi.org/10.1016/j.euf.2018.04.005" title="DOI URL">https://doi.org/10.1016/j.euf.2018.04.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.euf.2018.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.euf.2018.04.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Urology%2520Focus%26atitle%3DLower%252BUrinary%252BTract%252BSymptoms%25253A%252BWhat%2525E2%252580%252599s%252BNew%252Bin%252BMedical%252BTreatment%25253F%26aulast%3DPeyronnet%26aufirst%3DBenoit%26date%3D2018%26volume%3D4%26issue%3D1%26spage%3D17%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Tan</span>, <span class="hlFld-ContribAuthor ">Yong  Liu</span>, <span class="hlFld-ContribAuthor ">Roy  Helmy</span>, <span class="hlFld-ContribAuthor ">Nelo R.  Rivera</span>, <span class="hlFld-ContribAuthor ">David  Hesk</span>, <span class="hlFld-ContribAuthor ">Sriram  Tyagarajan</span>, <span class="hlFld-ContribAuthor ">Lu  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Su</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemical bromination of late stage intermediates and drug molecules. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (31)
                                     , 3014-3018. <a href="https://doi.org/10.1016/j.tetlet.2017.06.019" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DElectrochemical%252Bbromination%252Bof%252Blate%252Bstage%252Bintermediates%252Band%252Bdrug%252Bmolecules%26aulast%3DTan%26aufirst%3DZheng%26date%3D2017%26volume%3D58%26issue%3D31%26spage%3D3014%26epage%3D3018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gastón  Apablaza</span>, <span class="hlFld-ContribAuthor ">Luisa  Montoya</span>, <span class="hlFld-ContribAuthor ">Cesar  Morales-Verdejo</span>, <span class="hlFld-ContribAuthor ">Marco  Mellado</span>, <span class="hlFld-ContribAuthor ">Mauricio  Cuellar</span>, <span class="hlFld-ContribAuthor ">Carlos  Lagos</span>, <span class="hlFld-ContribAuthor ">Jorge  Soto-Delgado</span>, <span class="hlFld-ContribAuthor ">Hery  Chung</span>, <span class="hlFld-ContribAuthor ">Carlos  Pessoa-Mahana</span>, <span class="hlFld-ContribAuthor ">Jaime  Mella</span>. </span><span class="cited-content_cbyCitation_article-title">2D-QSAR and 3D-QSAR/CoMSIA Studies on a Series of (R)-2-((2-(1H-Indol-2-yl)ethyl)amino)-1-Phenylethan-1-ol with Human β3-Adrenergic Activity. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (3)
                                     , 404. <a href="https://doi.org/10.3390/molecules22030404" title="DOI URL">https://doi.org/10.3390/molecules22030404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22030404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22030404%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3D2D-QSAR%252Band%252B3D-QSAR%25252FCoMSIA%252BStudies%252Bon%252Ba%252BSeries%252Bof%252B%252528R%252529-2-%252528%2525282-%2525281H-Indol-2-yl%252529ethyl%252529amino%252529-1-Phenylethan-1-ol%252Bwith%252BHuman%252B%2525CE%2525B23-Adrenergic%252BActivity%26aulast%3DApablaza%26aufirst%3DGast%25C3%25B3n%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D3%26spage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bart H.  Harper</span>, <span class="hlFld-ContribAuthor ">Liping  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Nam F.  Kar</span>, <span class="hlFld-ContribAuthor ">Bing  Li</span>, <span class="hlFld-ContribAuthor ">Christopher R.  Moyes</span>, <span class="hlFld-ContribAuthor ">Stephen D.  Goble</span>, <span class="hlFld-ContribAuthor ">Melissa  Costa</span>, <span class="hlFld-ContribAuthor ">Karen  Dingley</span>, <span class="hlFld-ContribAuthor ">Jerry  Di Salvo</span>, <span class="hlFld-ContribAuthor ">Sookhee N.  Ha</span>, <span class="hlFld-ContribAuthor ">Amanda  Hurley</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Li</span>, <span class="hlFld-ContribAuthor ">Randy R.  Miller</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Nagabukuro</span>, <span class="hlFld-ContribAuthor ">Gino M.  Salituro</span>, <span class="hlFld-ContribAuthor ">Sean  Smith</span>, <span class="hlFld-ContribAuthor ">Mary  Struthers</span>, <span class="hlFld-ContribAuthor ">Jeffrey J.  Hale</span>, <span class="hlFld-ContribAuthor ">Scott D.  Edmondson</span>, <span class="hlFld-ContribAuthor ">Richard  Berger</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of piperazine benzamides as human β 3 adrenergic receptor agonists for the treatment of overactive bladder. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (4)
                                     , 1094-1098. <a href="https://doi.org/10.1016/j.bmcl.2016.12.033" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.12.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.12.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInvestigation%252Bof%252Bpiperazine%252Bbenzamides%252Bas%252Bhuman%252B%2525CE%2525B2%252B3%252Badrenergic%252Breceptor%252Bagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Boveractive%252Bbladder%26aulast%3DHarper%26aufirst%3DBart%2BH.%26date%3D2017%26volume%3D27%26issue%3D4%26spage%3D1094%26epage%3D1098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.  Di Salvo</span>, <span class="hlFld-ContribAuthor ">H.  Nagabukuro</span>, <span class="hlFld-ContribAuthor ">L. A.  Wickham</span>, <span class="hlFld-ContribAuthor ">C.  Abbadie</span>, <span class="hlFld-ContribAuthor ">J. A.  DeMartino</span>, <span class="hlFld-ContribAuthor ">A.  Fitzmaurice</span>, <span class="hlFld-ContribAuthor ">L.  Gichuru</span>, <span class="hlFld-ContribAuthor ">A.  Kulick</span>, <span class="hlFld-ContribAuthor ">M. J.  Donnelly</span>, <span class="hlFld-ContribAuthor ">N.  Jochnowitz</span>, <span class="hlFld-ContribAuthor ">A. L.  Hurley</span>, <span class="hlFld-ContribAuthor ">A.  Pereira</span>, <span class="hlFld-ContribAuthor ">A.  Sanfiz</span>, <span class="hlFld-ContribAuthor ">G.  Veronin</span>, <span class="hlFld-ContribAuthor ">K.  Villa</span>, <span class="hlFld-ContribAuthor ">J.  Woods</span>, <span class="hlFld-ContribAuthor ">B.  Zamlynny</span>, <span class="hlFld-ContribAuthor ">E.  Zycband</span>, <span class="hlFld-ContribAuthor ">G.M.  Salituro</span>, <span class="hlFld-ContribAuthor ">T.  Frenkl</span>, <span class="hlFld-ContribAuthor ">A. E.  Weber</span>, <span class="hlFld-ContribAuthor ">S. D.  Edmondson</span>, <span class="hlFld-ContribAuthor ">M.  Struthers</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2017,</strong> <em>360 </em>
                                    (2)
                                     , 346-355. <a href="https://doi.org/10.1124/jpet.116.237313" title="DOI URL">https://doi.org/10.1124/jpet.116.237313</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.116.237313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.116.237313%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DPharmacological%252BCharacterization%252Bof%252Ba%252BNovel%252BBeta%252B3%252BAdrenergic%252BAgonist%25252C%252BVibegron%25253A%252BEvaluation%252Bof%252BAntimuscarinic%252BReceptor%252BSelectivity%252Bfor%252BCombination%252BTherapy%252Bfor%252BOveractive%252BBladder%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26date%3D2017%26date%3D2016%26volume%3D360%26issue%3D2%26spage%3D346%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S.D.  Edmondson</span>. </span><span class="cited-content_cbyCitation_article-title">β 3 -AR Agonists for the Treatment of Overactive Bladder. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 714-737. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12788-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12788-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12788-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12788-X%26sid%3Dliteratum%253Aachs%26atitle%3D%2525CE%2525B2%252B3%252B-AR%252BAgonists%252Bfor%252Bthe%252BTreatment%252Bof%252BOveractive%252BBladder%26aulast%3DEdmondson%26aufirst%3DS.D.%26date%3D2017%26spage%3D714%26epage%3D737%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung Ho  Lee</span>, <span class="hlFld-ContribAuthor ">Young Bin  Choy</span>. </span><span class="cited-content_cbyCitation_article-title">Implantable Devices for Sustained, Intravesical Drug Delivery. </span><span class="cited-content_cbyCitation_journal-name">International Neurourology Journal</span><span> <strong>2016,</strong> <em>20 </em>
                                    (2)
                                     , 101-106. <a href="https://doi.org/10.5213/inj.1632664.332" title="DOI URL">https://doi.org/10.5213/inj.1632664.332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5213/inj.1632664.332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5213%2Finj.1632664.332%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Neurourology%2520Journal%26atitle%3DImplantable%252BDevices%252Bfor%252BSustained%25252C%252BIntravesical%252BDrug%252BDelivery%26aulast%3DLee%26aufirst%3DSeung%2BHo%26date%3D2016%26volume%3D20%26issue%3D2%26spage%3D101%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of β<sub>3</sub>-AR agonists that entered clinical trials for OAB.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of second-generation pyrrolidine-based β<sub>3</sub>-AR agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis Route to Six-Membered Ring Targets<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents: (a) EDC, HOAt, Hünig’s Base, dimethylformamide (DMF); (b) chiral HPLC separation; (c) trifluoroacetic acid (TFA), dichloromethane (DCM).</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ORTEP diagram of compound <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of RHS Carboxylic Acid Intermediates <b>10–14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) H<sub>2</sub>, 10% Pd/C, MeOH; (b) 5N NaOH, Δ.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Fused Pyridone <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, Δ; (b) LiOH<sub>aq</sub>, tetrahydrofuran (THF).</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Fused Pyrimidinone <b>16</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) (MeO)<sub>2</sub>SO<sub>2</sub>; (b) (OCN)SO<sub>2</sub>Cl; (c) Na<sub>2</sub>SO<sub>3</sub>; (d) 110 °C; (e) 150 °C; (f) LiOH, H<sub>2</sub>O, MeOH.</p></p></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of intravenous (iv) dosed compounds <b>18</b>, <b>22</b>, and <b>7</b> on (A) functional bladder capacity and (B) micturition pressure in the acetic-acid-induced bladder hyperreflexia model. Percent of baseline was calculated as ratio of predose values. Mean + SEM <i>N</i> = 5–7 per group. *<i>P</i> < 0.05, **<i>P</i> < 0.01, Dunnett’s multiple comparison test. Unbound drug concentrations at the doses tested are noted in the bars in panel A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compounds <b>1</b> and <b>7</b> on plasma glycerol (A) and FFA (B) levels in anesthetized rats. Each plot represents mean ± SEM <i>N</i> = 4–5 per group. *<i>P</i> < 0.05, **<i>P</i> < 0.01, Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Comparison of compounds <b>3</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/medium/jm-2015-013722_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Preliminary docking of compound <b>7</b> with the human β<sub>3</sub>-AR based on the β<sub>2</sub>-AR crystal structure (EC = extracellular loop, TM = transmembrane helices).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-2/acs.jmedchem.5b01372/20160122/images/large/jm-2015-013722_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01372&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">β<sub>3</sub>-Adrenergic receptor agonists for the treatment of obesity</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1016/S0065-7743(08)61084-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2FS0065-7743%2808%2961084-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1998&pages=193-202&author=A.+E.+Weber&title=%CE%B23-Adrenergic+receptor+agonists+for+the+treatment+of+obesity&doi=10.1016%2FS0065-7743%2808%2961084-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2808%2961084-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252808%252961084-2%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3D%25CE%25B23-Adrenergic%2520receptor%2520agonists%2520for%2520the%2520treatment%2520of%2520obesity%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D1998%26volume%3D33%26spage%3D193%26epage%3D202%26doi%3D10.1016%2FS0065-7743%2808%2961084-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Cernecka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sand, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span> </span><span class="NLM_article-title">The Odd Sibling: Features of β<sub>3</sub>-Adrenoceptor Pharmacology</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1124/mol.114.092817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fmol.114.092817" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=479-484&author=H.+Cerneckaauthor=C.+Sandauthor=M.+C.+Michel&title=The+Odd+Sibling%3A+Features+of+%CE%B23-Adrenoceptor+Pharmacology&doi=10.1124%2Fmol.114.092817"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.092817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.092817%26sid%3Dliteratum%253Aachs%26aulast%3DCernecka%26aufirst%3DH.%26aulast%3DSand%26aufirst%3DC.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DThe%2520Odd%2520Sibling%253A%2520Features%2520of%2520%25CE%25B23-Adrenoceptor%2520Pharmacology%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D86%26spage%3D479%26epage%3D484%26doi%3D10.1124%2Fmol.114.092817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Ursino, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raschi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crema, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span> </span><span class="NLM_article-title">The β<sub>3</sub>-Adrenoceptor as a Therapeutic Target: Current Perspectives</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">221</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.phrs.2009.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.phrs.2009.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=19429463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2009&pages=221-234&author=M.+G.+Ursinoauthor=V.+Vasinaauthor=E.+Raschiauthor=F.+Cremaauthor=F.+De+Ponti&title=The+%CE%B23-Adrenoceptor+as+a+Therapeutic+Target%3A+Current+Perspectives&doi=10.1016%2Fj.phrs.2009.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The β3-adrenoceptor as a therapeutic target: Current perspectives</span></div><div class="casAuthors">Ursino, Maria Grazia; Vasina, Valentina; Raschi, Emanuel; Crema, Francesca; De Ponti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">221-234</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  β3-Adrenoceptors (β3-ARs) are located not only on the plasma membrane of both white and brown adipocytes, but also exist in human heart, gall bladder, gastrointestinal tract, prostate, urinary bladder detrusor, brain and in near-term myometrium.  They are now recognized as an attractive target for drug discovery and several efforts have been made in this field to understand their function and regulation in different human tissues.  The aim of this review is to highlight the functional role of β3-ARs as well as to discuss their potential for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFwN6K0dBHLVg90H21EOLACvtfcHk0lhM0-KcnlJmZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVWls7Y%253D&md5=0638652d4bb93a1e8b275aec8eb37575</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2009.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2009.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DUrsino%26aufirst%3DM.%2BG.%26aulast%3DVasina%26aufirst%3DV.%26aulast%3DRaschi%26aufirst%3DE.%26aulast%3DCrema%26aufirst%3DF.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26atitle%3DThe%2520%25CE%25B23-Adrenoceptor%2520as%2520a%2520Therapeutic%2520Target%253A%2520Current%2520Perspectives%26jtitle%3DPharmacol.%2520Res.%26date%3D2009%26volume%3D59%26spage%3D221%26epage%3D234%26doi%3D10.1016%2Fj.phrs.2009.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Baker, J. G.</span><span> </span><span class="NLM_article-title">The selectivity of β-adrenoceptor agonists at the human β <sub>1</sub>, β <sub>2</sub>, and β <sub>3</sub> adrenoceptors</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">160</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00754.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1111%2Fj.1476-5381.2010.00754.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=20590599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=2010&pages=1048-1061&author=J.+G.+Baker&title=The+selectivity+of+%CE%B2-adrenoceptor+agonists+at+the+human+%CE%B2+1%2C+%CE%B2+2%2C+and+%CE%B2+3+adrenoceptors&doi=10.1111%2Fj.1476-5381.2010.00754.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors</span></div><div class="casAuthors">Baker, Jillian G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1048-1061</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and efficacy (the ability of the receptor-ligand complex to induce a response).  Ligands are classified as agonists or antagonists depending on whether or not they have efficacy.  In theory, it is possible to develop selective agonists based on selective affinity, selective intrinsic efficacy or both.  This study examd. the affinity and intrinsic efficacy of β-adrenoceptor agonists at the three human β-adrenoceptors to det. whether the current agonists are subtype selective because of affinity or intrinsic efficacy.  Stable clonal CHO-K1 cell lines, transfected with either the human β1, β2 or β3-adrenoceptor, were used, and whole-cell [3H]-CGP 12177 radioligand binding and [3H]-cAMP accumulation were measured.  Several agonists were highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the β2-adrenoceptor over the β1 or β3), while others (e.g. isoprenaline) had little affinity-selectivity.  However, the intrinsic efficacy of salmeterol, formoterol and isoprenaline was similar across all three receptor subtypes.  Other ligands (e.g. denopamine for β1; clenbuterol, AZ 40140d, salbutamol for β2) were found to have subtype-selective intrinsic efficacy.  Several ligands appeared to activate two agonist conformations of the β1- and β3-adrenoceptors.  There are agonists with subtype selectivity based upon both selective affinity and selective intrinsic efficacy.  Therefore, there is scope to develop better selective agonists based upon both selective affinity and selective intrinsic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopuUPn04Hp7LVg90H21EOLACvtfcHk0lhM0-KcnlJmZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFGjtrw%253D&md5=daff8f97b1dfc4732135d3aa79e7de0f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00754.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00754.x%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26atitle%3DThe%2520selectivity%2520of%2520%25CE%25B2-adrenoceptor%2520agonists%2520at%2520the%2520human%2520%25CE%25B2%25201%252C%2520%25CE%25B2%25202%252C%2520and%2520%25CE%25B2%25203%2520adrenoceptors%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D160%26spage%3D1048%26epage%3D1061%26doi%3D10.1111%2Fj.1476-5381.2010.00754.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Tyagi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyagi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimura, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chancellor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">β<sub>3</sub>-Adrenoceptor Agonists for the Treatment of Overactive Bladder</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1358/dof.2009.034.08.1401947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1358%2Fdof.2009.034.08.1401947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1alsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=635-640&author=P.+Tyagiauthor=V.+Tyagiauthor=N.+Yoshimuraauthor=M.+Chancellorauthor=O.+Yamaguchi&title=%CE%B23-Adrenoceptor+Agonists+for+the+Treatment+of+Overactive+Bladder&doi=10.1358%2Fdof.2009.034.08.1401947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">β3-adrenoceptor agonists for the treatment of overactive bladder</span></div><div class="casAuthors">Tyagi, P.; Tyagi, V.; Yoshimura, N.; Chancellor, M.; Yamaguchi, O.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">635-640</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a medical condition that refers to the bothersome symptoms of increased frequency of voiding episodes and involuntary urinary urgency, with or without subsequent urinary incontinence and often assocd. with nocturia.  The disorder afflicts more than 17 million people of both genders in the United States, with a higher prevalence in the elderly population.  The etiol. of OAB is uncertain, but it is known that voiding in the healthy condition involves bladder contractions triggered by acetylcholine released from parasympathetic nerves, activating postjunctional muscarinic receptors in the detrusor.  Muscarinic receptor antagonists are therefore the most common form of therapy prescribed for treating OAB, but their assocn. with mechanistic side effects has prompted the search for new drugs.  Functional studies have demonstrated that adrenoceptor agonist-evoked bladder relaxation is mediated primarily by β3-adrenoceptors (β3-AR) in humans.  These receptors are an attractive target for the treatment of OAB because of their unique ability to produce detrusor relaxation only during the storage phase, which may allow unimpeded bladder voiding without the risk of urinary retention.  The recently completed phase II clin. proof-of-concept study BLOSSOM (Beta3-adrenoceptor agonist in Lowering OAB Symptoms Study compared to Oral anti-Muscarinic) revealed that a novel selective β3-AR agonist (YM-178) was well tolerated and effective in treating OAB symptoms, further supporting the β3-AR as a valid therapeutic target for OAB treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV9XH3QG-GrrVg90H21EOLACvtfcHk0lhM0-KcnlJmZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1alsA%253D%253D&md5=d286794d8362aa0757c85f75e95815a1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1358%2Fdof.2009.034.08.1401947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2009.034.08.1401947%26sid%3Dliteratum%253Aachs%26aulast%3DTyagi%26aufirst%3DP.%26aulast%3DTyagi%26aufirst%3DV.%26aulast%3DYoshimura%26aufirst%3DN.%26aulast%3DChancellor%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3D%25CE%25B23-Adrenoceptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%26jtitle%3DDrugs%2520Future%26date%3D2009%26volume%3D34%26spage%3D635%26epage%3D640%26doi%3D10.1358%2Fdof.2009.034.08.1401947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gillespie, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rouget, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Granato, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korstanje, C.</span><span> </span><span class="NLM_article-title">Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">388</span><span class="NLM_x">, </span> <span class="NLM_fpage">719</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1007/s00210-015-1136-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1007%2Fs00210-015-1136-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=26047780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtL%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2015&pages=719-726&author=J.+I.+Gillespieauthor=C.+Rougetauthor=S.+Paleaauthor=C.+Granatoauthor=C.+Korstanje&title=Beta+adrenergic+modulation+of+spontaneous+microcontractions+and+electrical+field-stimulated+contractions+in+isolated+strips+of+rat+urinary+bladder+from+normal+animals+and+animals+with+partial+bladder+outflow+obstruction&doi=10.1007%2Fs00210-015-1136-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction</span></div><div class="casAuthors">Gillespie, J. I.; Rouget, C.; Palea, S.; Granato, C.; Korstanje, C.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">719-726</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Spontaneous microcontractions and elec. field stimulation (EFS)-evoked contractions in isolated rat bladder strips from normal and from 6 wk partial bladder outflow obstruction (pBOO) animals were studied to identify the potential site of action for the β3-adrenoceptor (AR) agonist mirabegron in detrusor overactivity in rats.  For this, effects of the β-AR agonist isoprenaline and mirabegron were tested in presence or absence of selective antagonists for β-AR subtypes, namely CGP-20712A for β1-AR, ICI-118,551 for β2-AR, and L-748,337 for β3-AR.  In detrusor strips from both normal and obstructed animals, EFS-induced contractions were weakly affected by isoprenaline and even less so by mirabegron.  In contrast, microcontraction activity was more potently reduced by isoprenaline (pIC50 7.3; Emax ±85 %), whereas mirabegron showed a small effect.  In pBOO strips, concn. response curves for isoprenaline and mirabegron at inhibition of EFS and spontaneous microcontractions were similar to those in normal strips.  Isoprenaline-induced inhibition of microcontractions and EFS was antagonized by the β1-AR antagonist, but not by the β2- and β3-AR antagonists.  In the context of β3-AR-mediated bladder functions for mirabegron in other expts., the current data question a role for effects at spontaneous microcontractions, or neurogenic detrusor stimulation in the mode of action for mirabegron in vivo, since functional bladder effects for mirabegron are reported to occur at much lower concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ_lUBLqjTmLVg90H21EOLACvtfcHk0lgEe9D2yyMIGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtL%252FI&md5=b4a098d0377e2dc4e0cc9990bf660da2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs00210-015-1136-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-015-1136-z%26sid%3Dliteratum%253Aachs%26aulast%3DGillespie%26aufirst%3DJ.%2BI.%26aulast%3DRouget%26aufirst%3DC.%26aulast%3DPalea%26aufirst%3DS.%26aulast%3DGranato%26aufirst%3DC.%26aulast%3DKorstanje%26aufirst%3DC.%26atitle%3DBeta%2520adrenergic%2520modulation%2520of%2520spontaneous%2520microcontractions%2520and%2520electrical%2520field-stimulated%2520contractions%2520in%2520isolated%2520strips%2520of%2520rat%2520urinary%2520bladder%2520from%2520normal%2520animals%2520and%2520animals%2520with%2520partial%2520bladder%2520outflow%2520obstruction%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2015%26volume%3D388%26spage%3D719%26epage%3D726%26doi%3D10.1007%2Fs00210-015-1136-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Rouget, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camparo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rischmann, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lluel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palea, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westfall, T. D.</span><span> </span><span class="NLM_article-title">Modulation of nerve-evoked contractions by β<sub>3</sub>-Adrenoceptor Agonism in Human and Rat Isolated Urinary Bladder</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1016/j.phrs.2013.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.phrs.2013.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=24378642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFCisLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2014&pages=14-20&author=C.+Rougetauthor=M.+Rekikauthor=P.+Camparoauthor=H.+Bottoauthor=P.+Rischmannauthor=P.+Lluelauthor=S.+Paleaauthor=T.+D.+Westfall&title=Modulation+of+nerve-evoked+contractions+by+%CE%B23-Adrenoceptor+Agonism+in+Human+and+Rat+Isolated+Urinary+Bladder&doi=10.1016%2Fj.phrs.2013.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder</span></div><div class="casAuthors">Rouget, Celine; Rekik, Moez; Camparo, Philippe; Botto, Henry; Rischmann, Pascal; Lluel, Philippe; Palea, Stefano; Westfall, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-20</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Activation of β3-adrenoceptors has been shown to have a direct relaxant effect on urinary bladder smooth muscle from both rats and humans, however there are very few studies investigating the effects of β3-adrenoceptor agonists on nerve-evoked bladder contractions.  Therefore in the current study, the role of β3-adrenoceptors in modulating efferent neurotransmission was evaluated.  The effects of β3-adrenoceptor agonism on neurogenic contractions induced by elec. field stimulation (EFS) were compared with effects on contractions induced by exogenous acetylcholine (Ach) and αβ-methylene ATP (αβ-meATP) in order to det. the site of action.  Isoproterenol inhibited EFS-induced neurogenic contractions of human bladder (pD2 = 6.79; Emax = 65%).  The effect of isoproterenol was selectively inhibited by the β3-adrenoceptor antagonist L-748,337 (pKB = 7.34).  Contractions induced by exogenous Ach (0.5-1 μM) were inhibited 25% by isoproterenol (3 μM) while contractions to 10 Hz in the same strip were inhibited 67%.  The selective β3-adrenoceptor agonist CL-316,243 inhibited EFS-induced neurogenic contractions of rat bladder (pD2 = 7.83; Emax = 65%).  The effects of CL-316,243 were inhibited in a concn. dependent manner by L-748,337 (pA2 = 6.42).  Contractions induced by exogenous Ach and αβ-meATP were significantly inhibited by CL-316,243, 29% and 40%, resp.  These results demonstrate that the activation of β3-adrenoceptors inhibits neurogenic contractions of both rat and human urinary bladder.  Contractions induced by exogenously applied parasympathetic neurotransmitters are also inhibited by β3-agonism however the effect is clearly less than on neurogenic contractions (particularly in human), suggesting that in addn. to a direct effect on smooth muscle, activation of prejunctional β3-adrenoceptors may inhibit neurotransmitter release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp501UAd-dGX7Vg90H21EOLACvtfcHk0lgEe9D2yyMIGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFCisLY%253D&md5=15c0a2525492bac0f1b63e5af39f6883</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2013.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2013.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DRouget%26aufirst%3DC.%26aulast%3DRekik%26aufirst%3DM.%26aulast%3DCamparo%26aufirst%3DP.%26aulast%3DBotto%26aufirst%3DH.%26aulast%3DRischmann%26aufirst%3DP.%26aulast%3DLluel%26aufirst%3DP.%26aulast%3DPalea%26aufirst%3DS.%26aulast%3DWestfall%26aufirst%3DT.%2BD.%26atitle%3DModulation%2520of%2520nerve-evoked%2520contractions%2520by%2520%25CE%25B23-Adrenoceptor%2520Agonism%2520in%2520Human%2520and%2520Rat%2520Isolated%2520Urinary%2520Bladder%26jtitle%3DPharmacol.%2520Res.%26date%3D2014%26volume%3D80%26spage%3D14%26epage%3D20%26doi%3D10.1016%2Fj.phrs.2013.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Takasu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ukai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsui, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagase, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasamata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchida, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, O.</span><span> </span><span class="NLM_article-title">Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide (YM178), A Novel and Selective β<sub>3</sub>-Adrenoceptor Agonist, on Bladder Function</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">321</span><span class="NLM_x">, </span> <span class="NLM_fpage">642</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span><span class="refDoi"> DOI: 10.1124/jpet.106.115840</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fjpet.106.115840" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17293563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=642-647&author=T.+Takasuauthor=M.+Ukaiauthor=S.+Satoauthor=T.+Matsuiauthor=I.+Nagaseauthor=T.+Maruyamaauthor=M.+Sasamataauthor=K.+Miyataauthor=H.+Uchidaauthor=O.+Yamaguchi&title=Effect+of+%28R%29-2-%282-Aminothiazol-4-yl%29-4%E2%80%B2-%7B2-%5B%282-hydroxy-2-phenylethyl%29amino%5Dethyl%7Dacetanilide+%28YM178%29%2C+A+Novel+and+Selective+%CE%B23-Adrenoceptor+Agonist%2C+on+Bladder+Function&doi=10.1124%2Fjpet.106.115840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function</span></div><div class="casAuthors">Takasu, Toshiyuki; Ukai, Masashi; Sato, Shuichi; Matsui, Tetsuo; Nagase, Itsuro; Maruyama, Tatsuya; Sasamata, Masao; Miyata, Keiji; Uchida, Hisashi; Yamaguchi, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">642-647</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We evaluated the pharmacol. characteristics of YM178.  YM178 increased cAMP accumulation in Chinese hamster ovary (CHO) cells expressing human β3-adrenoceptor (AR).  The half-maximal effective concn. (EC50) value was 22.4 nM.  EC50 values of YM178 for human β1- and β2-ARs were 10,000 nM or more, resp.  The ratio of intrinsic activities of YM178 vs. maximal response induced by isoproterenol (nonselective β-AR agonist) was 0.8 for human β3-ARs, 0.1 for human β1-ARs, and 0.1 for human β2-ARs.  The relaxant effects of YM178 were evaluated in rats and humans bladder strips precontracted with carbachol (CCh) and compared with those of isoproterenol and 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one hydrochloride (CGP-12177A) (β3-AR agonist).  EC50 values of YM178 and isoproterenol in rat bladder strips precontracted with 10-6 M CCh were 5.1 and 1.4 μM, resp., whereas those in human bladder strips precontracted with 10-7 M CCh were 0.78 and 0.28 μM, resp.  In in vivo study, YM178 at a dose of 3 mg/kg i.v. decreased the frequency of rhythmic bladder contraction induced by intravesical filling with saline without suppressing its amplitude in anesthetized rats.  These findings suggest the suitability of YM178 as a therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJoYI45QFLfbVg90H21EOLACvtfcHk0li4aSmdwBgQBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFehur0%253D&md5=607d913d56ea8378fc9f22c767cbc599</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.115840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.115840%26sid%3Dliteratum%253Aachs%26aulast%3DTakasu%26aufirst%3DT.%26aulast%3DUkai%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DNagase%26aufirst%3DI.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DSasamata%26aufirst%3DM.%26aulast%3DMiyata%26aufirst%3DK.%26aulast%3DUchida%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DO.%26atitle%3DEffect%2520of%2520%2528R%2529-2-%25282-Aminothiazol-4-yl%2529-4%25E2%2580%25B2-%257B2-%255B%25282-hydroxy-2-phenylethyl%2529amino%255Dethyl%257Dacetanilide%2520%2528YM178%2529%252C%2520A%2520Novel%2520and%2520Selective%2520%25CE%25B23-Adrenoceptor%2520Agonist%252C%2520on%2520Bladder%2520Function%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D642%26epage%3D647%26doi%3D10.1124%2Fjpet.106.115840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sadananda, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drake, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paton, J. F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickering, A. E.</span><span> </span><span class="NLM_article-title">A Functional Analysis of the Influence of β<sub>3</sub>-adrenoceptors on the Rat Micturition Cycle</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">506</span><span class="NLM_x">–</span> <span class="NLM_lpage">515</span><span class="refDoi"> DOI: 10.1124/jpet.113.207340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fjpet.113.207340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=24008334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSqsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=506-515&author=P.+Sadanandaauthor=M.+J.+Drakeauthor=J.+F.+R.+Patonauthor=A.+E.+Pickering&title=A+Functional+Analysis+of+the+Influence+of+%CE%B23-adrenoceptors+on+the+Rat+Micturition+Cycle&doi=10.1124%2Fjpet.113.207340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">A functional analysis of the influence of β3-adrenoceptors on the rat micturition cycle</span></div><div class="casAuthors">Sadananda, Prajni; Drake, Marcus J.; Paton, Julian F. R.; Pickering, Anthony E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">506-515</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dysfunctions of the lower urinary tract, such as overactive bladder syndrome and incontinence, are the product of storage failure.  Spontaneous regional bladder wall movements [nonmicturition contractions (NMCs)] are proposed to generate afferent activity that signals vol. status to the central nervous system.  The sympathetic nervous system, via activation of β-adrenoceptors (β-ARs), causes bladder relaxation and promotes urine storage.  We hypothesized that β-AR regulation of micturition is mediated by suppression of NMCs.  We used an unanesthetized, decerebrate, artificially perfused rat prepn. that allows simultaneous cystometry with external urethral sphincter and pelvic afferent nerve recordings.  Systemic isoprenaline (10 nM to 1 μM) increased intervoid interval and bladder compliance accompanied by a decrease in NMC amplitude, voiding pressure, and voiding threshold.  Isoprenaline also reduced arterial pressure and increased heart rate.  The β3-AR agonist Mirabegron (10-100 nM) increased intervoid interval and bladder compliance and reduced NMC amplitude, yet preserved active voiding function and had no effect on arterial pressure or heart rate.  All of these effects of Mirabegron were blocked by the selective β3-AR antagonist N-[[3-[(2S)-2-hydroxy-3-[[2-[4-[(phenylsulfonyl)amino] phenyl]ethyl]amino]propoxy]phenyl]methyl]-acetamide (L748,337), which alone shortened intervoid interval and decreased bladder compliance-suggesting the presence of a basal β3-AR-mediated sympathetic tone.  Similar effects of Mirabegron were seen in an acetic acid-sensitized bladder prepn. and in prepns. after loss of Spinobulbar reflex bladder control.  The β3-AR-mediated increase in intervoid interval correlated with increased bladder compliance but not with the decrease in NMC amplitude.  These findings indicate that β3-adrenoceptors have a selective effect that improves urine storage by increasing compliance without affecting the active components of voiding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK7hSOupzh7rVg90H21EOLACvtfcHk0li4aSmdwBgQBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSqsLrF&md5=8beefddf5895a91a9f9bb9a4da9ea96b</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207340%26sid%3Dliteratum%253Aachs%26aulast%3DSadananda%26aufirst%3DP.%26aulast%3DDrake%26aufirst%3DM.%2BJ.%26aulast%3DPaton%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DPickering%26aufirst%3DA.%2BE.%26atitle%3DA%2520Functional%2520Analysis%2520of%2520the%2520Influence%2520of%2520%25CE%25B23-adrenoceptors%2520on%2520the%2520Rat%2520Micturition%2520Cycle%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D506%26epage%3D515%26doi%3D10.1124%2Fjpet.113.207340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Hicks, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCafferty, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiyar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luce, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coatney, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westfall, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hieble, J. P.</span><span> </span><span class="NLM_article-title">GW427353 (Solabegron), A Novel, Selective β<sub>3</sub>-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">323</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">209</span><span class="refDoi"> DOI: 10.1124/jpet.107.125757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fjpet.107.125757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17626794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=202-209&author=A.+Hicksauthor=G.+P.+McCaffertyauthor=E.+Riedelauthor=N.+Aiyarauthor=M.+Pullenauthor=C.+Evansauthor=T.+D.+Luceauthor=R.+W.+Coatneyauthor=G.+C.+Riveraauthor=T.+D.+Westfallauthor=J.+P.+Hieble&title=GW427353+%28Solabegron%29%2C+A+Novel%2C+Selective+%CE%B23-Adrenergic+Receptor+Agonist%2C+Evokes+Bladder+Relaxation+and+Increases+Micturition+Reflex+Threshold+in+the+Dog&doi=10.1124%2Fjpet.107.125757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">GW427353 (solabegron), a novel, selective β3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog</span></div><div class="casAuthors">Hicks, Alexandra; McCafferty, Gerald P.; Riedel, Erin; Aiyar, Nambi; Pullen, Mark; Evans, Christopher; Luce, Trudy D.; Coatney, Robert W.; Rivera, Gian C.; Westfall, Timothy D.; Hieble, J. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Functional studies have demonstrated that adrenoceptor agonist-evoked relaxation is mediated primarily by β3-adrenergic receptors (ARs) in human bladder.  Thus, the use of selective β3-AR agonists in the pharmacol. treatment of overactive bladder is being explored.  The present studies investigated the effects of a novel selective β3-AR agonist, (R)-3'-[[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-[1,1'-biphenyl]-3-carboxylic acid (GW427353; solabegron) on bladder function in the dog using in vitro and in vivo techniques.  GW427353 stimulated cAMP accumulation in Chinese hamster ovary cells expressing the human β3-AR, with an EC50 value of 22 ± 6 nM and an intrinsic activity 90% of isoproterenol.  At concns. of 10,000 nM, GW427353 produced a minimal response in cells expressing either β1-ARs or β2-ARs (max. response <10% of that to isoproterenol).  In dog isolated bladder strips, GW427353 evoked relaxation that was attenuated by the non-selective β-AR antagonist bupranolol and 1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol (SR59230A) (reported to have β3-AR antagonist activity).  The relaxation was unaffected by atenolol, a selective β1-AR antagonist, or (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol (ICI 118551), a selective β2-AR antagonist.  GW427353 increased the vol. required to evoke micturition in the anesthetized dog following acetic acid-evoked bladder irritation, without affecting the ability of the bladder to void.  GW427353-evoked effects on bladder parameters in vivo were inhibited by bupranolol.  The present study demonstrates that selective activation of β3-AR with GW427353 evokes bladder relaxation and facilitates bladder storage mechanisms in the dog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgB2WHHmcNBrVg90H21EOLACvtfcHk0li4aSmdwBgQBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsLfK&md5=360088edb870525e082f8379d1b21779</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.125757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.125757%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DMcCafferty%26aufirst%3DG.%2BP.%26aulast%3DRiedel%26aufirst%3DE.%26aulast%3DAiyar%26aufirst%3DN.%26aulast%3DPullen%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DC.%26aulast%3DLuce%26aufirst%3DT.%2BD.%26aulast%3DCoatney%26aufirst%3DR.%2BW.%26aulast%3DRivera%26aufirst%3DG.%2BC.%26aulast%3DWestfall%26aufirst%3DT.%2BD.%26aulast%3DHieble%26aufirst%3DJ.%2BP.%26atitle%3DGW427353%2520%2528Solabegron%2529%252C%2520A%2520Novel%252C%2520Selective%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonist%252C%2520Evokes%2520Bladder%2520Relaxation%2520and%2520Increases%2520Micturition%2520Reflex%2520Threshold%2520in%2520the%2520Dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26spage%3D202%26epage%3D209%26doi%3D10.1124%2Fjpet.107.125757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulmsten, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kerrebroeck, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Victor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wein, A.</span><span> </span><span class="NLM_article-title">The Standardisation of Terminology of Lower Urinary Tract Function: Report from the Standardisation Sub-Committee of the International Continence Society</span> <span class="citation_source-journal">Neurourol. Urodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1002/nau.10052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1002%2Fnau.10052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=11857671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=167-178&author=P.+Abramsauthor=L.+Cardozoauthor=M.+Fallauthor=D.+Griffithsauthor=P.+Rosierauthor=U.+Ulmstenauthor=P.+van+Kerrebroeckauthor=A.+Victorauthor=A.+Wein&title=The+Standardisation+of+Terminology+of+Lower+Urinary+Tract+Function%3A+Report+from+the+Standardisation+Sub-Committee+of+the+International+Continence+Society&doi=10.1002%2Fnau.10052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society</span></div><div class="casAuthors">Abrams Paul; Cardozo Linda; Fall Magnus; Griffiths Derek; Rosier Peter; Ulmsten Ulf; van Kerrebroeck Philip; Victor Arne; Wein Alan</div><div class="citationInfo"><span class="NLM_cas:title">Neurourology and urodynamics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">167-78</span>
        ISSN:<span class="NLM_cas:issn">0733-2467</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5XK5Z-KmPwRgd2Wuil24tfW6udTcc2eZETbQPH_WNc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387it1CksQ%253D%253D&md5=bea718982e738444bc86683b568828fb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fnau.10052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fnau.10052%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DCardozo%26aufirst%3DL.%26aulast%3DFall%26aufirst%3DM.%26aulast%3DGriffiths%26aufirst%3DD.%26aulast%3DRosier%26aufirst%3DP.%26aulast%3DUlmsten%26aufirst%3DU.%26aulast%3Dvan%2BKerrebroeck%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DA.%26aulast%3DWein%26aufirst%3DA.%26atitle%3DThe%2520Standardisation%2520of%2520Terminology%2520of%2520Lower%2520Urinary%2520Tract%2520Function%253A%2520Report%2520from%2520the%2520Standardisation%2520Sub-Committee%2520of%2520the%2520International%2520Continence%2520Society%26jtitle%3DNeurourol.%2520Urodyn.%26date%3D2002%26volume%3D21%26spage%3D167%26epage%3D178%26doi%3D10.1002%2Fnau.10052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Irwin, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milsom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunskaar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herschorn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coyne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelleher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artibani, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, P.</span><span> </span><span class="NLM_article-title">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1306</span><span class="NLM_x">–</span> <span class="NLM_lpage">1315</span><span class="refDoi"> DOI: 10.1016/j.eururo.2006.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.eururo.2006.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17049716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2006&pages=1306-1315&author=D.+E.+Irwinauthor=I.+Milsomauthor=S.+Hunskaarauthor=K.+Reillyauthor=Z.+Koppauthor=S.+Herschornauthor=K.+Coyneauthor=C.+Kelleherauthor=C.+Hampelauthor=W.+Artibaniauthor=P.+Abrams&title=Population-based+survey+of+urinary+incontinence%2C+overactive+bladder%2C+and+other+lower+urinary+tract+symptoms+in+five+countries%3A+results+of+the+EPIC+study&doi=10.1016%2Fj.eururo.2006.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</span></div><div class="casAuthors">Irwin Debra E; Milsom Ian; Hunskaar Steinar; Reilly Kate; Kopp Zoe; Herschorn Sender; Coyne Karin; Kelleher Con; Hampel Christian; Artibani Walter; Abrams Paul</div><div class="citationInfo"><span class="NLM_cas:title">European urology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1306-14; discussion 1314-5</span>
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    </div><div class="casAbstract">OBJECTIVE:  Estimate the prevalence of urinary incontinence (UI), overactive bladder (OAB), and other lower urinary tract symptoms (LUTS) among men and women in five countries using the 2002 International Continence Society (ICS) definitions.  METHODS:  This population-based, cross-sectional survey was conducted between April and December 2005 in Canada, Germany, Italy, Sweden, and the United Kingdom using computer-assisted telephone interviews.  A random sample of men and women aged >/= 18 yr residing in the five countries and who were representative of the general populations in these countries was selected.  Using 2002 ICS definitions, the prevalence estimates of storage, voiding, and postmicturition LUTS were calculated.  Data were stratified by country, age cohort, and gender.  RESULTS:  A total of 19,165 individuals agreed to participate; 64.3% reported at least one LUTS.  Nocturia was the most prevalent LUTS (men, 48.6%; women, 54.5%).  The prevalence of storage LUTS (men, 51.3%; women, 59.2%) was greater than that for voiding (men, 25.7%; women, 19.5%) and postmicturition (men, 16.9%; women, 14.2%) symptoms combined.  The overall prevalence of OAB was 11.8%; rates were similar in men and women and increased with age.  OAB was more prevalent than all types of UI combined (9.4%).  CONCLUSIONS:  The EPIC study is the largest population-based survey to assess prevalence rates of OAB, UI, and other LUTS in five countries.  To date, this is the first study to evaluate these symptoms simultaneously using the 2002 ICS definitions.  The results indicate that these symptoms are highly prevalent in the countries surveyed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDX7KjsEQJ0vSAs_PE1QvifW6udTcc2eZETbQPH_WNc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28nmt1Kmsw%253D%253D&md5=8a24630cb261f6888e72b9dbd25ac55d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2006.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2006.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DIrwin%26aufirst%3DD.%2BE.%26aulast%3DMilsom%26aufirst%3DI.%26aulast%3DHunskaar%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DK.%26aulast%3DKopp%26aufirst%3DZ.%26aulast%3DHerschorn%26aufirst%3DS.%26aulast%3DCoyne%26aufirst%3DK.%26aulast%3DKelleher%26aufirst%3DC.%26aulast%3DHampel%26aufirst%3DC.%26aulast%3DArtibani%26aufirst%3DW.%26aulast%3DAbrams%26aufirst%3DP.%26atitle%3DPopulation-based%2520survey%2520of%2520urinary%2520incontinence%252C%2520overactive%2520bladder%252C%2520and%2520other%2520lower%2520urinary%2520tract%2520symptoms%2520in%2520five%2520countries%253A%2520results%2520of%2520the%2520EPIC%2520study%26jtitle%3DEur.%2520Urol.%26date%3D2006%26volume%3D50%26spage%3D1306%26epage%3D1315%26doi%3D10.1016%2Fj.eururo.2006.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Abrams, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, K. E.</span><span> </span><span class="NLM_article-title">Muscarinic receptor antagonists for overactive bladder</span> <span class="citation_source-journal">BJU Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">1006</span><span class="refDoi"> DOI: 10.1111/j.1464-410X.2007.07205.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1111%2Fj.1464-410X.2007.07205.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17922784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=987-1006&author=P.+Abramsauthor=K.+E.+Andersson&title=Muscarinic+receptor+antagonists+for+overactive+bladder&doi=10.1111%2Fj.1464-410X.2007.07205.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic receptor antagonists for overactive bladder</span></div><div class="casAuthors">Abrams, Paul; Andersson, Karl-Erik</div><div class="citationInfo"><span class="NLM_cas:title">BJU International</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">987-1006</span>CODEN:
                <span class="NLM_cas:coden">BJINFO</span>;
        ISSN:<span class="NLM_cas:issn">1464-4096</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Overactive bladder (OAB) is a syndrome characterized by urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia.  OAB symptoms are often assocd. with detrusor overactivity (DO).  Like OAB symptoms, the prevalence of DO increases with age and can have a neurogenic and/or myogenic etiol.  Bladder outlet obstruction can be a contributing factor in DO, possibly through cholinergic denervation of the detrusor and supersensitivity of muscarinic receptors to acetylcholine, although the prevalence of OAB is similar in men and women across age groups.  Acetylcholine is the primary contractile neurotransmitter in the human detrusor, and antimuscarinics exert their effects on OAB/DO by inhibiting the binding of acetylcholine at muscarinic receptors M2 and M3 on detrusor smooth muscle cells and other structures within the bladder wall.  Worldwide, there are six antimuscarinic drugs currently marketed for the treatment of OAB: oxybutynin, tolterodine, propiverine, trospium, darifenacin, and solifenacin.  Each has demonstrated efficacy for the treatment of OAB symptoms, but their pharmacokinetic and adverse event profiles differ somewhat due to structural differences (tertiary vs quaternary amines), muscarinic receptor subtype selectivities, and organ selectivities.  Antimuscarinics are generally well tolerated, even in special populations (e.g. men with bladder outlet obstruction, elderly patients, children).  The most frequently reported adverse events in clin. studies of antimuscarinics are dry mouth, constipation, headache, and blurred vision; few patients withdraw from clin. trials because of adverse events.  Development of an antimuscarinic with functional selectivity for the bladder would reduce the occurrence of antimuscarinic adverse events.  The therapeutic potential of several other agents, such as α3-adrenoceptor agonists, purinergic receptor antagonists, phosphodiesterase inhibitors, neurokinin-1 receptor antagonists, opioids, and Rho-kinase inhibitors, is also under investigation for the treatment of OAB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo46uZDo-vaI7Vg90H21EOLACvtfcHk0livkszDRbdtow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGgur7M&md5=ae74f99443663035095e793c43358bfa</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fj.1464-410X.2007.07205.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1464-410X.2007.07205.x%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DP.%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26atitle%3DMuscarinic%2520receptor%2520antagonists%2520for%2520overactive%2520bladder%26jtitle%3DBJU%2520Int.%26date%3D2007%26volume%3D100%26spage%3D987%26epage%3D1006%26doi%3D10.1111%2Fj.1464-410X.2007.07205.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Dmochowski, R.</span><span> </span><span class="NLM_article-title">Improving the tolerability of anticholinergic agents in the treatment of overactive bladder</span> <span class="citation_source-journal">Drug Saf.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span><span class="refDoi"> DOI: 10.2165/00002018-200528070-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.2165%2F00002018-200528070-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=15963006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2MXos1eisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2005&pages=583-600&author=R.+Dmochowski&title=Improving+the+tolerability+of+anticholinergic+agents+in+the+treatment+of+overactive+bladder&doi=10.2165%2F00002018-200528070-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Improving the tolerability of anticholinergic agents in the treatment of overactive bladder</span></div><div class="casAuthors">Dmochowski, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Drug Safety</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">583-600</span>CODEN:
                <span class="NLM_cas:coden">DRSAEA</span>;
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Pharmacol. treatment for overactive bladder has centered around the interruption of the detrusor activity that is central to urge and incontinence symptoms.  The majority of patients with this disorder are treated with antimus-carinic agents.  These drugs have been demonstrated to improve urgency, frequency of micturition and urge incontinence, all of which are primary symptoms of overactive bladder; however, they are also commonly assocd. with anticholin-ergic adverse effects, most notably dry mouth.  Attempts to increase tolerability have included the development of advanced formulations that regulate release of the active ingredient and the development of pharmacol. agents that target the desired bladder receptors more specifically and accurately.  Although all agents provide good efficacy, tolerability is greatly affected by the formulation used to deliver the active pharmacol. agent, as well as the specificity of the targeted receptors.  Clin. trials involving a transdermal formulation of oxybutynin have shown that this delivery method may be assocd. with a lower incidence of anticholinergic adverse events compared with both the immediate-release and the extended-release oral formulations of traditional agents, as well as the most recently approved agents - trospium chloride, solifenacin and darifenacin.  Much is still being learned about the function and specificity of muscarinic receptors, which will support the development of agents with sustained efficacy and enhanced tolerability compared with the available formulations to date.  These include the S-isomer of oxybutynin, as well as selective muscarinic M2 receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFJMlIaamoD7Vg90H21EOLACvtfcHk0lgOijRST36eyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXos1eisr0%253D&md5=7ab864abf97cfabdd2c80804f154a758</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F00002018-200528070-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200528070-00003%26sid%3Dliteratum%253Aachs%26aulast%3DDmochowski%26aufirst%3DR.%26atitle%3DImproving%2520the%2520tolerability%2520of%2520anticholinergic%2520agents%2520in%2520the%2520treatment%2520of%2520overactive%2520bladder%26jtitle%3DDrug%2520Saf.%26date%3D2005%26volume%3D28%26spage%3D583%26epage%3D600%26doi%3D10.2165%2F00002018-200528070-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Chapple, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khullar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitoun, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, D.</span><span> </span><span class="NLM_article-title">The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis</span> <span class="citation_source-journal">Eur. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1016/j.eururo.2008.06.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.eururo.2008.06.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=18599186" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2008&pages=543-562&author=C.+R.+Chappleauthor=V.+Khullarauthor=Z.+Gabrielauthor=D.+Mustonauthor=C.+E.+Bitounauthor=D.+Weinstein&title=The+Effects+of+Antimuscarinic+Treatments+in+Overactive+Bladder%3A+An+Update+of+a+Systematic+Review+and+Meta-Analysis&doi=10.1016%2Fj.eururo.2008.06.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis</span></div><div class="casAuthors">Chapple, Christopher R.; Khullar, Vik; Gabriel, Zahava; Muston, Dominic; Bitoun, Caty Ebel; Weinstein, David</div><div class="citationInfo"><span class="NLM_cas:title">European Urology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">543-562</span>CODEN:
                <span class="NLM_cas:coden">EUURAV</span>;
        ISSN:<span class="NLM_cas:issn">0302-2838</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Context: Antimuscarinic agents are currently the first-line pharmacotherapy for overactive bladder.  Objectives: A systematic review published in 2005 was updated, including data on a newly licensed antimuscarinic (fesoterodine).  The primary aim of this study was to systematically review evidence on the efficacy of licensed administration of antimuscarinic treatments in overactive bladder from randomised controlled trials.  Secondary aims were to review evidence on tolerability and safety and health-related quality of life (HRQL).  Evidence acquisition: All relevant data sources from randomised controlled trials were searched, and two independent reviewers considered publications for inclusion and extd. relevant data.  Meta-anal. was used to pool efficacy, tolerability, safety, and HRQL outcomes by treatment.  Efficacy was measured by continent days, mean voided vol., urgency episodes, and micturition frequency.  Tolerability and safety were measured by means of adverse event and withdrawal rates.  HRQL was measured by various instruments.  Evidence synthesis: An addnl. 1118 refs. were retrieved with data on 83 studies extd.  Antimuscarinics were found to be more effective than placebo.  Tolerability was good; few of the antimuscarinics were found to have significantly higher withdrawal rates in comparison to placebo.  No serious adverse event for any product was statistically significant compared to placebo.  Dry mouth (mild, moderate, severe) was the most commonly reported adverse event (29.6% on treatment vs 7.9% on placebo), followed by pruritus (15.4% on treatment vs 5.2% on placebo).  Improvements were seen in HRQL with treatment by darifenacin, fesoterodine, oxybutynin transdermal delivery system, propiverine extended release (ER), solifenacin, tolterodine ER and immediate release, and trospium.  Limitations of the study include restrictions on the types of patients typically included in overactive bladder trials and topics that have not been adequately addressed in the current antimuscarinic literature.  Conclusions: Antimuscarinics are efficacious, safe, and well-tolerated treatments that improve HRQL.  Profiles of each drug and dosage differ and should be considered in making treatment choices.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAxiEtWQKM7Vg90H21EOLACvtfcHk0lgOijRST36eyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKisb%252FK&md5=5bfba69dca14592a3212db8ef9a69630</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.eururo.2008.06.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eururo.2008.06.047%26sid%3Dliteratum%253Aachs%26aulast%3DChapple%26aufirst%3DC.%2BR.%26aulast%3DKhullar%26aufirst%3DV.%26aulast%3DGabriel%26aufirst%3DZ.%26aulast%3DMuston%26aufirst%3DD.%26aulast%3DBitoun%26aufirst%3DC.%2BE.%26aulast%3DWeinstein%26aufirst%3DD.%26atitle%3DThe%2520Effects%2520of%2520Antimuscarinic%2520Treatments%2520in%2520Overactive%2520Bladder%253A%2520An%2520Update%2520of%2520a%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DEur.%2520Urol.%26date%3D2008%26volume%3D54%26spage%3D543%26epage%3D562%26doi%3D10.1016%2Fj.eururo.2008.06.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morimoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasahara, K.-i.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuto, S.</span><span> </span><span class="NLM_article-title">Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β<sub>3</sub>-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side-Effects</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6048</span><span class="NLM_x">–</span> <span class="NLM_lpage">6057</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00638</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00638" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6048-6057&author=Y.+Wadaauthor=H.+Shirahashiauthor=T.+Iwanamiauthor=M.+Ogawaauthor=S.+Nakanoauthor=A.+Morimotoauthor=K.-i.+Kasaharaauthor=E.+Tanakaauthor=Y.+Takadaauthor=S.+Ohashiauthor=M.+Moriauthor=S.+Shuto&title=Discovery+of+Novel+Indazole+Derivatives+as+Highly+Potent+and+Selective+Human+%CE%B23-Adrenergic+Receptor+Agonists+with+the+Possibility+of+Having+No+Cardiovascular+Side-Effects&doi=10.1021%2Facs.jmedchem.5b00638"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00638%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DY.%26aulast%3DShirahashi%26aufirst%3DH.%26aulast%3DIwanami%26aufirst%3DT.%26aulast%3DOgawa%26aufirst%3DM.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DMorimoto%26aufirst%3DA.%26aulast%3DKasahara%26aufirst%3DK.-i.%26aulast%3DTanaka%26aufirst%3DE.%26aulast%3DTakada%26aufirst%3DY.%26aulast%3DOhashi%26aufirst%3DS.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DShuto%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%2520Indazole%2520Derivatives%2520as%2520Highly%2520Potent%2520and%2520Selective%2520Human%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonists%2520with%2520the%2520Possibility%2520of%2520Having%2520No%2520Cardiovascular%2520Side-Effects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6048%26epage%3D6057%26doi%3D10.1021%2Facs.jmedchem.5b00638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ota, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span> </span><span class="NLM_article-title">Absorption, Disposition, Metabolism, and Excretion of Ritobegron (KUC-7483), A Novel and Selective β<sub>3</sub> Adrenoceptor Agonist, in Rats</span> <span class="citation_source-journal">Pharmazie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">888</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=881-888&author=Y.+Abeauthor=E.+Otaauthor=T.+Endoauthor=M.+Murakamiauthor=M.+Kobayashi&title=Absorption%2C+Disposition%2C+Metabolism%2C+and+Excretion+of+Ritobegron+%28KUC-7483%29%2C+A+Novel+and+Selective+%CE%B23+Adrenoceptor+Agonist%2C+in+Rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DOta%26aufirst%3DE.%26aulast%3DEndo%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26atitle%3DAbsorption%252C%2520Disposition%252C%2520Metabolism%252C%2520and%2520Excretion%2520of%2520Ritobegron%2520%2528KUC-7483%2529%252C%2520A%2520Novel%2520and%2520Selective%2520%25CE%25B23%2520Adrenoceptor%2520Agonist%252C%2520in%2520Rats%26jtitle%3DPharmazie%26date%3D2014%26volume%3D69%26spage%3D881%26epage%3D888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jesudason, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaich, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahl, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kriauciunas, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiman, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rito, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satterwhite, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinsley, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trankle, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuker, A. J.</span><span> </span><span class="NLM_article-title">Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">583</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1021/ml200071k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200071k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=583-586&author=C.+D.+Jesudasonauthor=J.+E.+Bakerauthor=R.+D.+Bryantauthor=J.+W.+Fisherauthor=L.+S.+O%E2%80%99Farrellauthor=G.+A.+Gaichauthor=M.+M.+Heauthor=S.+D.+Kahlauthor=A.+V.+Kriauciunasauthor=M.+L.+Heimanauthor=M.+A.+Petersauthor=C.+J.+Ritoauthor=J.+H.+Satterwhiteauthor=F.+C.+Tinsleyauthor=W.+G.+Trankleauthor=A.+J.+Shuker&title=Combination+of+a+Beta+Adrenoceptor+Modulator+and+a+Norepinephrine-Serotonin+Uptake+Inhibitor+for+the+Treatment+of+Obesity&doi=10.1021%2Fml200071k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fml200071k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200071k%26sid%3Dliteratum%253Aachs%26aulast%3DJesudason%26aufirst%3DC.%2BD.%26aulast%3DBaker%26aufirst%3DJ.%2BE.%26aulast%3DBryant%26aufirst%3DR.%2BD.%26aulast%3DFisher%26aufirst%3DJ.%2BW.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DL.%2BS.%26aulast%3DGaich%26aufirst%3DG.%2BA.%26aulast%3DHe%26aufirst%3DM.%2BM.%26aulast%3DKahl%26aufirst%3DS.%2BD.%26aulast%3DKriauciunas%26aufirst%3DA.%2BV.%26aulast%3DHeiman%26aufirst%3DM.%2BL.%26aulast%3DPeters%26aufirst%3DM.%2BA.%26aulast%3DRito%26aufirst%3DC.%2BJ.%26aulast%3DSatterwhite%26aufirst%3DJ.%2BH.%26aulast%3DTinsley%26aufirst%3DF.%2BC.%26aulast%3DTrankle%26aufirst%3DW.%2BG.%26aulast%3DShuker%26aufirst%3DA.%2BJ.%26atitle%3DCombination%2520of%2520a%2520Beta%2520Adrenoceptor%2520Modulator%2520and%2520a%2520Norepinephrine-Serotonin%2520Uptake%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D583%26epage%3D586%26doi%3D10.1021%2Fml200071k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sacco, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bientinesi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tienforti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Racioppi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gulino, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Agostino, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vittori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassi, P.</span><span> </span><span class="NLM_article-title">Discovery History and Clinical Development of Mirabegron for the Treatment of Overactive Bladder and Urinary Incontinence</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">448</span><span class="refDoi"> DOI: 10.1517/17460441.2014.892923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1517%2F17460441.2014.892923" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=433-448&author=E.+Saccoauthor=R.+Bientinesiauthor=D.+Tienfortiauthor=M.+Racioppiauthor=G.+Gulinoauthor=D.+D%E2%80%99Agostinoauthor=M.+Vittoriauthor=P.+Bassi&title=Discovery+History+and+Clinical+Development+of+Mirabegron+for+the+Treatment+of+Overactive+Bladder+and+Urinary+Incontinence&doi=10.1517%2F17460441.2014.892923"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.892923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.892923%26sid%3Dliteratum%253Aachs%26aulast%3DSacco%26aufirst%3DE.%26aulast%3DBientinesi%26aufirst%3DR.%26aulast%3DTienforti%26aufirst%3DD.%26aulast%3DRacioppi%26aufirst%3DM.%26aulast%3DGulino%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Agostino%26aufirst%3DD.%26aulast%3DVittori%26aufirst%3DM.%26aulast%3DBassi%26aufirst%3DP.%26atitle%3DDiscovery%2520History%2520and%2520Clinical%2520Development%2520of%2520Mirabegron%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%2520and%2520Urinary%2520Incontinence%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D433%26epage%3D448%26doi%3D10.1517%2F17460441.2014.892923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Bragg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hebel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vouri, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitlick, J. M.</span><span> </span><span class="NLM_article-title">Mirabegron: A Beta-3 Agonist for Overactive Bladder</span> <span class="citation_source-journal">Consult. Pharmacist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">823</span><span class="NLM_x">–</span> <span class="NLM_lpage">837</span><span class="refDoi"> DOI: 10.4140/TCP.n.2014.823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.4140%2FTCP.n.2014.823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=25521658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=823-837&author=R.+Braggauthor=D.+Hebelauthor=S.+M.+Vouriauthor=J.+M.+Pitlick&title=Mirabegron%3A+A+Beta-3+Agonist+for+Overactive+Bladder&doi=10.4140%2FTCP.n.2014.823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Mirabegron: a Beta-3 agonist for overactive bladder</span></div><div class="casAuthors">Bragg Rebecca; Hebel Danielle; Vouri Scott Martin; Pitlick Jamie M</div><div class="citationInfo"><span class="NLM_cas:title">The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">823-37</span>
        ISSN:<span class="NLM_cas:issn">0888-5109</span>.
    </div><div class="casAbstract">OBJECTIVE:  To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB).  DATA SOURCES:  A literature search was performed using MEDLINE (PubMed) prior to December 31, 2013, using the terms "mirabegron" and "randomized-controlled trial."  STUDY SELECTION/DATA EXTRACTION:  All published, double-blind, randomized-controlled trials assessing mirabegron were included.  Articles were reviewed and included if mirabegron was used as monotherapy and if the primary outcome analyzed drug efficacy.  DATA SYNTHESIS:  The efficacy of mirabegron for the treatment of OAB has been demonstrated in the selected five randomized, placebo-controlled trials.  The majority of these trials lasted 12 weeks and compared various doses of mirabegron with placebo and/or tolterodine extended-release (ER).  Primary efficacy outcomes for the trials included mean number of micturitions per 24 hours and mean number of incontinence episodes per 24 hours.  Included trials showed statistically significant reductions in both efficacy outcomes for various doses of mirabegron when compared with placebo.  CONCLUSION:  Based on the trials reviewed, mirabegron has been efficacious in reducing mean number of micturitions and incontinence episodes per 24 hours, as well as in improving other secondary outcomes such as OAB symptoms and quality-of-life measures.  Common adverse drug events seen with mirabegron include: hypertension, nasopharyngitis, urinary tract infections, headache, constipation, upper respiratory tract infection, arthralgia, diarrhea, tachycardia, abdominal pain, and fatigue.  Given the efficacy and safety data currently available, mirabegron represents a reasonable alternative to antimuscarinics for patients with OAB.  Future studies are needed to determine the utility of mirabegron for OAB in a variety of demographics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8R_CrClfSRxWfpMXQLRstfW6udTcc2eYRDb-9BDbYfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvgvFajtg%253D%253D&md5=77c9f399bbcc48ffc99b3a39fc075116</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.4140%2FTCP.n.2014.823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4140%252FTCP.n.2014.823%26sid%3Dliteratum%253Aachs%26aulast%3DBragg%26aufirst%3DR.%26aulast%3DHebel%26aufirst%3DD.%26aulast%3DVouri%26aufirst%3DS.%2BM.%26aulast%3DPitlick%26aufirst%3DJ.%2BM.%26atitle%3DMirabegron%253A%2520A%2520Beta-3%2520Agonist%2520for%2520Overactive%2520Bladder%26jtitle%3DConsult.%2520Pharmacist%26date%3D2014%26volume%3D29%26spage%3D823%26epage%3D837%26doi%3D10.4140%2FTCP.n.2014.823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Martin, M.; Von Keitz, A.; Ohlstein, E.</span> <span class="citation_source-book">Abstracts of Papers</span>, Americal Urological Association’s 2012 Annual Meeting, Atlanta, GA; <span class="NLM_publisher-name">American Urological Association</span>: <span class="NLM_publisher-loc">Linthicum, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Abstract 520.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=M.+Martin&author=A.+Von+Keitz&author=E.+Ohlstein&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DM.%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Urological%2520Association%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ellsworth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantasia, J.</span><span> </span><span class="NLM_article-title">Solabegron: A Potential Future Addition to the β<sub>3</sub> Adrenoceptor Agonist Armamentarium for the Management of Overactive Bladder</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">413</span><span class="NLM_x">–</span> <span class="NLM_lpage">419</span><span class="refDoi"> DOI: 10.1517/13543784.2015.1001836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1517%2F13543784.2015.1001836" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=413-419&author=P.+Ellsworthauthor=J.+Fantasia&title=Solabegron%3A+A+Potential+Future+Addition+to+the+%CE%B23+Adrenoceptor+Agonist+Armamentarium+for+the+Management+of+Overactive+Bladder&doi=10.1517%2F13543784.2015.1001836"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1001836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1001836%26sid%3Dliteratum%253Aachs%26aulast%3DEllsworth%26aufirst%3DP.%26aulast%3DFantasia%26aufirst%3DJ.%26atitle%3DSolabegron%253A%2520A%2520Potential%2520Future%2520Addition%2520to%2520the%2520%25CE%25B23%2520Adrenoceptor%2520Agonist%2520Armamentarium%2520for%2520the%2520Management%2520of%2520Overactive%2520Bladder%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D413%26epage%3D419%26doi%3D10.1517%2F13543784.2015.1001836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mathvink, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candelore, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colwell, L. F.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Discovery of a potent, orally bioavailable β<sub>3</sub> adrenergic receptor agonist, (R)-<i>N</i>-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3832</span><span class="NLM_x">–</span> <span class="NLM_lpage">3836</span><span class="refDoi"> DOI: 10.1021/jm000286i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000286i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3832-3836&author=R.+J.+Mathvinkauthor=J.+S.+Tolmanauthor=D.+Chittyauthor=M.+R.+Candeloreauthor=M.+A.+Cascieriauthor=L.+F.+Colwellauthor=L.+Dengauthor=W.+P.+Feeneyauthor=M.+J.+Forrestauthor=G.+J.+Homauthor=D.+E.+MacIntyreauthor=R.+R.+Millerauthor=R.+A.+Stearnsauthor=L.+Totaauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=A.+E.+Weber&title=Discovery+of+a+potent%2C+orally+bioavailable+%CE%B23+adrenergic+receptor+agonist%2C+%28R%29-N-%5B4-%5B2-%5B%5B2-hydroxy-2-%283-pyridinyl%29ethyl%5Damino%5Dethyl%5Dphenyl%5D-4-%5B4-%5B4-%28trifluoromethyl%29phenyl%5Dthiazol-2-yl%5Dbenzenesulfonamide&doi=10.1021%2Fjm000286i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm000286i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000286i%26sid%3Dliteratum%253Aachs%26aulast%3DMathvink%26aufirst%3DR.%2BJ.%26aulast%3DTolman%26aufirst%3DJ.%2BS.%26aulast%3DChitty%26aufirst%3DD.%26aulast%3DCandelore%26aufirst%3DM.%2BR.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DColwell%26aufirst%3DL.%2BF.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DFeeney%26aufirst%3DW.%2BP.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DHom%26aufirst%3DG.%2BJ.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DTota%26aufirst%3DL.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520orally%2520bioavailable%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonist%252C%2520%2528R%2529-N-%255B4-%255B2-%255B%255B2-hydroxy-2-%25283-pyridinyl%2529ethyl%255Damino%255Dethyl%255Dphenyl%255D-4-%255B4-%255B4-%2528trifluoromethyl%2529phenyl%255Dthiazol-2-yl%255Dbenzenesulfonamide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3832%26epage%3D3836%26doi%3D10.1021%2Fjm000286i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Van Baak, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hul, G. B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toubro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astrup, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSmet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saris, W. H. M.</span><span> </span><span class="NLM_article-title">Acute Effect of L-796568, A Novel β<sub>3</sub>-Adrenergic Receptor Agonist, on Energy Expenditure in Obese Men</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1067/mcp.2002.122527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1067%2Fmcp.2002.122527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=11956510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjs1ersbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=272-279&author=M.+A.+Van+Baakauthor=G.+B.+J.+Hulauthor=S.+Toubroauthor=A.+Astrupauthor=K.+M.+Gottesdienerauthor=M.+DeSmetauthor=W.+H.+M.+Saris&title=Acute+Effect+of+L-796568%2C+A+Novel+%CE%B23-Adrenergic+Receptor+Agonist%2C+on+Energy+Expenditure+in+Obese+Men&doi=10.1067%2Fmcp.2002.122527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Acute effect of L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure in obese men</span></div><div class="casAuthors">Van Baak, Marleen A.; Hul, Gabby B. J.; Toubro, Soren; Astrup, Arne; Gottesdiener, Keith M.; DeSmet, Marina; Saris, Wim H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (St. Louis, MO, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">272-279</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">Our objective was to investigate the thermogenic efficacy of single oral doses of the novel β3-adrenergic receptor agonist L-796568 [(R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl) ethyl]amino]ethyl]-phenyl] -4-[4-[4-(trifluoromethyl)phenyl] thiazol-2-yl]-benzenesulfonamide, dihydrochloride] in humans.  Twelve healthy overweight to obese men participated in this 2-center, 3-period, randomized, placebo-controlled, crossover trial.  In each period subjects received 250 mg L-796568, 1000 mg L-796568, or placebo.  Energy expenditure and RQ were detd. by indirect calorimetry; blood samples were taken; and ear temp., heart rate, and blood pressure were measured at baseline and during the 4-h period after administration.  Energy expenditure increased significantly after the 1000-mg dose (about 8%) and this was accompanied by an increase in plasma glycerol and free fatty acid concns.  Systolic blood pressure also increased significantly.  No changes in heart rate, diastolic blood pressure, ear temp., plasma catecholamine, potassium, or leptin were found.  Single-dose administration of 1000 mg of the novel β3-adrenergic receptor agonist L-796568 increased lipolysis and energy expenditure in overweight men.  This is the first study to show such an effect of β3-adrenergic receptor agonists in humans without significant evidence for β2-adrenergic receptor involvement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmtaP0O2WKbrVg90H21EOLACvtfcHk0lh4AGu5-W0WPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjs1ersbc%253D&md5=3435a2e5dec16a4f2d408d19836b2509</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1067%2Fmcp.2002.122527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmcp.2002.122527%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BBaak%26aufirst%3DM.%2BA.%26aulast%3DHul%26aufirst%3DG.%2BB.%2BJ.%26aulast%3DToubro%26aufirst%3DS.%26aulast%3DAstrup%26aufirst%3DA.%26aulast%3DGottesdiener%26aufirst%3DK.%2BM.%26aulast%3DDeSmet%26aufirst%3DM.%26aulast%3DSaris%26aufirst%3DW.%2BH.%2BM.%26atitle%3DAcute%2520Effect%2520of%2520L-796568%252C%2520A%2520Novel%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonist%252C%2520on%2520Energy%2520Expenditure%2520in%2520Obese%2520Men%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2002%26volume%3D71%26spage%3D272%26epage%3D279%26doi%3D10.1067%2Fmcp.2002.122527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Larsen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toubro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Baak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saris, W. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Astrup, A.</span><span> </span><span class="NLM_article-title">Effects of a 28-d Treatment with L-796568, A Novel β<sub>3</sub>-Adrenergic Receptor Agonist, on Energy Expenditure and Body Composition in Obese Men</span> <span class="citation_source-journal">Am. J. Clin. Nutr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">788</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=12324291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD38Xns1eqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2002&pages=780-788&author=T.+M.+Larsenauthor=S.+Toubroauthor=M.+van+Baakauthor=K.+M.+Gottesdienerauthor=P.+Larsonauthor=W.+H.+M.+Sarisauthor=A.+Astrup&title=Effects+of+a+28-d+Treatment+with+L-796568%2C+A+Novel+%CE%B23-Adrenergic+Receptor+Agonist%2C+on+Energy+Expenditure+and+Body+Composition+in+Obese+Men"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of a 28-d treatment with L-796568, a novel β3-adrenergic receptor agonist, on energy expenditure and body composition in obese men</span></div><div class="casAuthors">Larsen, Thomas M.; Toubro, Soren; van Baak, Marleen A.; Gottesdiener, Keith M.; Larson, Patrick; Saris, Wim H. M.; Astrup, Arne</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Nutrition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">780-788</span>CODEN:
                <span class="NLM_cas:coden">AJCNAC</span>;
        ISSN:<span class="NLM_cas:issn">0002-9165</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Nutrition</span>)
        </div><div class="casAbstract">Stimulation of energy expenditure (EE) with selective thermogenic β-adrenergic agonists may be a promising approach for treating obesity.  We analyzed the effects of the highly selective human β3-adrenergic agonist L-796568 on 24-h EE, substrate oxidn., and body compn. in obese, wt.-stable men.  In this 2-center, double-blind, randomized, parallel-group study, we measured 24-h EE before and after 28 d of treatment with L-796568 (375 mg/d) or placebo during wt. maintenance (ie, without dietary intervention) in nondiabetic, nonsmoking men aged 25-49 yr with body mass index (in kg/m2) of 28-35 (n = 10 subjects per treatment group).  The mean change in 24-h EE from before to after treatment did not differ significantly between groups (92±586 and 86±512 kJ/24 h for the L-796568 and placebo groups, resp.).  The change in 24-h nonprotein RQ from before to after treatment did not differ significantly between groups (0.009±0.021 and 0.009±0.029, resp.).  No changes in glucose tolerance were obsd., but triacylglycerol concns. decreased significantly with L-796568 treatment compared with placebo (-0.76±0.76 and 0.42±0.31 mmol/L, resp.; P < 0.002).  Overall, treatment-related changes in body compn. were not obsd., but higher plasma L-796568 concns. in the L-796568 group were assocd. with greater decreases in fat mass (r = -0.69, P < 0.03).  Treatment with L-796568 for 28 d had no major lipolytic or thermogenic effect but it lowered triacylglycerol concns.  This lack of chronic effect on energy balance is likely explained by insufficient recruitment of β3-responsive tissues in humans, down-regulation of the β3-adrenergic receptor-mediated effects with chronic dosing, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogKuqIefRBVbVg90H21EOLACvtfcHk0lh4AGu5-W0WPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xns1eqsLg%253D&md5=a1437ac79c034a5eb3ea710bb556b356</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLarsen%26aufirst%3DT.%2BM.%26aulast%3DToubro%26aufirst%3DS.%26aulast%3Dvan%2BBaak%26aufirst%3DM.%26aulast%3DGottesdiener%26aufirst%3DK.%2BM.%26aulast%3DLarson%26aufirst%3DP.%26aulast%3DSaris%26aufirst%3DW.%2BH.%2BM.%26aulast%3DAstrup%26aufirst%3DA.%26atitle%3DEffects%2520of%2520a%252028-d%2520Treatment%2520with%2520L-796568%252C%2520A%2520Novel%2520%25CE%25B23-Adrenergic%2520Receptor%2520Agonist%252C%2520on%2520Energy%2520Expenditure%2520and%2520Body%2520Composition%2520in%2520Obese%2520Men%26jtitle%3DAm.%2520J.%2520Clin.%2520Nutr.%26date%3D2002%26volume%3D76%26spage%3D780%26epage%3D788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zinner, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattiasson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, S. L.</span><span> </span><span class="NLM_article-title">Efficacy, Safety, and Tolerability of Extended-Release Once-Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients</span> <span class="citation_source-journal">J. Am. Geriatr. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">799</span><span class="NLM_x">–</span> <span class="NLM_lpage">807</span><span class="refDoi"> DOI: 10.1046/j.1532-5415.2002.50203.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1046%2Fj.1532-5415.2002.50203.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=12028164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A280%3ADC%252BD383osFSrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2002&pages=799-807&author=N.+R.+Zinnerauthor=A.+Mattiassonauthor=S.+L.+Stanton&title=Efficacy%2C+Safety%2C+and+Tolerability+of+Extended-Release+Once-Daily+Tolterodine+Treatment+for+Overactive+Bladder+in+Older+versus+Younger+Patients&doi=10.1046%2Fj.1532-5415.2002.50203.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients</span></div><div class="casAuthors">Zinner Norman R; Mattiasson Anders; Stanton Stuart L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Geriatrics Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">799-807</span>
        ISSN:<span class="NLM_cas:issn">0002-8614</span>.
    </div><div class="casAbstract">OBJECTIVES:  To evaluate the efficacy, safety, and tolerability of a new, once-daily extended-release (ER) formulation of tolterodine in treating overactive bladder in older (> or =65) and younger (<65) patients.  DESIGN:  A 12-week double-blind, placebo-controlled clinical trial.  SETTING:  An international study conducted at 167 medical centers.  PARTICIPANTS:  One thousand fifteen patients (43.1% aged > or =65) with urge incontinence and urinary frequency.  INTERVENTION:  Patients were randomized to treatment with tolterodine ER 4 mg once daily (qd) (n = 507) or placebo (n = 508) for 12 weeks.  MEASUREMENTS:  Efficacy, measured with micturition charts (incontinence episodes, micturitions, volume voided per micturition) and subjective patient assessments, safety, and tolerability endpoints were evaluated, relative to placebo, according to two age cohorts: younger than 65 and 65 and older.  RESULTS:  Mean age in the older and younger patient cohorts was 74 (range 65-93) and 51 (range 20-64), respectively.  Compared with placebo, significant improvements in micturition chart variables with tolterodine ER showed no age-related differences.  Irrespective of age, significantly more tolterodine ER recipients than placebo recipients reported an improvement in urgency symptoms.  After 12 weeks of treatment with tolterodine ER, a fivefold increase in the percentage of patients able to finish tasks before voiding in response to urgency was noted in both age groups (<65: from 6.5-32.8%, > or =65: from 5.1-26.2%).  Tolterodine ER recipients, irrespective of age, also had significant improvements in their bladder condition than did placebo recipients.  Overall, a greater percentage of patients, irrespective of age, perceived any benefit with tolterodine ER than with placebo (P <.001).  Dry mouth (of any severity) was the most common adverse event in both the tolterodine ER and placebo treatment arms, irrespective of age (<65: ER 22.7%, placebo 8.1%; > or =65: ER 24.3%, placebo 7.2%).  Few patients (<2%) experienced severe dry mouth.  No central nervous system, visual, cardiac (per electrocardiogram), or laboratory safety concerns were noted.  Withdrawal rates due to adverse events on tolterodine ER 4 mg qd were comparable in the two age cohorts (<65: 5.5%; > or =65: 5.1%; P =.87).  CONCLUSIONS:  The new, once-daily ER formulation of tolterodine is efficacious, safe, and well tolerated in the treatment of patients with symptoms of overactive bladder, irrespective of age.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn9iue94-DWw5nADWVYHg1fW6udTcc2eaauorCtHadnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD383osFSrtQ%253D%253D&md5=7d852994f4dd4a731df09d4b90a05121</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1046%2Fj.1532-5415.2002.50203.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1532-5415.2002.50203.x%26sid%3Dliteratum%253Aachs%26aulast%3DZinner%26aufirst%3DN.%2BR.%26aulast%3DMattiasson%26aufirst%3DA.%26aulast%3DStanton%26aufirst%3DS.%2BL.%26atitle%3DEfficacy%252C%2520Safety%252C%2520and%2520Tolerability%2520of%2520Extended-Release%2520Once-Daily%2520Tolterodine%2520Treatment%2520for%2520Overactive%2520Bladder%2520in%2520Older%2520versus%2520Younger%2520Patients%26jtitle%3DJ.%2520Am.%2520Geriatr.%2520Soc.%26date%3D2002%26volume%3D50%26spage%3D799%26epage%3D807%26doi%3D10.1046%2Fj.1532-5415.2002.50203.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="citation_source-book">Detrol LA, tolterodine tartrate, extended release capsules</span>; Pharmacia & Upjohn Company: 2004; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21228se8-006_detrol_lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21228se8-006_detrol_lbl.pdf</a> (accessed November<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Detrol+LA%2C+tolterodine+tartrate%2C+extended+release+capsules%3B+Pharmacia+%26+Upjohn+Company%3A+2004%3B+U.S.+Food+and+Drug+Administration%2C+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2004%2F21228se8-006_detrol_lbl.pdf+%28accessed+November+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DDetrol%2520LA%252C%2520tolterodine%2520tartrate%252C%2520extended%2520release%2520capsules%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandrell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairaudeau, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennie, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, A.</span><span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lirfLnJPChR3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDonald, S. J. F.</span><span> </span><span class="NLM_article-title">The Impact of Aromatic Ring Compound Developability – Are too Many Aromatic Rings A Liability in Drug Design?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-20&author=T.+J.+Ritchieauthor=S.+J.+F.+MacDonald&title=The+Impact+of+Aromatic+Ring+Compound+Developability+%E2%80%93+Are+too+Many+Aromatic+Rings+A+Liability+in+Drug+Design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacDonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520Impact%2520of%2520Aromatic%2520Ring%2520Compound%2520Developability%2520%25E2%2580%2593%2520Are%2520too%2520Many%2520Aromatic%2520Rings%2520A%2520Liability%2520in%2520Drug%2520Design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D20%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stearns, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngui, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwei, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strauss, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keohane, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span> </span><span class="NLM_article-title">Metabolism of a thiazole benzenesulfonamide derivative, a potent and selective agonist of the human β<sub>3</sub>-adrenergic receptor, in rats: identification of a novel isethionic acid conjugate</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">778</span><span class="NLM_x">–</span> <span class="NLM_lpage">787</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=778-787&author=W.+Tangauthor=R.+A.+Stearnsauthor=R.+R.+Millerauthor=J.+S.+Nguiauthor=R.+J.+Mathvinkauthor=A.+E.+Weberauthor=G.+Y.+Kweiauthor=J.+R.+Straussauthor=C.+A.+Keohaneauthor=G.+A.+Dossauthor=S.+H.+Chiuauthor=T.+A.+Baillie&title=Metabolism+of+a+thiazole+benzenesulfonamide+derivative%2C+a+potent+and+selective+agonist+of+the+human+%CE%B23-adrenergic+receptor%2C+in+rats%3A+identification+of+a+novel+isethionic+acid+conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DStearns%26aufirst%3DR.%2BA.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DNgui%26aufirst%3DJ.%2BS.%26aulast%3DMathvink%26aufirst%3DR.%2BJ.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DKwei%26aufirst%3DG.%2BY.%26aulast%3DStrauss%26aufirst%3DJ.%2BR.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DChiu%26aufirst%3DS.%2BH.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26atitle%3DMetabolism%2520of%2520a%2520thiazole%2520benzenesulfonamide%2520derivative%252C%2520a%2520potent%2520and%2520selective%2520agonist%2520of%2520the%2520human%2520%25CE%25B23-adrenergic%2520receptor%252C%2520in%2520rats%253A%2520identification%2520of%2520a%2520novel%2520isethionic%2520acid%2520conjugate%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D778%26epage%3D787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Morriello, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feighner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hreniuk, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galloway, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGettigan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laws, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKnight, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doss, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streckfuss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β<sub>3</sub> adrenergic receptor agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1865</span><span class="NLM_x">–</span> <span class="NLM_lpage">1870</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.bmcl.2010.12.087" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1865-1870&author=G.+J.+Morrielloauthor=H.+R.+Wendtauthor=A.+Bansalauthor=J.+Di+Salvoauthor=S.+Feighnerauthor=J.+Heauthor=A.+L.+Hurleyauthor=D.+L.+Hreniukauthor=G.+M.+Salituroauthor=M.+V.+Reddyauthor=S.+M.+Gallowayauthor=K.+K.+McGettiganauthor=G.+Lawsauthor=C.+McKnightauthor=G.+A.+Dossauthor=N.+N.+Tsouauthor=R.+M.+Blackauthor=J.+Morrisauthor=R.+G.+Ballauthor=A.+T.+Sanfizauthor=E.+Streckfussauthor=M.+Struthersauthor=S.+D.+Edmondson&title=Design+of+a+novel+pyrrolidine+scaffold+utilized+in+the+discovery+of+potent+and+selective+human+%CE%B23+adrenergic+receptor+agonists&doi=10.1016%2Fj.bmcl.2010.12.087"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.087%26sid%3Dliteratum%253Aachs%26aulast%3DMorriello%26aufirst%3DG.%2BJ.%26aulast%3DWendt%26aufirst%3DH.%2BR.%26aulast%3DBansal%26aufirst%3DA.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DFeighner%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DHreniuk%26aufirst%3DD.%2BL.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DGalloway%26aufirst%3DS.%2BM.%26aulast%3DMcGettigan%26aufirst%3DK.%2BK.%26aulast%3DLaws%26aufirst%3DG.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DDoss%26aufirst%3DG.%2BA.%26aulast%3DTsou%26aufirst%3DN.%2BN.%26aulast%3DBlack%26aufirst%3DR.%2BM.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DBall%26aufirst%3DR.%2BG.%26aulast%3DSanfiz%26aufirst%3DA.%2BT.%26aulast%3DStreckfuss%26aufirst%3DE.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDesign%2520of%2520a%2520novel%2520pyrrolidine%2520scaffold%2520utilized%2520in%2520the%2520discovery%2520of%2520potent%2520and%2520selective%2520human%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1865%26epage%3D1870%26doi%3D10.1016%2Fj.bmcl.2010.12.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Moyes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goble, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingley, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzmaurice, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gichuru, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochnowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagabukuro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevenson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamlynny, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β<sub>3</sub> Adrenergic Receptor Agonists for the Treatment of Overactive Bladder</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1021/jm4017224</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017224" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1437-1453&author=C.+R.+Moyesauthor=R.+Bergerauthor=S.+D.+Gobleauthor=B.+Harperauthor=D.-M.+Shenauthor=L.+Wangauthor=A.+Bansalauthor=P.+N.+Brownauthor=A.+S.+Chenauthor=K.+H.+Dingleyauthor=J.+Di+Salvoauthor=A.+Fitzmauriceauthor=L.+N.+Gichuruauthor=A.+L.+Hurleyauthor=N.+Jochnowitzauthor=R.+R.+Millerauthor=S.+Mistryauthor=H.+Nagabukuroauthor=G.+M.+Salituroauthor=A.+Sanfizauthor=A.+S.+Stevensonauthor=K.+Villaauthor=B.+Zamlynnyauthor=M.+Struthersauthor=A.+E.+Weberauthor=S.+D.+Edmondson&title=Design%2C+Synthesis%2C+and+Evaluation+of+Conformationally+Restricted+Acetanilides+as+Potent+and+Selective+%CE%B23+Adrenergic+Receptor+Agonists+for+the+Treatment+of+Overactive+Bladder&doi=10.1021%2Fjm4017224"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm4017224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017224%26sid%3Dliteratum%253Aachs%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DD.-M.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DBansal%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DP.%2BN.%26aulast%3DChen%26aufirst%3DA.%2BS.%26aulast%3DDingley%26aufirst%3DK.%2BH.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DFitzmaurice%26aufirst%3DA.%26aulast%3DGichuru%26aufirst%3DL.%2BN.%26aulast%3DHurley%26aufirst%3DA.%2BL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DR.%2BR.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DSalituro%26aufirst%3DG.%2BM.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DA.%2BS.%26aulast%3DVilla%26aufirst%3DK.%26aulast%3DZamlynny%26aufirst%3DB.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Evaluation%2520of%2520Conformationally%2520Restricted%2520Acetanilides%2520as%2520Potent%2520and%2520Selective%2520%25CE%25B23%2520Adrenergic%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Overactive%2520Bladder%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1437%26epage%3D1453%26doi%3D10.1021%2Fjm4017224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hanessian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sailes, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, E.</span><span> </span><span class="NLM_article-title">Synthesis of Diversely Functionalized Indolizidinones and Related Bicyclic Lactams Using Intramolecular Grubbs Olefin Metathesis and Dieckmann Condensation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">7219</span><span class="NLM_x">–</span> <span class="NLM_lpage">7233</span><span class="refDoi"> DOI: 10.1021/jo030145z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo030145z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1eqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=7219-7233&author=S.+Hanessianauthor=H.+Sailesauthor=A.+Munroauthor=E.+Therrien&title=Synthesis+of+Diversely+Functionalized+Indolizidinones+and+Related+Bicyclic+Lactams+Using+Intramolecular+Grubbs+Olefin+Metathesis+and+Dieckmann+Condensation&doi=10.1021%2Fjo030145z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diversely Functionalized Indolizidinones and Related Bicyclic Lactams Using Intramolecular Grubbs Olefin Metathesis and Dieckmann Condensation</span></div><div class="casAuthors">Hanessian, Stephen; Sailes, Helen; Munro, Alexander; Therrien, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7219-7233</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bicyclic 1-aza-2-oxo ring systems with versatile functionality were synthesized from the Grubbs olefin metathesis of appropriate olefinic precursors, starting with L-pyroglutamic acid.  The carbocyclization products were further functionalized utilizing the double bond or by enolate chem. of the corresponding β,γ-unsatd. bicyclic lactam.  In an alternative strategy, indolizidinones were synthesized by application of an intramol. Dieckmann cyclization.  A constrained peptidomimetic thrombin inhibitor was prepd. from one of the bicyclic indolizidinones.  Mol. structures of (-)-(3S,6S,9S)-6-azido-3-[[(tert-butyldiphenylsilyl)oxy]methyl]hexahydro-5-indolizinone, (-)-(1R,3S,7S,8R,9S)-1-benzyl-7,8-oxa-5-oxooctahydroindolizine-3-carboxylic acid Me ester, (-)-(3S,6R,9S)-3-[[[(tert-butyldiphenyl)silyl]oxy]methyl]-6-azido-6-benzylhexahydroindolzin-5-one were reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRe4oebr4irVg90H21EOLACvtfcHk0lgmJHy6JtcD3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1eqsbw%253D&md5=a2e80c567a34037d9cfdfe263f8affc7</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1021%2Fjo030145z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo030145z%26sid%3Dliteratum%253Aachs%26aulast%3DHanessian%26aufirst%3DS.%26aulast%3DSailes%26aufirst%3DH.%26aulast%3DMunro%26aufirst%3DA.%26aulast%3DTherrien%26aufirst%3DE.%26atitle%3DSynthesis%2520of%2520Diversely%2520Functionalized%2520Indolizidinones%2520and%2520Related%2520Bicyclic%2520Lactams%2520Using%2520Intramolecular%2520Grubbs%2520Olefin%2520Metathesis%2520and%2520Dieckmann%2520Condensation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D7219%26epage%3D7233%26doi%3D10.1021%2Fjo030145z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vaswani, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlin, R.</span><span> </span><span class="NLM_article-title">Stereocontrolled Total Synthesis of (−)-Kaitocephalin</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">1661</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span><span class="refDoi"> DOI: 10.1021/jo702329z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702329z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=1661-1681&author=R.+G.+Vaswaniauthor=R.+Chamberlin&title=Stereocontrolled+Total+Synthesis+of+%28%E2%88%92%29-Kaitocephalin&doi=10.1021%2Fjo702329z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1021%2Fjo702329z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702329z%26sid%3Dliteratum%253Aachs%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DChamberlin%26aufirst%3DR.%26atitle%3DStereocontrolled%2520Total%2520Synthesis%2520of%2520%2528%25E2%2588%2592%2529-Kaitocephalin%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D1661%26epage%3D1681%26doi%3D10.1021%2Fjo702329z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Fülöp, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palkó, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernáth, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohár, P.</span><span> </span><span class="NLM_article-title">Synthesis and Retro Diels-Alder Decomposition of 1,4-Methanopyrrolo-,1,4-Methanoazepino[2,1-b]-quinazolinones</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1080/00397919708005019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1080%2F00397919708005019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1997&pages=195-203&author=F.+F%C3%BCl%C3%B6pauthor=M.+Palk%C3%B3author=G.+Bern%C3%A1thauthor=P.+Soh%C3%A1r&title=Synthesis+and+Retro+Diels-Alder+Decomposition+of+1%2C4-Methanopyrrolo-%2C1%2C4-Methanoazepino%5B2%2C1-b%5D-quinazolinones&doi=10.1080%2F00397919708005019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1080%2F00397919708005019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397919708005019%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCl%25C3%25B6p%26aufirst%3DF.%26aulast%3DPalk%25C3%25B3%26aufirst%3DM.%26aulast%3DBern%25C3%25A1th%26aufirst%3DG.%26aulast%3DSoh%25C3%25A1r%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520Retro%2520Diels-Alder%2520Decomposition%2520of%25201%252C4-Methanopyrrolo-%252C1%252C4-Methanoazepino%255B2%252C1-b%255D-quinazolinones%26jtitle%3DSynth.%2520Commun.%26date%3D1997%26volume%3D27%26spage%3D195%26epage%3D203%26doi%3D10.1080%2F00397919708005019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><div class="note"><p class="first last">The reason for comparing β<sub>3</sub>-AR EC<sub>50</sub>’s and β<sub>1</sub>-AR and β<sub>2</sub>-AR IC<sub>50</sub>’s as an assessment of selectivity is described in</p></div><span class="NLM_contrib-group">Mathvink, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chitty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Candelore, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cascieri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colwell, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hom, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacIntyre, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tota, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span> </span><span class="NLM_article-title">Potent, selective 3-pyridylethanoloamine β<sub>3</sub> adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1971</span><span class="NLM_x">–</span> <span class="NLM_lpage">1973</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00390-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2FS0960-894X%2800%2900390-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=1971-1973&author=R.+J.+Mathvinkauthor=J.+S.+Tolmanauthor=D.+Chittyauthor=M.+R.+Candeloreauthor=M.+A.+Cascieriauthor=L.+F.+Colwellauthor=L.+Dengauthor=W.+P.+Feeneyauthor=M.+J.+Forrestauthor=G.+J.+Homauthor=E.+MacIntyreauthor=L.+Totaauthor=M.+J.+Wyvrattauthor=M.+H.+Fisherauthor=A.+E.+Weber&title=Potent%2C+selective+3-pyridylethanoloamine+%CE%B23+adrenergic+receptor+agonists+possessing+a+thiazole+benzenesulfonamide+pharmacophore&doi=10.1016%2FS0960-894X%2800%2900390-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900390-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900390-5%26sid%3Dliteratum%253Aachs%26aulast%3DMathvink%26aufirst%3DR.%2BJ.%26aulast%3DTolman%26aufirst%3DJ.%2BS.%26aulast%3DChitty%26aufirst%3DD.%26aulast%3DCandelore%26aufirst%3DM.%2BR.%26aulast%3DCascieri%26aufirst%3DM.%2BA.%26aulast%3DColwell%26aufirst%3DL.%2BF.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DFeeney%26aufirst%3DW.%2BP.%26aulast%3DForrest%26aufirst%3DM.%2BJ.%26aulast%3DHom%26aufirst%3DG.%2BJ.%26aulast%3DMacIntyre%26aufirst%3DE.%26aulast%3DTota%26aufirst%3DL.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26atitle%3DPotent%252C%2520selective%25203-pyridylethanoloamine%2520%25CE%25B23%2520adrenergic%2520receptor%2520agonists%2520possessing%2520a%2520thiazole%2520benzenesulfonamide%2520pharmacophore%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D1971%26epage%3D1973%26doi%3D10.1016%2FS0960-894X%2800%2900390-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lynch, J. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stupienski, R. F.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beare, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleby, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurkiewicz, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanguinetti, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. B.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">541</span><span class="NLM_x">–</span> <span class="NLM_lpage">554</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=7802864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADyaK2cXkt1KmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=541-554&author=J.+J.+Lynchauthor=A.+A.+Wallaceauthor=R.+F.+Stupienskiauthor=E.+P.+Baskinauthor=C.+M.+Beareauthor=S.+D.+Applebyauthor=J.+J.+Salataauthor=N.+K.+Jurkiewiczauthor=M.+C.+Sanguinettiauthor=R.+B.+Stein&title=Cardiac+electrophysiologic+and+antiarrhythmic+actions+of+two+long-acting+spirobenzopyran+piperidine+class+III+agents%2C+L-702%2C958+and+L-706%2C000+%5BMK-499%5D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]</span></div><div class="casAuthors">Lynch, Joseph J., Jr.; Wallace, Audrey A.; Stupienski, Raymond F., III; Baskin, Elizabeth P.; Beare, Carolann M.; Appleby, Sandra D.; Salata, Joseph J.; Jurkiewicz, Nancy K.; Sanguinetti, Michael; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">541-54</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The cardiac electrophysiol. and antiarrhythmic actions of two Class III ketone- and alc.-contg. spirobenzopyran piperidine analogs, L-702,958 and L-706,000 [MK-499], resp., were assessed in vitro and in vivo.  L-702,958 and L-706,000 [MK-499] selectively blocked the rapidly activating component of the delayed rectifier K+ current in guinea pig isolated ventricular myocytes (IC50 values, 14.6 and 43.9 nM, resp.), and prolonged effective refractory period in ferret isolated papillary muscles (EC25 values, 10.5 and 53.8 nM, resp.).  In anesthetized dogs, L-702,958 and L-706,000 [MK-499] increased ventricular refractory periods (ED20 values, 3.3 and 9.2 μg/kg i.v., resp.) and concomitantly increased ECG QT interval and left ventricular + dP/dt.  Cumulative i.v. administrations of ≤100 μg/kg of L-702,958 and 300 μg/kg L-706,000 [MK-499] in anesthetized dogs increased atrial and ventricular refractoriness and prolonged the ECG QT interval, but did not alter atrial, atrioventricular nodal, His-Purkinje or ventricular conduction indexes.  In anesthetized dogs studied chronically (9.2 days) after anterior myocardial infarction, the cumulative i.v. administrations of 100 μg/kg of L-702,958 and 300 μg/kg L-706,000 [MK-499] suppressed the induction of ventricular tachyarrhythmia by programmed ventricular stimulation (suppression rates: 8 of 10, 80% and 9 of 11, 82%, resp.) and reduced the incidence of lethal ventricular arrhythmias (incidences of lethal ischemic arrhythmias: 4 of 10, 40% and 1 of 11 9%, resp., compared to 34 of 40, 85%, in vehicle controls).  L-702,958 and L-706,000 [MK-499] (cumulative 100 and 300 μg/kg i.v., resp.) did not facilitate the induction of arrhythmias by programmed ventricular stimulation in postinfarction dogs.  After equivalently effective p.o. doses in conscious dogs, L-702,958 (10 μg/kg) and L-706,000 [MK-499] (30 μg/kg) increased ECG QT interval with long durations of action of approx. 9 and 14 h, resp.  L-706,000 [MK-499] elicited a more consistent and sustained prolongation of the QT interval than L-702,958.  These findings show that both L-702,958 and L-706,000 [MK-499] are potentially useful agents for the prevention of malignant ventricular arrhythmias in the setting of myocardial ischemic injury.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoodlHaDa4-FrVg90H21EOLACvtfcHk0lhrd_nloKJZVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkt1KmtLY%253D&md5=b13505c41ffd30d723860c4b9e13dfb8</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DWallace%26aufirst%3DA.%2BA.%26aulast%3DStupienski%26aufirst%3DR.%2BF.%26aulast%3DBaskin%26aufirst%3DE.%2BP.%26aulast%3DBeare%26aufirst%3DC.%2BM.%26aulast%3DAppleby%26aufirst%3DS.%2BD.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26aulast%3DJurkiewicz%26aufirst%3DN.%2BK.%26aulast%3DSanguinetti%26aufirst%3DM.%2BC.%26aulast%3DStein%26aufirst%3DR.%2BB.%26atitle%3DCardiac%2520electrophysiologic%2520and%2520antiarrhythmic%2520actions%2520of%2520two%2520long-acting%2520spirobenzopyran%2520piperidine%2520class%2520III%2520agents%252C%2520L-702%252C958%2520and%2520L-706%252C000%2520%255BMK-499%255D%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1994%26volume%3D269%26spage%3D541%26epage%3D554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schoemaker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, S.</span><span> </span><span class="NLM_article-title">Calcium Channel Receptor Binding Studies for Diltiazem and Its Major Metabolites: Fuctional Correlation to Inhibition of Portal Vein Myogenic Activity</span> <span class="citation_source-journal">J. Cardiovasc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1097/00005344-198702000-00008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1097%2F00005344-198702000-00008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1987&pages=173-180&author=H.+Schoemakerauthor=P.+Hicksauthor=S.+Langer&title=Calcium+Channel+Receptor+Binding+Studies+for+Diltiazem+and+Its+Major+Metabolites%3A+Fuctional+Correlation+to+Inhibition+of+Portal+Vein+Myogenic+Activity&doi=10.1097%2F00005344-198702000-00008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1097%2F00005344-198702000-00008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-198702000-00008%26sid%3Dliteratum%253Aachs%26aulast%3DSchoemaker%26aufirst%3DH.%26aulast%3DHicks%26aufirst%3DP.%26aulast%3DLanger%26aufirst%3DS.%26atitle%3DCalcium%2520Channel%2520Receptor%2520Binding%2520Studies%2520for%2520Diltiazem%2520and%2520Its%2520Major%2520Metabolites%253A%2520Fuctional%2520Correlation%2520to%2520Inhibition%2520of%2520Portal%2520Vein%2520Myogenic%2520Activity%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1987%26volume%3D9%26spage%3D173%26epage%3D180%26doi%3D10.1097%2F00005344-198702000-00008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hartmann, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiedeman, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, G. E.</span><span> </span><span class="NLM_article-title">Effects of III-IV Linker Mutations on Human Heart Na<sup>+</sup> Channel Inactivation Gating</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">122</span><span class="refDoi"> DOI: 10.1161/01.RES.75.1.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1161%2F01.RES.75.1.114" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1994&pages=114-122&author=H.+A.+Hartmannauthor=A.+A.+Tiedemanauthor=S.+F.+Chenauthor=A.+M.+Brownauthor=G.+E.+Kirsch&title=Effects+of+III-IV+Linker+Mutations+on+Human+Heart+Na%2B+Channel+Inactivation+Gating&doi=10.1161%2F01.RES.75.1.114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1161%2F01.RES.75.1.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.75.1.114%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DH.%2BA.%26aulast%3DTiedeman%26aufirst%3DA.%2BA.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26aulast%3DKirsch%26aufirst%3DG.%2BE.%26atitle%3DEffects%2520of%2520III-IV%2520Linker%2520Mutations%2520on%2520Human%2520Heart%2520Na%252B%2520Channel%2520Inactivation%2520Gating%26jtitle%3DCirc.%2520Res.%26date%3D1994%26volume%3D75%26spage%3D114%26epage%3D122%26doi%3D10.1161%2F01.RES.75.1.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bhandari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figueroa, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerhold, D. L.</span><span> </span><span class="NLM_article-title">Phospholipidosis Assay in HepG2 Cells and Rat or Rhesus Hepatocytes Using Phospholipid Probe NBD-PE</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">420</span><span class="refDoi"> DOI: 10.1089/adt.2007.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1089%2Fadt.2007.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=18537465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnvFCgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=407-420&author=N.+Bhandariauthor=D.+J.+Figueroaauthor=J.+W.+Lawrenceauthor=D.+L.+Gerhold&title=Phospholipidosis+Assay+in+HepG2+Cells+and+Rat+or+Rhesus+Hepatocytes+Using+Phospholipid+Probe+NBD-PE&doi=10.1089%2Fadt.2007.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phospholipidosis Assay in HepG2 Cells and Rat or Rhesus Hepatocytes Using Phospholipid Probe NBD-PE</span></div><div class="casAuthors">Bhandari, Neetesh; Figueroa, David J.; Lawrence, Jeffrey W.; Gerhold, David Lee</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-419</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Phospholipidosis (PLD) is an accumulation of phospholipids in lysosome-derived multilamellar vesicles.  More than 50 com. drugs are known to cause PLD.  In vitro screening assays were developed in HepG2 cells, rat primary hepatocytes, and rhesus monkey hepatocytes using the fluorescent-labeled phospholipid probe N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE) or Nile Red lipid stain.  The assays were qualified using amiodarone and fluoxetine as pos. controls and precocene and valproic acid as neg. controls.  NBD-PE accumulation and Nile Red staining were first measured using fluorescence microscopy with morphometric anal., and the throughput of the NBD-PE assay in HepG2 cells was increased by measuring fluorescence with a multiwell spectrofluorometer.  The PLD potential values obtained for the tested compds. from the morphometric anal. were similar to the values obtained from the spectrofluorometer, suggesting the plate reader assay was effective at measuring the induction of NBD-PE accumulation.  Fifteen com. compds. were evaluated using the NBD-PE assay in HepG2 cells, rat primary hepatocytes, and rhesus monkey hepatocytes.  The relative NBD-PE accumulation and PLD potentials of the evaluated compds. were similar and comparable to the values obsd. from other in vitro PLD assays referenced in the literature using different probes and cell lines.  NBD-PE accumulations obsd. in rat hepatocytes after drug treatments were similar to those in HepG2 cells.  NBD-PE accumulation potential obsd. in rhesus monkey hepatocytes after drug treatment was different for tamoxifen, perhexiline, clomipramine, and haloperidol.  These agents caused potent NBD-PE accumulation in HepG2 cells, but minimal or no activity was obsd. in rhesus monkey hepatocytes.  These data suggest that the NBD-PE spectrofluorometer assay in HepG2 cells has the speed and throughput to sensitively and quant. det. the PLD potential of various drug candidates.  In addn., these data demonstrate the species differences in PLD potential between rat and monkey hepatocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyDkd0BQfYSbVg90H21EOLACvtfcHk0lgaqXlDVZgrpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnvFCgsrk%253D&md5=9776b2e6b248258d65c2668c29f599e0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.119%26sid%3Dliteratum%253Aachs%26aulast%3DBhandari%26aufirst%3DN.%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DLawrence%26aufirst%3DJ.%2BW.%26aulast%3DGerhold%26aufirst%3DD.%2BL.%26atitle%3DPhospholipidosis%2520Assay%2520in%2520HepG2%2520Cells%2520and%2520Rat%2520or%2520Rhesus%2520Hepatocytes%2520Using%2520Phospholipid%2520Probe%2520NBD-PE%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2008%26volume%3D6%26spage%3D407%26epage%3D420%26doi%3D10.1089%2Fadt.2007.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Goble, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brockunier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiSalvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feighner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hreniuk, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parmee, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robbins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanfiz, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streckfuss, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Struthers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edmondson, S. D.</span><span> </span><span class="NLM_article-title">Heterocyclic Acetamide and Benzamide Derivatives as potent and selective β<sub>3</sub>-adrenergic receptor agonists with improved rodent pharmacokinetic profiles</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1899</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.bmcl.2010.01.130" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1895-1899&author=S.+D.+Gobleauthor=L.+Wangauthor=K.+L.+Howellauthor=A.+Bansalauthor=R.+Bergerauthor=L.+Brockunierauthor=J.+DiSalvoauthor=S.+Feighnerauthor=B.+Harperauthor=J.+Heauthor=A.+Hurleyauthor=D.+Hreniukauthor=E.+Parmeeauthor=M.+Robbinsauthor=G.+Salituroauthor=A.+Sanfizauthor=E.+Streckfussauthor=E.+Watkinsauthor=A.+E.+Weberauthor=M.+Struthersauthor=S.+D.+Edmondson&title=Heterocyclic+Acetamide+and+Benzamide+Derivatives+as+potent+and+selective+%CE%B23-adrenergic+receptor+agonists+with+improved+rodent+pharmacokinetic+profiles&doi=10.1016%2Fj.bmcl.2010.01.130"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.130%26sid%3Dliteratum%253Aachs%26aulast%3DGoble%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHowell%26aufirst%3DK.%2BL.%26aulast%3DBansal%26aufirst%3DA.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBrockunier%26aufirst%3DL.%26aulast%3DDiSalvo%26aufirst%3DJ.%26aulast%3DFeighner%26aufirst%3DS.%26aulast%3DHarper%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHurley%26aufirst%3DA.%26aulast%3DHreniuk%26aufirst%3DD.%26aulast%3DParmee%26aufirst%3DE.%26aulast%3DRobbins%26aufirst%3DM.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DSanfiz%26aufirst%3DA.%26aulast%3DStreckfuss%26aufirst%3DE.%26aulast%3DWatkins%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DA.%2BE.%26aulast%3DStruthers%26aufirst%3DM.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26atitle%3DHeterocyclic%2520Acetamide%2520and%2520Benzamide%2520Derivatives%2520as%2520potent%2520and%2520selective%2520%25CE%25B23-adrenergic%2520receptor%2520agonists%2520with%2520improved%2520rodent%2520pharmacokinetic%2520profiles%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1895%26epage%3D1899%26doi%3D10.1016%2Fj.bmcl.2010.01.130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liggett, S. B.</span><span> </span><span class="NLM_article-title">Functional Properties of the Rat and Human β<sub>3</sub>-Adrenergic Receptors: Differential Agonist Activation of Recombinant Receptors in Chinese Hamster Ovary Cells</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">634</span><span class="NLM_x">–</span> <span class="NLM_lpage">637</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1992&pages=634-637&author=S.+B.+Liggett&title=Functional+Properties+of+the+Rat+and+Human+%CE%B23-Adrenergic+Receptors%3A+Differential+Agonist+Activation+of+Recombinant+Receptors+in+Chinese+Hamster+Ovary+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiggett%26aufirst%3DS.%2BB.%26atitle%3DFunctional%2520Properties%2520of%2520the%2520Rat%2520and%2520Human%2520%25CE%25B23-Adrenergic%2520Receptors%253A%2520Differential%2520Agonist%2520Activation%2520of%2520Recombinant%2520Receptors%2520in%2520Chinese%2520Hamster%2520Ovary%2520Cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1992%26volume%3D42%26spage%3D634%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Vrydag, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, M. C.</span><span> </span><span class="NLM_article-title">Tools to Study β<sub>3</sub>-Adrenoceptors</span> <span class="citation_source-journal">Naunyn-Schmiedeberg's Arch. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1007/s00210-006-0127-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1007%2Fs00210-006-0127-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17211601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVersrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2007&pages=385-98&author=W.+Vrydagauthor=M.+C.+Michel&title=Tools+to+Study+%CE%B23-Adrenoceptors&doi=10.1007%2Fs00210-006-0127-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33bR"><div class="casContent"><span class="casTitleNuber">33b</span><div class="casTitle"><span class="NLM_cas:atitle">Tools to study β3-adrenoceptors</span></div><div class="casAuthors">Vrydag, Wim; Michel, Martin C.</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">385-398</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  β3-Adrenoceptors mediate some of the effects of catecholamines on tissues such as blood vessels or the urinary bladder and are putative targets for the treatment of diseases such as the overactive bladder syndrome.  Progress in the understanding of the presence, function, and regulation of β3-adrenoceptors has been hampered by a lack of highly specific tools.  "Classical" β3-adrenoceptor agonists such as BRL 37,344 [(R*, R*)-(±)-4[2-[(3-chlorophenyl)-2-hydroxyethyl amino] propyl] phenoxyacetic acid] and CGP 12,177 [(±)-4-(3-t-butylamino-2-hydroxypropoxy)benzimidazol-2-one] are only partial agonists in many settings, have limited selectivity over other β-adrenoceptor subtypes, and may addnl. act on receptors other than β-adrenoceptors.  More efficacious and more selective agonists have been reported and, in some cases, are in clin. development but are not widely available for exptl. studies.  The widely used antagonist SR 59,230 [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronaphth-1-ylamino]-2S-2-propanoloxalate] is not selective for β3-adrenoceptors, at least in humans, and may actually be a partial agonist.  Radioligands, which are suitable either for the selective labeling of β3-adrenoceptors or for the nonselective labeling of all β-adrenoceptor subtypes, are also missing. β3- and β1/β2 double knockout mice have been reported, but their usefulness for extrapolations in humans is questionable based upon major differences between humans and rodents with regard to the ligand recognition and expression profiles of β3-adrenoceptors.  While the common availability of more selective agonists and antagonists at the β3-adrenoceptor is urgently awaited, the limitations of the currently available tools need to be considered in studies of β3-adrenoceptor for the time being.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFuFA8A8dRELVg90H21EOLACvtfcHk0lhP1s7lRurHow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVersrs%253D&md5=46ae123b753946122873eaea5adaf76e</span></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1007%2Fs00210-006-0127-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-006-0127-5%26sid%3Dliteratum%253Aachs%26aulast%3DVrydag%26aufirst%3DW.%26aulast%3DMichel%26aufirst%3DM.%2BC.%26atitle%3DTools%2520to%2520Study%2520%25CE%25B23-Adrenoceptors%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2007%26volume%3D374%26spage%3D385%26epage%3D98%26doi%3D10.1007%2Fs00210-006-0127-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Birder, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Groat, W. C.</span><span> </span><span class="NLM_article-title">Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">4878</span><span class="NLM_x">–</span> <span class="NLM_lpage">4889</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1464772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADyaK3sXht1aht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1992&pages=4878-4889&author=L.+A.+Birderauthor=W.+C.+de+Groat&title=Increased+c-fos+expression+in+spinal+neurons+after+irritation+of+the+lower+urinary+tract+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Increased c-fos expression in spinal neurons after irritation of the lower urinary tract in the rat</span></div><div class="casAuthors">Birder, Lori A.; De Groat, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4878-89</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    </div><div class="casAbstract">This study utilized neuronal c-fos expression to examine the spinal pathways involved in processing nociceptive and non-nociceptive afferent input from the lower urinary tract (LUT) of the urethane-anesthetized rat.  C-fos protein was detected immunocytochem. in only a small no. of cells (<2 cells/L6 section) in control animals.  However, chem. irritation with 1% acetic acid or mech. stimulation of the LUT markedly increased the no. of c-fos-pos. neurons (56-180 cells/L6 section) in four regions of the caudal lumbosacral (L6-S1) spinal cord: medial dorsal horn (MDH), lateral dorsal horn, dorsal commissure (DCM), and sacral parasympathetic nucleus (SPN).  Only small nos. of c-fos-pos. cells were detected in rostral lumbar segments, a region that is though to receive nociceptive input from the LUT via afferent pathways in sympathetic nerves.  The distribution of c-fos-pos. cells in the L6 spinal cord varied according to the stimulus (i.e., urethral catheter, bladder distension, or chem. irritation).  Distension of the urinary bladder increased the no. of c-fos-pos. cells mainly in DCM and SPN regions of the cord.  In contrast, irritation of the LUT increased c-fos expression largely in DCM and MDH areas.  Spinal cord transection (T8 level) did not alter the c-fos expression induced by a catheter or chem. irritation, indicating that gene expression was mediated by spinal pathways.  Denervation expts. showed that c-fos expression was induced by activation of afferent pathways in the pelvic and pudendal nerves.  These results suggest that neurons in several regions of the spinal cord are involved in processing afferent input from different parts of the LUT.  Neurons in the DCM appear to have an important role since they respond to both nociceptive and non-nociceptive inputs and to visceral (pelvic nerve) and somatic (pudendal nerve) afferent pathways.  Thus, these neurons may be involved in the mechanisms of visceral-somatic referred pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23_bMKp_6CbVg90H21EOLACvtfcHk0lhP1s7lRurHow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXht1aht7o%253D&md5=89d69a06b5be4eff23c8e3b34d8e8804</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBirder%26aufirst%3DL.%2BA.%26aulast%3Dde%2BGroat%26aufirst%3DW.%2BC.%26atitle%3DIncreased%2520c-fos%2520expression%2520in%2520spinal%2520neurons%2520after%2520irritation%2520of%2520the%2520lower%2520urinary%2520tract%2520in%2520the%2520rat%26jtitle%3DJ.%2520Neurosci.%26date%3D1992%26volume%3D12%26spage%3D4878%26epage%3D4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Nagabukuro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistry, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gichuru, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jochnowitz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbadie, C.</span><span> </span><span class="NLM_article-title">Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats</span> <span class="citation_source-journal">Auton. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">156</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">26</span><span class="refDoi"> DOI: 10.1016/j.autneu.2010.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.autneu.2010.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=20335078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1aqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2010&pages=19-26&author=H.+Nagabukuroauthor=A.+Degenhardtauthor=K.+L.+Villaauthor=S.+L.+Mistryauthor=L.+Gichuruauthor=N.+Jochnowitzauthor=C.+Abbadie&title=Correlation+between+pharmacologically-induced+changes+in+cystometric+parameters+and+spinal+c-Fos+expression+in+rats&doi=10.1016%2Fj.autneu.2010.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats</span></div><div class="casAuthors">Nagabukuro, Hiroshi; Degenhardt, Amanda; Villa, Katherine L.; Mistry, Shruti L.; Gichuru, Loise; Jochnowitz, Nina; Abbadie, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Autonomic Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-26</span>CODEN:
                <span class="NLM_cas:coden">ANUEB2</span>;
        ISSN:<span class="NLM_cas:issn">1566-0702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The inhibition of bladder sensory transmission is crit. for the pharmacotherapy of urine storage symptoms.  The purpose of this study is to examine the correlation between pharmacol.-induced changes in cystometric parameters and spinal c-Fos expression in anesthetized rats with bladder hyperactivity induced by the intravesical infusion of acetic acid.  Animals were i.v. infused with either oxybutynin (OXY), a muscarinic receptor antagonist, tamsulosin (TAM), an α1-adrenoceptor antagonist, CL316243 (CL), a β3-adrenoceptor agonist, or saline.  Morphine (MOR) treatment served as a pos. control to inhibit bladder afferent activity.  Intermicturition intervals, micturition pressure and pressure threshold were measured after intravesical acetic acid infusion.  Animals were then perfused and spinal cords were removed.  Sections from the L6 spinal cord were immunostained with an anti-c-Fos antibody, and c-Fos pos. cells in the dorsal region were counted.  CL and MOR significantly increased intermicturition intervals, whereas OXY and TAM had no significant effect on intermicturition intervals.  While TAM and MOR did not affect the micturition pressure, OXY and CL caused a significant decrease.  Pressure threshold was significantly decreased by CL and increased by MOR.  All drugs significantly decreased the no. of c-Fos pos. cells with the following order of efficacy: MOR > CL > OXT > TAM.  The no. of c-Fos pos. cells in each animal from all treatment groups was neg. correlated with its av. intermicturition interval and pressure threshold, but not with its micturition pressure.  Bladder afferent activity is suppressed by several clin. proven mechanisms as measured by c-Fos expression, despite the varied effects on cystometric parameters of each pharmacol. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OrWBZy2DaLVg90H21EOLACvtfcHk0lhP1s7lRurHow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1aqsrc%253D&md5=ba706884210b87c5c212b4b44335023a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.autneu.2010.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.autneu.2010.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DNagabukuro%26aufirst%3DH.%26aulast%3DDegenhardt%26aufirst%3DA.%26aulast%3DVilla%26aufirst%3DK.%2BL.%26aulast%3DMistry%26aufirst%3DS.%2BL.%26aulast%3DGichuru%26aufirst%3DL.%26aulast%3DJochnowitz%26aufirst%3DN.%26aulast%3DAbbadie%26aufirst%3DC.%26atitle%3DCorrelation%2520between%2520pharmacologically-induced%2520changes%2520in%2520cystometric%2520parameters%2520and%2520spinal%2520c-Fos%2520expression%2520in%2520rats%26jtitle%3DAuton.%2520Neurosci.%26date%3D2010%26volume%3D156%26spage%3D19%26epage%3D26%26doi%3D10.1016%2Fj.autneu.2010.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">36</a></strong><div class="note"><p class="first last">For lead references to rodent lipolytic effects of β<sub>3</sub>-AR agonists, see</p></div><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Weyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gautier, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danforth, E.,  Jr.</span><span> </span><span class="NLM_article-title">Development of Beta3-Adrenoceptor Agonists for the Treatment of Obesity and Diabetes – An Update</span> <span class="citation_source-journal">Diabetes Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10335419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADyaK1MXjt1Cruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1999&pages=11-21&author=C.+Weyerauthor=J.+F.+Gautierauthor=E.+Danforth&title=Development+of+Beta3-Adrenoceptor+Agonists+for+the+Treatment+of+Obesity+and+Diabetes+%E2%80%93+An+Update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Development of beta3-adrenoceptor agonists for the treatment of obesity and diabetes - an update</span></div><div class="casAuthors">Weyer, C.; Gautier, J. F.; Danforth, E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes & Metabolism</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-21</span>CODEN:
                <span class="NLM_cas:coden">DIMEFW</span>;
        ISSN:<span class="NLM_cas:issn">1262-3636</span>.
    
            (<span class="NLM_cas:orgname">Masson Editeur</span>)
        </div><div class="casAbstract">A review with 94 refs.  Beta3-adrenoceptor (β3-AR) agonists were found to have remarkable anti-obesity and anti-diabetic effects in rodents shortly after their discovery in the early 1980s.  Despite these promising qualities, several pharmaceutical problems and theor. concerns have slowed the development of these products as therapeutic agents in humans during the last 15 yr.  To date, the pharmaceutical industry has not been successful in developing a β3-AR agonist for use in the treatment of human obesity and type 2 diabetes.  Pharmaceutical problems in this area concern important differences between rodent and human β3-AR and the difficulty in finding a compd. with sufficient bioavailability that is a highly selective and full agonist at the human receptor.  Some of these problems seem to have been solved with the cloning of the human β3-AR, which has made it possible to develop novel compds. directly and specifically against the human receptor.  However, several theor. concerns still remain.  These include the major question as to whether the no. of biol. active β3-ARs in adult humans is sufficient to produce relevant metabolic effects and, if so, whether their long-term stimulation is safe and free of unwarranted side effects.  In addn., the mechanisms of action of β3-AR agonists remain poorly understood.  Recent studies using CL 316,243, a highly selective β3-adrenergic compd., have provided new insights into the potential mechanisms of action of these drugs in rodents as well as the first evidence that treatment with a highly selective β3-AR agonist exerts relevant metabolic effects in humans.  It appears that chronic β3-adrenergic stimulation in white adipose tissue increases the expression of newly discovered mitochondrial uncoupling proteins (UCP 2 and 3) and a "reawakening" of dormant brown adipocytes.  In addn., β3-ARs may be present in skeletal muscle where ectopic expression of UCP-1 has been reported.  If these findings are confirmed, tissues other than brown fat may play an important role in mediating β3-adrenergic effects on thermogenesis and substrate oxidn.  In humans, treatment with CL 316,243 for 8 wk, in spite of limited bioavailability, induced marked plasma concn.-dependent increases in insulin sensitivity, lipolysis, and fat oxidn. in lean volunteers, without causing β1-, or β2-mediated side effects.  These results clearly indicate that favorable metabolic effects can be achieved by selective β3-AR stimulation in humans.  The compds. of the next generation currently emerging from preclin. development are full agonists at the human β3-AR.  These agents have demonstrated promising results in non-human primates.  It will be interesting to see whether their efficacy in clin. trials is superior to that achieved with previous (rodent) β3-AR agonists and, if so, whether their effects will eventually translate into wt. loss and improved metabolic control that could facilitate their use as effective drugs for the treatment of obesity and Type 2 diabetes in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLau4LifmzNbVg90H21EOLACvtfcHk0lij7MFfAwhupA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjt1Cruro%253D&md5=85718d61dafe1aac00e999e5ef3cb48b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeyer%26aufirst%3DC.%26aulast%3DGautier%26aufirst%3DJ.%2BF.%26aulast%3DDanforth%26aufirst%3DE.%26atitle%3DDevelopment%2520of%2520Beta3-Adrenoceptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Obesity%2520and%2520Diabetes%2520%25E2%2580%2593%2520An%2520Update%26jtitle%3DDiabetes%2520Metab.%26date%3D1999%26volume%3D25%26spage%3D11%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Vose, C. W.; Ings, R. M. J.</span><span> </span><span class="NLM_article-title">Drug Metabolism</span>. In  <span class="citation_source-book">The Handbook of Medicinal Chemistry: Principles and Practice</span>; <span class="NLM_contrib-group">Davis, A.; Ward, S. E.</span>, Eds; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&pages=184-207&author=C.+W.+Vose&author=R.+M.+J.+Ingsauthor=A.+Davis&author=S.+E.+Ward&title=The+Handbook+of+Medicinal+Chemistry%3A+Principles+and+Practice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVose%26aufirst%3DC.%2BW.%26atitle%3DDrug%2520Metabolism%26btitle%3DThe%2520Handbook%2520of%2520Medicinal%2520Chemistry%253A%2520Principles%2520and%2520Practice%26aulast%3DDavis%26aufirst%3DA.%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2014%26spage%3D184%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zientek, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, K.</span><span> </span><span class="NLM_article-title">Reaction phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug Metabolizing Enzymes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1124/dmd.114.058750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1124%2Fdmd.114.058750" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=163-81&author=M.+A.+Zientekauthor=K.+Youdim&title=Reaction+phenotyping%3A+Advances+in+the+Experimental+Strategies+Used+to+Characterize+the+Contribution+of+Drug+Metabolizing+Enzymes&doi=10.1124%2Fdmd.114.058750"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.058750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.058750%26sid%3Dliteratum%253Aachs%26aulast%3DZientek%26aufirst%3DM.%2BA.%26aulast%3DYoudim%26aufirst%3DK.%26atitle%3DReaction%2520phenotyping%253A%2520Advances%2520in%2520the%2520Experimental%2520Strategies%2520Used%2520to%2520Characterize%2520the%2520Contribution%2520of%2520Drug%2520Metabolizing%2520Enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D163%26epage%3D81%26doi%3D10.1124%2Fdmd.114.058750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Sinz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahi, J.</span><span> </span><span class="NLM_article-title">Current Industrial Practices in Assessing CYP450 Enzyme Induction: Preclnical and Clinical</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span><span class="refDoi"> DOI: 10.1208/s12248-008-9037-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1208%2Fs12248-008-9037-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=391-400&author=M.+Sinzauthor=G.+Wallaceauthor=J.+Sahi&title=Current+Industrial+Practices+in+Assessing+CYP450+Enzyme+Induction%3A+Preclnical+and+Clinical&doi=10.1208%2Fs12248-008-9037-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1208%2Fs12248-008-9037-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-008-9037-4%26sid%3Dliteratum%253Aachs%26aulast%3DSinz%26aufirst%3DM.%26aulast%3DWallace%26aufirst%3DG.%26aulast%3DSahi%26aufirst%3DJ.%26atitle%3DCurrent%2520Industrial%2520Practices%2520in%2520Assessing%2520CYP450%2520Enzyme%2520Induction%253A%2520Preclnical%2520and%2520Clinical%26jtitle%3DAAPS%2520J.%26date%3D2008%26volume%3D10%26spage%3D391%26epage%3D400%26doi%3D10.1208%2Fs12248-008-9037-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nettleton, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span> </span><span class="NLM_article-title">Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">382</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span><span class="refDoi"> DOI: 10.2174/156802611794480882</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.2174%2F156802611794480882" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=21320066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=382-403&author=D.+O.+Nettletonauthor=H.+J.+Einolf&title=Assessment+of+Cytochrome+P450+Enzyme+Inhibition+and+Inactivation+in+Drug+Discovery+and+Development&doi=10.2174%2F156802611794480882"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">38b</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of cytochrome P450 enzyme inhibition and inactivation in drug discovery and development</span></div><div class="casAuthors">Nettleton, David O.; Einolf, Heidi J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">382-403</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Evaluation of the potential of a drug candidate to inhibit or inactivate cytochrome P 450 (CYP) enzymes remains an important part of pharmaceutical drug Discovery and Development programs.  CYP enzymes are considered to be one of the most important enzyme families involved in the metabolic clearance of the vast majority of prescribed drugs.  Clin. drug-drug interactions (DDI) involving inhibition or time-dependent inactivation of these enzymes can result in dangerous side effects resulting from reduced clearance/increased exposure of the drug being affected (the "victim" drug).  In this regard, pharmaceutical companies have become quite vigilant in mitigating CYP inhibition/inactivation liabilities of drug candidates early in Discovery including continued risk assessment throughout Development.  In this review, common strategies and decision making processes for the assessment of DDI risk in the different stages of pharmaceutical development are discussed.  In addn., in vitro study designs, anal., and interpretation of CYP inhibition and inactivation data are described in stage appropriate context.  The in vitro tools and knowledge available now enable the Discovery Chemist to place the potential CYP DDI liability of a drug candidate into perspective and to aid in the optimization of chem. drug design to further mitigate this risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnthGt_UtSfLVg90H21EOLACvtfcHk0lhrzxlcRwHmQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSnur8%253D&md5=985d26afbff18426f2dc6e4559addde1</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.2174%2F156802611794480882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611794480882%26sid%3Dliteratum%253Aachs%26aulast%3DNettleton%26aufirst%3DD.%2BO.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26atitle%3DAssessment%2520of%2520Cytochrome%2520P450%2520Enzyme%2520Inhibition%2520and%2520Inactivation%2520in%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D382%26epage%3D403%26doi%3D10.2174%2F156802611794480882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>U.S. Department of Health & Human Services, U.S. Food and Drug Administration, The Biopharmaceutics Classification System (BCS) Guidance. <a href="http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219" class="extLink">http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219</a> (accessed November<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=U.S.+Department+of+Health+%26+Human+Services%2C+U.S.+Food+and+Drug+Administration%2C+The+Biopharmaceutics+Classification+System+%28BCS%29+Guidance.+http%3A%2F%2Fwww.fda.gov%2FAboutFDA%2FCentersOffices%2FOfficeofMedicalProductsandTobacco%2FCDER%2Fucm128219+%28accessed+November+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving Drug Candidates by Design: A Focus on Physicochemical Properties as a Means of Improving Compound Disposition and Safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span><span class="refDoi"> DOI: 10.1021/tx200211v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&author=N.+A.+Meanwell&title=Improving+Drug+Candidates+by+Design%3A+A+Focus+on+Physicochemical+Properties+as+a+Means+of+Improving+Compound+Disposition+and+Safety&doi=10.1021%2Ftx200211v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0lhrzxlcRwHmQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Candidates%2520by%2520Design%253A%2520A%2520Focus%2520on%2520Physicochemical%2520Properties%2520as%2520a%2520Means%2520of%2520Improving%2520Compound%2520Disposition%2520and%2520Safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1420%26epage%3D1456%26doi%3D10.1021%2Ftx200211v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cherezov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenbaum, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thian, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhn, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weis, W. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. C.</span><span> </span><span class="NLM_article-title">High-Resolution Crystal Structure of an Engineered Human β<sub>2</sub>-Adrenergic G Protein–Coupled Receptor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">318</span><span class="NLM_x">, </span> <span class="NLM_fpage">1258</span><span class="refDoi"> DOI: 10.1126/science.1150577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1126%2Fscience.1150577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=17962520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2007&pages=1258&author=V.+Cherezovauthor=D.+M.+Rosenbaumauthor=M.+A.+Hansonauthor=S.+G.+Rasmussenauthor=F.+S.+Thianauthor=T.+S.+Kobilkaauthor=H.+J.+Choiauthor=P.+Kuhnauthor=W.+I.+Weisauthor=B.+K.+Kobilkaauthor=R.+C.+Stevens&title=High-Resolution+Crystal+Structure+of+an+Engineered+Human+%CE%B22-Adrenergic+G+Protein%E2%80%93Coupled+Receptor&doi=10.1126%2Fscience.1150577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein-Coupled Receptor</span></div><div class="casAuthors">Cherezov, Vadim; Rosenbaum, Daniel M.; Hanson, Michael A.; Rasmussen, Soren G. F.; Thian, Foon Sun; Kobilka, Tong Sun; Choi, Hee-Jung; Kuhn, Peter; Weis, William I.; Kobilka, Brian K.; Stevens, Raymond C.; Takeda, S.; Kadowaki, S.; Haga, T.; Takaesu, H.; Mitaku, S.; Fredriksson, R.; Lagerstrom, M. C.; Lundin, L. G.; Schioth, H. B.; Pierce, K. L.; Premont, R. T.; Lefkowitz, R. J.; Lefkowitz, R. J.; Shenoy, S. K.; Rosenbaum, D. M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">5854</span>),
    <span class="NLM_cas:pages">1258-1265</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Second extracellular loop, which in the β2-adrenergic receptor contains an unusual pair of disulfide bonds and an extra helix.  This loop and the absence Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane.  We report the crystal structure of a human β2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resoln.  The structure provides a high-resoln. view of a human G protein-coupled receptor bound to a diffusible ligand.  Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop.  Cholesterol, a necessary component for crystn., mediates an intriguing parallel assocn. of receptor mols. in the crystal lattice.  Although the location of carazolol in the β2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC-8wZ2k2GHLVg90H21EOLACvtfcHk0liOhViCyQkljw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmur7I&md5=12c5bacb8464a4b243fe9341192b5b3b</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1150577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1150577%26sid%3Dliteratum%253Aachs%26aulast%3DCherezov%26aufirst%3DV.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26aulast%3DHanson%26aufirst%3DM.%2BA.%26aulast%3DRasmussen%26aufirst%3DS.%2BG.%26aulast%3DThian%26aufirst%3DF.%2BS.%26aulast%3DKobilka%26aufirst%3DT.%2BS.%26aulast%3DChoi%26aufirst%3DH.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DW.%2BI.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26atitle%3DHigh-Resolution%2520Crystal%2520Structure%2520of%2520an%2520Engineered%2520Human%2520%25CE%25B22-Adrenergic%2520G%2520Protein%25E2%2580%2593Coupled%2520Receptor%26jtitle%3DScience%26date%3D2007%26volume%3D318%26spage%3D1258%26doi%3D10.1126%2Fscience.1150577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Warne, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serrano-Vega, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moukhametzianov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, P. C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schertler, G. F. X.</span><span> </span><span class="NLM_article-title">Structure of β<sub>1</sub>-Adrenergic G Protein-Coupled Receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1038/nature07101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnature07101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2008&pages=486-91&author=T.+Warneauthor=M.+J.+Serrano-Vegaauthor=J.+G.+Bakerauthor=R.+Moukhametzianovauthor=P.+C.+E.+Edwardsauthor=R.+Hendersonauthor=A.+G.+W.+Leslieauthor=C.+G.+Tateauthor=G.+F.+X.+Schertler&title=Structure+of+%CE%B21-Adrenergic+G+Protein-Coupled+Receptor&doi=10.1038%2Fnature07101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1038%2Fnature07101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07101%26sid%3Dliteratum%253Aachs%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DSerrano-Vega%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DJ.%2BG.%26aulast%3DMoukhametzianov%26aufirst%3DR.%26aulast%3DEdwards%26aufirst%3DP.%2BC.%2BE.%26aulast%3DHenderson%26aufirst%3DR.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DTate%26aufirst%3DC.%2BG.%26aulast%3DSchertler%26aufirst%3DG.%2BF.%2BX.%26atitle%3DStructure%2520of%2520%25CE%25B21-Adrenergic%2520G%2520Protein-Coupled%2520Receptor%26jtitle%3DNature%26date%3D2008%26volume%3D454%26spage%3D486%26epage%3D91%26doi%3D10.1038%2Fnature07101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit41c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lebon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tate, C. G.</span> <span class="citation_source-journal">Curr. Opin. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">482</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.1016/j.sbi.2012.03.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.sbi.2012.03.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=22480933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVeit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Lebon%2C+G.%3B+Warne%2C+T.%3B+Tate%2C+C.+G.Curr.+Opin.+Struct.+Biol.+2012%2C+22%2C+482%E2%80%9390+10.1016%2Fj.sbi.2012.03.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41cR"><div class="casContent"><span class="casTitleNuber">41c</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-bound structures of G protein-coupled receptors</span></div><div class="casAuthors">Lebon, Guillaume; Warne, Tony; Tate, Christopher G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">482-490</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) play a major role in intercellular communication by binding small diffusible ligands (agonists) at the extracellular surface.  Agonist-binding induces a conformational change in the receptor, which results in the binding and activation of heterotrimeric G proteins within the cell.  Ten agonist-bound structures of non-rhodopsin GPCRs published last year defined for the 1st time the mol. details of receptor activated states and how inverse agonists, partial agonists, and full agonists bind to produce different effects on the receptor.  In addn., the structure of the β2-adrenoceptor coupled to a heterotrimeric G protein showed how the opening of a cleft in the cytoplasmic face of the receptor as a consequence of agonist binding results in G protein coupling and activation of the G protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9IZFD6OPS4bVg90H21EOLACvtfcHk0liOhViCyQkljw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVeit7g%253D&md5=9d9a390eca0636d08918938c7a7e2eea</span></div><a href="/servlet/linkout?suffix=cit41c&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2012.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2012.03.007%26sid%3Dliteratum%253Aachs%26aulast%3DLebon%26aufirst%3DG.%26aulast%3DWarne%26aufirst%3DT.%26aulast%3DTate%26aufirst%3DC.%2BG.%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2012%26volume%3D22%26spage%3D482%26epage%3D90%26doi%3D10.1016%2Fj.sbi.2012.03.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Klebe, G.</span><span> </span><span class="NLM_article-title">Applying Thermodynamic Profiling in Lead Finding and Optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1038/nrd4486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnrd4486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=25614222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVemtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=95-110&author=G.+Klebe&title=Applying+Thermodynamic+Profiling+in+Lead+Finding+and+Optimization&doi=10.1038%2Fnrd4486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Applying thermodynamic profiling in lead finding and optimization</span></div><div class="casAuthors">Klebe, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-110</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery involves the optimization of various physicochem. properties of a ligand, particularly its binding affinity for its target receptor (or receptors).  In recent years, there has been growing interest in using thermodn. profiling of ligand-receptor interactions in order to select and optimize those ligands that might be most likely to become drug candidates with desirable physicochem. properties.  The thermodn. of binding is influenced by multiple factors, including hydrogen bonding and hydrophobic interactions, desolvation, residual mobility, dynamics and the local water structure.  This article discusses key issues in understanding the effects of these factors and applying this knowledge in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqtHj7SsL6rrVg90H21EOLACvtfcHk0liOhViCyQkljw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVemtr4%253D&md5=c2e12760623de81335ce252cb804c602</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd4486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4486%26sid%3Dliteratum%253Aachs%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DApplying%2520Thermodynamic%2520Profiling%2520in%2520Lead%2520Finding%2520and%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D95%26epage%3D110%26doi%3D10.1038%2Fnrd4486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Morgan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Der Graaf, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrowsmith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drummond, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Street, S. D. A.</span><span> </span><span class="NLM_article-title">Can the Flow of Medicines be Improved? Fundamental Pharmacokinetic and Pharmacological Principles Toward Improving Phase II Survival</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1016/j.drudis.2011.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1016%2Fj.drudis.2011.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=22227532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=419-424&author=P.+Morganauthor=P.+H.+Van+Der+Graafauthor=J.+Arrowsmithauthor=D.+E.+Feltnerauthor=K.+S.+Drummondauthor=C.+D.+Wegnerauthor=S.+D.+A.+Street&title=Can+the+Flow+of+Medicines+be+Improved%3F+Fundamental+Pharmacokinetic+and+Pharmacological+Principles+Toward+Improving+Phase+II+Survival&doi=10.1016%2Fj.drudis.2011.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival</span></div><div class="casAuthors">Morgan, Paul; Van Der Graaf, Piet H.; Arrowsmith, John; Feltner, Doug E.; Drummond, Kira S.; Wegner, Craig D.; Street, Steve D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">419-424</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In an effort to uncover systematic learnings that can be applied to improve compd. survival, an anal. was performed on data from Phase II decisions for 44 programs at Pfizer.  It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large no. of cases (43%), it was not possible to conclude whether the mechanism had been tested adequately.  A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacol. activity (termed together as the three Pillars of survival') all det. the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFyWWmU_ARMLVg90H21EOLACvtfcHk0lgUJjJGLb2DHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D&md5=18816036124edb3d50c4e063fdc40614</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DVan%2BDer%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DFeltner%26aufirst%3DD.%2BE.%26aulast%3DDrummond%26aufirst%3DK.%2BS.%26aulast%3DWegner%26aufirst%3DC.%2BD.%26aulast%3DStreet%26aufirst%3DS.%2BD.%2BA.%26atitle%3DCan%2520the%2520Flow%2520of%2520Medicines%2520be%2520Improved%253F%2520Fundamental%2520Pharmacokinetic%2520and%2520Pharmacological%2520Principles%2520Toward%2520Improving%2520Phase%2520II%2520Survival%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D419%26epage%3D424%26doi%3D10.1016%2Fj.drudis.2011.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Cook, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexander, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">March, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satterthwaite, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangalos, M. N.</span><span> </span><span class="NLM_article-title">Lessons Learned from the Fate of AstraZeneca’s Drug Pipeline: A Five-Dimensional Framework</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">419</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+AstraZeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0lgUJjJGLb2DHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520AstraZeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i41"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01372">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_14704"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01372">10.1021/acs.jmedchem.5b01372</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystallographic information for compound <b>7</b> and the algorithm for determination of calculated Log <i>D </i>(cLogD) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01372/suppl_file/jm5b01372_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01372/suppl_file/jm5b01372_si_001.pdf">jm5b01372_si_001.pdf (176.08 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01372&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-2%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01372%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01372" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679923605b343c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
